R U 2 4 1 3 0 6I  
A d de n d u m 9  
 
 
    Aca de mic a n d C o m m u nit y Ca ncer Researc h U nite d ( A C C R U)  
 
R a n d o mize d D o u ble -Bli n d P h ase II St u d y of R a di o acti ve I o di ne ( R AI)  i n C o m bi n ati o n wit h Pl ace b o or 
Sel u meti ni b  f or t he Tre at me nt of R AI -A vi d Rec urre nt/ Met ast atic  T h yr oi d C a ncers   
 
F or a ny c o m m u nic at i o ns re g ar di n g t his pr ot oc ol, ple ase  c o nt act t he pr ot oc ol res o urce pers o n o n t he 
f oll o wi n g p a ge. 
 
St u d y C hairs    
 A C C R U:  Ala n H o, M. D.  
[ADDRESS_410674]  
Ne w Y or k, N Y 1 0 0 6 5  
P h o ne: 2 1 2 -6 3 9 -7 2 0 2  
e-mail: h oa @ ms kcc. or g  
 
   
 C o -c hair:  
[ADDRESS_410675] S W  
R oc hester, M N 5 5 9 0 5  
 
 
 
 Statisticia n:   
 
 
Dr u g A v ail a bilit y  
Dr u g C o m p a n y S u p plie d:  Sel u meti ni b ( Astra Ze neca; I N D  0 7 4, 6 6 7 )  
 
  St u d y c o ntri b ut or(s) n ot res p o nsi ble f or patie nt care.  
 
St u d y P artici p a nts  D ate Acti v ate d  
A C C R U Me m bers hi p  Ma y 1, [ADDRESS_410676] or y  (effecti ve d ate) 
Pre -acti vati o n A C C R U  Dece m ber 5, 2 0 1 4  
Acti vati o n A C C R U  / 
A d de n d u m [ADDRESS_410677] ors  
  6. 0  Re gistrati o n/ Ra n d o mizat i o n Pr oce d ures 
  7. 0  Pr ot oc ol Treat me nt  
  8. 0  D osa ge M o dificati o n Base d o n A d verse E ve nts  
  9. 0  A ncillar y Treat me nt/ S u p p orti ve Care  
1 0. 0  A d verse E ve nt ( A E) Re p orti n g a n d M o nit ori n g  
[ADDRESS_410678] ors  
1 3. 0  Treat me nt/ F oll o w -u p Decisi o n at E val uati o n of Patie nt  
[ADDRESS_410679] u g I nf or mati o n  
1 6. 0  Statistical C o nsi derati o ns a n d Met h o d ol o g y  
1 7. 0  Pat h ol o g y C o nsi derati o ns/ Tiss ue Bi os peci me ns  
1 8. 0  Rec or ds a n d Data C ollecti o n Pr oce d ures  
1 9 . 0 B u d get  
2 0. 0  Refere nces  
 
A p pe n di x I - C o nse nt F or m  
 
A p pe n di x II–  Patie nt Me dicati o n Diar y  
 
A p pe n di x III –  T he L o w I o di ne Diet  
 
A p pe n di x I V – G ui da nce f or M a na ge me nt a n d In vesti gati o n of S el u meti ni b R elate d A d verse E ve nts  
 
 4   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
                                                                   Sc he m a  
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* O bser vati o n ti me p oi nts:  [ADDRESS_410680]-
treat me nt, f oll o we d b y e ver y 6 m o nt hs f or a ma xi m u m of 2 years fr o m ra n d o mizati o n.   
* * C a n be gi ve n u p t o 8 wee ks  (i.e. t he ti me o n treat me nt i ncl u di n g treat me nt i nterr u pti o ns) (see secti o n 7) 
 
 
Ge neric na me:    Sel u meti ni b  
Bra n d na me(s):  
A C C R U A b bre viati o n:   A Z D 6 2 4 4    
A vaila bilit y:   Astra Ze neca  Ge neric na me:    Place b o   
Bra n d na me(s):  
A C C R U A b bre viati o n:   P L A C E B    
A vaila bilit y:   Astra Ze neca  
 R a n d o miz ati o n 
Pl ace b o + R a di o acti ve 
I o di ne ( R AI) t her a p y Sel u meti ni b ( 7 5 m g P O  BI D 
x 4 wee ks) * *  + R a di o acti ve 
I o di ne ( R AI) t her a p y 
O bser v ati o n *  
E ve nt M o nit ori n g  
U n acce pt a ble a d verse e ve nts, 
alter n ati ve tre at me nt, dise ase 
pr o gressi o n, p atie nt ref us al at 
a n y ti me  
                           
                            
 
E ve nt M o nit ori n g  
 5   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
1. 0  B ac k gr o u n d   
 
Utility of 1 3 1I t her a py f or r a di oi o di ne-avi d t hyr oi d c a ncers : T he maj orit y of t h yr oi d ca ncers are 
differe ntiate d carci n o mas of f ollic ular ori gi n wit h pa pi[INVESTIGATOR_5778] y t h yr oi d ca ncer ( P T C) bei n g t he m ost 
c o m m o n f oll o we d b y f ollic ular t h yr oi d ca ncer ( F T C)  ( use of t he ter m “t h yr oi d ca ncer” i n t his pr ot oc ol 
refers s pecificall y t o f ollic ular cell deri ve d t h yr oi d mali g na ncies). Metastatic disease re prese nts t he  m ost 
fre q ue nt ca use of t h yr oi d ca ncer-relate d deat h (Mazzaferri a n d Kl o os, 2 0 0 1 ). Si nce t he a bilit y t o 
tra ns p ort i o did e is retai ne d i n t h yr oi d carci n o mas of f ollic ular ori gi n  a n d is restricte d t o o nl y a fe w cell 
t y pes, ra di oacti ve i o di ne ( R AI or 1 3 1I) ca n be use d t hera pe uticall y t o deli ver t u m orici dal d oses of 
ra diati o n, eliciti n g cli nical be nefit wit h f e w si de effects a n d m o dest  l o n g-ter m t o xicit y. 
 
1 3 1I ca n be partic ularl y effecti ve f or s mall v ol u me ( < 1 c m), R AI-a vi d ( R AI A; t u m ors wit h detecta ble 
R AI u pta ke) disease wit h c o m plete re missi o n ac hie ve d i n re p orte dl y o ver 5 0 % of patie nts (D ura nte et 
al., 2 0 0 6). H o we ver, [ADDRESS_410681] -li ne 1 3 1I t hera p y ( R AI 
a d mi nistere d f or re m na nt a blati o n a n d e vi de nce of R AI A dista nt metastasis o n p ost -a blati o n sca n)  f or 
patie nts wit h metastatic, R AI A t h yr oi d ca ncer . I n [ADDRESS_410682] ural disease, t he res p o nse rate of 
metastatic lesi o n(s)  t o i nitial R AI a blati o n t hera p y was 2 2 % (Sa bra et al., 2 0 1 3 ). T his o bser vati o n  is 
c o nsiste nt wit h t he 1 0 % t o 2 4 % res p o nse rates re p orte d i n ot her retr os pecti ve series f or si milar s u bsets 
o f patie nts (D ura nte et al., 2 0 0 6 ; Kl u b o -G wiez dzi ns ka et al., 2 0 1 1a ; Kl u b o -G wiez dzi ns ka et al., 2 0 1 1 b ; 
Tala et al., 2 0 1 1 ). 
 
[ADDRESS_410683] t h yr oi d metastases is deter mi ne d b y t he 1 3 1I acti vit y t hat ca n be s uccessf ull y 
deli vere d t o metas tatic lesi o ns (D or n et al., 2 0 0 3 ; Ma x o n et al., 1 9 9 2 ; Ma x o n et al. , 1 9 8 3; T h o mas et al., 
1 9 7 6 ). B ot h 1 3 1I u pta ke a n d rete nti o n  ca n be i m paire d b y di mi nis he d e x pressi o n of se veral t h yr oi d-
s pecific ge nes, i ncl u di n g t he s o di u m i o di de s y m p orter ( NI S; m e diates i o di de u pta ke i nt o t h yr oi d cells) 
a n d t h yr o per o xi dase ( T P O; critical f or i o di de rete nti o n). Ma n y i n vesti gat ors ha ve searc he d f or dr u gs t o 
“re-differe ntiate” metastatic t h yr oi d ca ncers t o rest ore e x pressi o n of t hese ge nes i n a n atte m pt t o 
e n ha nce [ADDRESS_410684] 
effects u p o n 1 3 1I acti o n.  
 
T hyr oi d c a ncer m ut ati o ns t h at activ ate t he M A P K p at h w ay de -differe nti ate t hyr oi d c a ncer cells : 
M ut uall y e xcl usi ve ge netic alterati o ns i n t he gr o wt h fact or rece pt or R E T , t he t hree is of or ms of R A S (N, 
H, K), a n d B R A F are prese nt i n ~ 7 0 % of P T Cs  (C o he n et al., 2 0 0 3 ; Ki m ura e t al., 2 0 0 3; K na uf a n d 
Fa gi n, 2 0 0 9 ; S oares et al., 2 0 0 3 ). T hese o nc o pr otei ns partici pate i n M A P K si g nali n g t o acti vate 
d o w nstrea m ki nases M E K a n d E R K ( R E T -> R A S -> R A F -> M E K -> E R K). T he B R A FV [ADDRESS_410685] c o m m o n ge netic alterati o n i n P T C (i n v ol vi n g a b o ut 4 5 % of t u m ors)  (Ki m ura et al., 2 0 0 3 ; Ricarte -
Fil h o et al., 2 0 0 9 ). B R A F M U T t u m ors  h a ve a m ore a g gressi ve cli nical be ha vi or a n d are pr o ne t o bei n g 
R AI -refract or y (Elisei et al., 2 0 0 8 ; Lee et al., 2 0 0 7 ). Be y o n d pr o m oti n g cell ular pr oliferati o n a n d 
s ur vi val, B R A F m utati o ns i n t h yr oi d ca ncer ha ve als o bee n i m plicate d i n disr u pti n g f ollic ular cell  
differe ntiati o n, i ncl u di n g t he s u p pressi o n of ke y ge nes i n v ol ve d i n i o di d e meta b olis m (D ura nte et al., 
2 0 0 7 ; Li u et  al., 2 0 0 7 ; Riesc o -Eiza g uirre et al., 2 0 0 6 ) a n d i o di de u pta ke, s uc h as NI S (Riesc o -Eiza g u irre 
et al., 2 0 0 6 ). I n rat t h yr oi d P C C L [ADDRESS_410686] ore d e x pressi o n of NI S as well as t h yr oi d sti m ulati n g h or m o ne ( T S H) 
rece pt or a n d t h yr o gl o b uli n (Li u et al., 2 0 0 7 ). 
 
Ot her M A P K acti vati n g alterati o ns c o m m o n t o t h yr oi d ca ncer ca n als o ca use de -differe ntiati o n. R A S  
m utati o ns are f o u n d i n a p pr o xi matel y 1 0 -2 0 % of P T Cs a n d 4 0 -5 0 % of F T Cs (Ni kif or o v a n d Ni kif or o va, 
2 0 1 1 ). Rec o m bi nati o n e ve nts t hat lea d t o t he f usi o n of t he R E T t yr osi ne ki nase rece pt or wit h o ne of  
se veral part ner ge nes ( k n o w n as R E T/ P T C  rearra n ge me nts) occ ur i n 1 0 -2 0 % of P T Cs (Ni kif or o v a n d 
Ni kif or o va, 2 0 1 1 ; S oares et al., 2 0 0 3 ; Z h u et al., 2 0 0 6 ). O vere x pressi o n of eit her t he H R A SV 1 2 m uta nt or 
R E T/ P T C  i n t h yr oi d ca ncer cells s u p presses NI S e x pressi o n, w hic h ca n be rest ore d wit h M E K i n hi bit or  
 6   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
treat me nt (De Vita et al., 2 0 0 5 ; K na uf et al., 2 0 0 3 ). He nce, ge netic alterati o ns t hat acc o u nt f or M A P K 
acti vati o n i n of t he vast maj orit y of  t h yr oi d ca ncers ca n pr o m ote M E K-d e pe n de nt NI S s u p pressi o n, 
di mi nis he d i o di de a vi dit y, a n d resista nce t o [ADDRESS_410687] ore i o di d e i nc or p or ati o n i n a n i n viv o t hyr oi d c a ncer a ni m al m o del : 
I n a t h yr oi d ca ncer m o use m o del wit h d o x yc ycli ne ( d o x) i n d uci ble t h yr o i d e x pressi o n of B R A FV [ADDRESS_410688]. 
Ja mes Fa gi n’s gr o u p ( Me m orial Sl oa n-Ketteri n g Ca ncer Ce nter ( M S K C C))  de m o nstrate d t hat d o x 
treat me nt res ulte d i n B R A FV 6 0 0 E o vere x pressi o n, M A P K acti vati o n, de vel o p me nt of P T C, a n d 
s u p pressi o n of se veral t h yr oi d s pecific ge nes, i ncl u di n g NI S  (C ha kra vart y et al., 2 0 1 1 ). Wit h dra wal of 
d o x t o eli mi nate B R A FV 6 0 0 E e x pressi o n res ulte d i n s u p pressi o n of M A P K acti vat i o n a n d re-i n d ucti o n of 
t h yr oi d ge ne e x pressi o n, s u g gesti n g t hat o nc o ge nic B R A F  i n d uce d ge ne patter ns ca n be re verse d w he n 
B R A F  acti vati o n  of M A P K si g nali n g is n ullifie d . T his ge netic pr o of of c o nce pt was reca pit ulate d wit h 
p h ar mac ol o gic i n hi biti o n of B R A F  acti vati o n: B R A FV 6 0 0 E was i n d uce d wit h o ne wee k of d o x treat me nt 
a n d s u bse q ue ntl y mai ntai ne d w hile t he a ni mals were treate d wit h t he M E K i n hi bit or P D 0 3 2 5 9 0 1 
( P D 9 0 1) or t he selecti ve o nc o ge nic B R A F i n hi bit or P L X 4 7 2 0 ( Ple x xi k o n/ R oc he). I n hi biti o n of B R A F 
sig nali n g wit h eit her dr u g i ncrease d R AI i nc or p orati o n o ver ve hicle treat me nt , s u g gesti n g t hat i n hi biti n g 
M A P K si g nali n g wit h s mall m olec ule i n hi bit ors ca n rest ore i o di d e u pta ke i n t h yr oi d t u m ors dri ve n b y a 
M A P K acti vati n g ge netic alterati o n.  
 
Res ults of a pil ot st u dy ev al u ati n g t he i m p act of  M E K i n hi biti o n u p o n  R AI i nc or p or ati o n a n d 1 3 1I 
effic acy: We tra nslate d t hese precli nical fi n di n gs i nt o a pil ot st u d y e val uati n g t he i m pact of t he 
Astra Ze neca M E K i n hi bit or sel u meti ni b u p o n i o di de u pta ke i n patie nts wit h  R AI -refract or y t h yr oi d 
ca ncers  (H o et al., 2 0 1 3 ). A critical c o m p o ne nt of t he st u d y was t he utilizati o n of 1 2 4I P E T/ C T lesi o nal 
d osi metr y t o precisel y q ua ntif y dr u g -in d uce d c ha n ges i n i o di d e i nc or p orati o n wit hi n s pecific lesi o ns  
(Pe ntl o w et al., 1 9 9 6 ; S g o ur os et al., 2 0 0 4 ) an d pre dict t he [ADDRESS_410689] or y disease as defi ne d b y o ne of t he 
f oll o wi n g criteria: 1) n o n-R AI -a vi d lesi o n/s o n a dia g n ostic a n d/ or p os t-t hera p y R AI sca n, 2) R AI-a vi d 
lesi o n/s t hat re mai ne d sta ble or i ncrease d i n size after R AI t hera p y, or 3) fl u or o de o x y gl uc ose ( F D G)-
a vi d lesi o n/s b y P E T s ca n. I n or der t o o pti mize i o di d e u pta ke, h u ma n rec o m bi na nt T S H (r h T S H or 
T h yr o ge n ™  fr o m Ge nz y me) was a d mi nistere d pri or t o eac h 1 2 4I P E T, w hic h was perf or me d bef ore a n d 
after treat me nt wit h sel u meti ni b  f or 4 wee ks. If t he sec o n d 1 2 4I P E T sca n pre dicte d t hat a lesi o nal 1 3 1I 
d ose of >  2, 0 0 0 c G y c o ul d be ac hie ve d, 1 3 1I was a d mi nistere d c o nc o mita ntl y wit h  selu meti ni b. Of t he 2 0 
e val ua ble patie nts, 1 2 ( 6 0 %) ha d ne w or i ncrease d 1 2 4I i nc or p orati o n after sel u meti ni b. For 8 ( 4 0 %) 
patie nts, t he sec o n d 1 2 4I P E T sca n pre dicte d t hat t he lesi o nal a bs or be d 1 3 1I ra diati o n d ose w o ul d e q ual or 
e xcee d 2, 0 0 0 c G y; t hese patie nts were c o nti n ue d o n sel u meti ni b a n d recei ve d t hera pe utic [ADDRESS_410690], 4 o ut of 9 B R A F  M U T patie nts ha d sel u meti ni b -i n d uce d i ncreases i n 1 2 4I i nc or p orati o n, b ut 
o nl y o ne ac hie ve d t he d ose t hres h ol d t o warra nt 1 3 1I treat me nt. T w o o ut of 3 R E T/ P T C  a n d 1 o ut of 3 
W T  patie nts als o ha d greater i o di d e i nc or p orati o n o n t he sec o n d 1 2 4I P E T sca n, a n d o ne of eac h of t h ose 
ge n ot y pes we nt o n t o be trea te d wit h 1 3 1I. T hese c ha n ges i n i o di de i nc or p orati o n tra nslate d t o cli nical 
be nefit as all 8 patie nts treate d wit h 1 3 1I e x perience d re d ucti o ns i n t u m or size. I n t otal, t here were 5 
c o nfir me d partial res p o nses (c P Rs) a n d 3 wit h sta ble disease ( S D). S u bsta nt ial decreases i n ser u m 
t h yr o gl o b uli n f oll o wi n g R AI t hera p y were als o ac hie ve d i n all patie nts. 
 
All e val ua ble patie nts c o m plete d t he f ull c o urse of sel u meti ni b wit h o ut d ose re d ucti o n or dela y. 
T o xicities attri b ute d t o sel u meti ni b were Gra de [ADDRESS_410691] u dies (Ha yes et al., 2 0 1 2 ; Kir k w o o d et al., 2 0 1 1 ), i ncl u di n g fati g ue ( 8 0 %), 
mac ul o pa p ular ras h ( 7 0 %), a n d ac neif or m ras h ( 2 5 %). F o urtee n ( 7 0 %) patie nts e x perie nce d Gra de [ADDRESS_410692] o me m ore t ha n 5 1 wee ks later; t he disease e ve nt uall y tra nsf or me d t o ac ute le u ke mia. Pri or t o 
e nr oll me nt, t his patie nt ha d recei ve d t hree c o urses of 1 3 1I (c u m ulati ve pre-st u d y dose of 9 7 6. 2 m Ci) as 
well as 8 6 4 0 c G y of e xter nal bea m ra diati o n f or pr ostate ca ncer. He nce, t his sec o n dar y mali g na nc y was 
attri b ute d t o c u m ulati ve 1 3 1I a n d e xter nal bea m ra diati o n t o xicities, a n d n ot t o sel u meti ni b.  
 
Sel u meti ni b( A R R Y 1 4 2 8 8 6; A Z D 6 2 4 4) : Sel u meti ni b is a p ote nt, selecti ve, n o nc o m petiti ve i n hi bit or of 
M E K, lice nse d f or de vel o p me nt b y Astra Ze neca P har mace uticals fr o m Arra y Bi o P har ma. Sel u meti ni b 
was disc o vere d b y Arra y Bi o p har ma a n d ha d t he desi g nati o n A R R Y 1 4 2 8 8 6. Ot her la b orat or y c o de 
na mes u se d d uri n g t he de vel o p me nt of t his m olec ule are A R 0 0 1 4 2 8 8 6 a n d A R-1 4 2 8 8 6 -X ( w here X 
refers t o a se q ue ntial l ot n u m ber). Arra y Bi o P har ma was res p o nsi ble f or t he first-i nt o-h u ma n st u d y; t he 
re mai n der of t he cli nical de vel o p me nt pr o gra m f or o nc ol o g y i n dicati ons is t he res p o nsi bilit y of 
Astra Ze neca. A Z D 6 2 4 4 has n o w bee n assi g ne d t he i nter nati o nal n o n pr o prietar y na me sel u meti ni b.  
 
Sel u meti ni b i n hi bits t he acti vit y of is olate d mit o ge n -acti vate d pr otei n ki nase ki nase ( M E K) t o 
p h os p h or ylate e xtracell ular si g nal -re gulate d ki nase ( E R K) 2 i n e nz y me assa ys, wit h a c o nce ntrati o n 
w hic h res ulte d i n 5 0 % i n hi biti o n (I C 5 0) of a p pr o xi matel y [ADDRESS_410693] a pa nel of ot her ki nases. N-des met h yl sel u meti ni b (a 
p har mac ol o gicall y acti ve meta b olite) was i de ntifie d t o be a p pr o xi matel y [ADDRESS_410694] u dies. I n a d diti o n, 
a p pr o xi matel y 1 2 0 healt h y v ol u nteers ha ve bee n e x p ose d t o sel u meti ni b H y d -S ulfate.  
 
Sel u meti ni b has bee n use d  as b ot h m o n ot hera p y a n d i n c o m bi nati o n wit h ot her a nti -ca ncer a ge nts, i n a 
variet y of a d ult s oli d t u m or setti n gs (e .g ., pa ncreatic ca ncer, c ol orectal ca ncer, mela n o ma a n d N S C L C), 
a n d pe diatric ca ncer patie nts.  
 
T he f or m ulati o n ta ke n i nt o t he p hase I cli ni cal pr o gra m b y Arra y Bi o p har ma was a n e xte m p ora ne o us 
pre parati o n of a n oral s us pe nsi o n of sel u meti ni b as t he free -base i n a n a q ue o us s ol uti o n of 
s ul p h o b ut ylet her β -c ycl o de xtri n ( S B E -C D, Ca ptis ol ®), referre d t o as t he free -base s us pe nsi o n 
f or m ulati o n ( mi x an d dri n k).  
 
T he Astra Ze neca p hase II m o n ot hera p y cli nical pr o gra m als o utilize d t his f or m ulati o n. S u bse q ue nt 
f or m ulati o n de vel o p me nt res ulte d i n a ca ps ule f or m ulati o n of sel u meti ni b as t he h y dr o ge n s ul p hate salt 
( A Z D 6 2 4 4 H y d-S ulfate), w hic h will be use d i n  t his st u d y. T he ma xi m u m t olerate d d ose ( M T D) f or t he 
s us pe nsi o n f or m ulati o n was deter mi ne d t o be [ADDRESS_410695] u dies ( D 1 5 3 2 C 0 0 0 0 5, D 1 5 3 2 C 0 0 0 2 0) were perf or me d wit h t he H y d -S ulfate f or m ulati o n. 
C o m paris o n of t he fre q ue ncies fr o m St u d y D [ADDRESS_410696] u d y 
D 1 5 3 2 C 0 0 0 0 5 ha vi n g l o wer t olera nces t o de vel o pi n g t o xicit y.  
 
 8   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
T w o h u n dre d a n d si xt y ni ne ( 2 6 9) patie nts recei ve d sel u meti ni b free base s us pe nsi o n [ADDRESS_410697] u dies ( D 1 5 3 2 C 0 0 0 0 3, D 1 5 3 2 C 0 0 0 0 8, D 1 5 3 2 C 0 0 0 1 1, a n d 
D 1 5 3 2 C 0 0 0 1 2).  
 
•  Ras hes (i ncl u di n g t he preferre d ter ms der matitis ac neif or m, ras h, ras h mac ul o pa p ular, ras h mac ular, 
ras h pa p ular, ac ne, a n d f ollic ulitis) were re p orte d i n a p pr o xi matel y 7 0 % of patie nts recei vi n g 
treat me nt wit h sel u meti ni b, a n d der matitis ac neif or m was t he m ost c o m m o n A E ter m o verall ( 5 4 %). 
Ot her c o m m o nl y re p orte d A Es were diarr hea ( 4 9 %), na usea ( 3 3 %) a n d v o miti n g ( 2 4 %). A d verse 
e ve nts of peri p heral e de ma, peri or bital e de ma, a n d facial e de ma were re p orte d i n 3 1 %, 9 %, a n d 4 % 
of patie nts, res pecti vel y. T he A Es of fati g ue or ast he nia were re p orte d i n a p pr o xi matel y 3 0 % of 
patie nt s i n t his p hase II p o p ulati o n. E xerti o nal dys p nea or d ys p nea was re p orte d i n 1 3 % of patie nts 
a n d, i n i n di vi d ual st u dies, e xerti o nal  d ys p nea was re p orte d at a hi g her i nci de nce i n t he sel u meti ni b 
gr o u ps t ha n i n t he c o m parat or c he m ot hera p y gr o u ps.  
 
•  Seri o us A Es were re p orte d i n 2 4 % of patie nts recei vi n g sel u meti ni b m o n ot hera p y. T he m ost 
fre q ue ntl y re p orte d serio us A Es were v o miti n g ( 1. 5 %), diarr hea, er ysi pelas, a n d p ul m o nar y 
e m b olis m (i n 1. 1 % patie nts eac h). Seri o us A Es of i nfecti o ns ( bacterial se psis, se psis, i nfecti o n, a n d 
bacterial art hritis) were re p orte d i n 2. 2 % of patie nts. T he m ost fre q ue ntl y relate d re p o rte d treat me nt-
relate d S A E was v o miti n g ( 3 patie nts). 
 
•  I n St u d y D 1 5 3 2 C 0 0 0 0 3, s mall i ncreases i n bl o o d press ure were o bser ve d after 1 wee k o n 
sel u meti ni b, wit h mea n i ncreases of 7. 4 m m H g (s yst olic, S B P) a n d 5. 3 m m H g ( diast olic, D B P) at 
Wee k 8, c o m pare d wit h  mea n i ncreases of 1. 1 m m H g ( S B P) a n d 0. 5 m m H g ( D B P) i n t he 
te m oz ol o mi de c o m parat or ar m. T he A E of h y perte nsi o n was re p orte d i n 1 8 patie nts ( 6. 7 %) 
recei vi n g sel u meti ni b i n p hase II m o n ot hera p y st u dies; [ADDRESS_410698] ors f or h y perte nsi o n. 
 
•  Re versi ble as y m pt o matic re d ucti o n i n left ve ntric ular ejecti o n fracti o n ( L V E F) t o bel o w 5 5 % has 
bee n re p orte d i n a s mall pr o p orti o n of patie nts wit h a d va nce d ca ncers i n t he m o n ot hera p y a n d 
ra n d o mize d place b o c o ntr olle d st u dies i n c o m bi nati o n wit h sta n dar d c he m ot hera pi[INVESTIGATOR_014], wit h b ot h 
f or m ulati o ns of sel u meti ni b. I n b ot h place b o-c o ntr olle d st u dies , n o patie nt treate d wit h sel u meti ni b 
ha d se vere L V E F i m pair me nt ( < 3 5 %) or s y m pt o matic h eart fail ure. E vi de nce of re versi bilit y o n 
c o nti n ui n g treat me nt wit h sel u meti ni b has bee n de m o nstrate d i n s o me patie nts. L V E F sc he d ule d 
assess me nts were o nl y i ncl u de d i n o ne p hase II st u d y ( D 1 5 3 2 C 0 0 0 0 3) a n d i n t he sel u meti ni b gr o u p 
t o e val uate a p ossi ble car diac eti ol o g y of t he peri p heral e de ma re p orte d i n earlier st u dies. T he 
me dia n c ha n ge i n L V E F at Wee k 4 was 1. 2 perce nta ge p oi nts, a n d t he i n di vi d ual c ha n ge fr o m 
baseli ne ra n ge d fr o m – 2 0 t o + 1 9 perce nta ge p oi nts. A d verse e ve nts of ejecti o n fracti o n decrea se d, 
left ve ntric ular d ysf u ncti o n, or ve ntric ular d ysf u ncti o n were re p orte d i n a t otal of 5 patie nts ( 3. 3 %) 
recei vi n g sel u meti ni b (i ncl u di n g 1 patie nt w h o ha d s witc he d fr o m te m oz ol o mi de treat me nt after 
disease pr o gressi o n) vers us 1 patie nt ( 1 %) i n t he c o m p arat or gr o u p. 
 
•  Re vie w of cli nical la b orat or y para meters i n p hase II m o n ot hera p y st u dies i de ntifie d a tre n d t o war d 
i ncrease d ala ni ne a mi n otra nsferase ( A L T) a n d as partate a mi n otra nsferase ( A S T) le vels after starti n g 
treat me nt wit h sel u meti ni b. A n i ncrease i n ser u m p h os p hate was o bser ve d i n s o me patie nts after 
i nitiati o n of sel u meti ni b, c o m pare d wit h patie nts ra n d o mize d t o c o m parat or treat me nts. T here was a 
tre n d t o war d a s mall mea n decrease i n al b u mi n relati ve t o t he c o m parat or. N o ot her re p orts of 
sel u meti nib -relate d c ha n ges i n la b orat or y para meters were c o nsi dere d t o be of cli nical rele va nce at 
t his ti me. T here was n o e vi de nce of m yel os u p pressi o n or re nal i m pair me nt. 
 
•  A d verse e ve nts relate d t o vis ual f u ncti o n ha ve bee n re p orte d acr oss t he pr o gra m wit h sel u me ti ni b. 
M ost ofte n t here were n o s pecific cli nical fi n di n gs re p orte d fr o m patie nts t hat u n der we nt 
o p ht hal m ol o gical e val uati o n after re p orti n g t he A E of vis ual dist ur ba nce. A Es c o nsiste nt wit h 
ce ntral ser o us reti n o pat h y ha ve bee n re p orte d i n a s mall n u m ber of patie nts recei vi n g treat me nt wit h 
sel u meti ni b, ge nerall y i n c o m bi nati o n wit h ot her a nti-ca ncer a ge nts. 
 9   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
 
•  T here ha ve bee n re p orts of p ne u m o nitis -t y pe e ve nts i n a s mall n u m ber of patie nts recei vi n g 
treat me nt wit h sel u meti ni b. A n ass ociati o n wit h sel u meti ni b has n ot bee n esta blis he d.  
 
•  Wea k ness of nec k e xte ns or m uscles i n c o nj u ncti o n wit h creati ne p h os p h o ki nase ( C P K) i ncreases 
(re versi ble o n treat me nt i nterr u pti o n) ha ve bee n re p orte d i n [ADDRESS_410699] or y t h yr oi d ca ncer patie nts were 
treate d wit h a 4 wee k c o urse of sel u meti ni b 7 5 m g t wice dail y  (t he H y d-S ulfate f or m ulati o n ) t o 
f oll o we d b y 1 3 1I i n a s u bset of patie nts (H o et al., 2 0 1 3 ), all e ve nts attri b ute d t o sel u meti ni b were Gra de 
1 or 2, a n d i ncl u de d fati g ue ( 8 0 %), mac ul o pa p ular ras h ( 7 0 %), ac neif or m ras h ( 2 5 %), ele vati o n i n A S T 
( 7 0 %; all Gra de 1), ele vati o n i n A L T ( 4 5 %; all Gra de 1), diarr hea ( 4 5 %), na usea ( 4 0 %), li m b e de ma 
( 3 0 %), oral m uc ositis ( 3 5 %), c o nsti pati o n ( 2 0 %), h y poal b u mi ne mia ( 1 5 %), decrease d w hite bl o o d cell 
c o u nt ( 1 5 %), face e de ma ( 1 0 %), scal p pai n ( 1 0 %), decrease d platelet c o u nt ( 1 patie nt; Gra de 1), e ye 
dis or der ( 1 patie nt; Gra de [ADDRESS_410700] op pe d), h y perte nsi o n ( 1 patie nt; Gra de 1), peri or bital e de ma ( 1 patie nt; Gra de 1), a n d v o miti n g ( 1 
patie nt, Gra de 1). O ne patie nt w h o was treate d wit h [ADDRESS_410701] o me 5 1 wee ks after 1 3 1I a d mi nistrati o n w hic h s u b se q ue ntl y e v ol ve d i nt o ac ute 
le u ke mia (t his was deter mi ne d t o be u nrelate d t o sel u meti ni b a n d li kel y relate d t o c u m ulati ve R AI 
t o xicit y as well as pre vi o us e xter nal bea m ra diati o n t hera p y).  
 
I n t he o nl y ot her st u d y t o s pecificall y i n vesti gate sel u meti ni b i n differe ntiate d t h yr oi d ca ncer patie nts 
(t he p hase II st u d y of 1 0 0 m g bi d sel u meti ni b, pre vi o us mi x-a n d-dri n k f or m ulati o n) i n [ADDRESS_410702] u g -relate d A Es i ncl u de d ras h ( 7 7 %), fati g ue ( 4 9 %), diarr hea ( 4 9 %), a n d peri p heral e de ma 
( 3 6 %). Gra de 3 a n d 4 A Es were c o nsiste nt wit h t h ose acr oss t he sel u meti ni b pr o gra m a n d als o i ncl u de d 
ras h ( 1 8 %), fati g ue ( 8 %), diarr hea ( 5 %) a n d peri p heral e de ma ( 5 %). T wel ve patie nts re q uire d d ose 
re d ucti o ns f or re p orte d A Es acr oss t he le n gt h of t he st u d y (t he d urati o n of treat me nt was greater t ha n 1 6 
wee ks f or 6 9 % of patie nts). Si x patie nts ( 1 5 %) disc o nti n ue d treat me nt d ue t o a d verse e ve nts.  
 
Sel u meti ni b is n ot m uta g e nic or clast o ge nic i n vitr o b ut pr o d uce d i ncreases i n micr o n ucleate d , i m mat ure 
er yt hr oc ytes i n m o use b o ne marr o w micr o n ucle us st u dies. I n vesti gat or y st u dies s h o w t hat t his is 
pre d o mi na ntl y via a n a ne u ge nic mec ha nis m w hic h is c o nsiste nt wit h disr u pti o n of n or mal s pi n dle 
f u ncti o n as a c o nse q ue nce of t he k n o w n p har mac ol o gical acti o n of a M E K i n hi bit or. Wit h sel u meti ni b 
H y d -S ulfate, a N O E L of 2 4 m g/ k g/ da y (f or 2 da ys) was esta blis he d f or i n d ucti o n of micr o n uclei, wit h 
plas ma e x p os ures si g nifica ntl y a b o ve t h ose  o bser ve d i n ca ncer patie nts at t he ma xi m u m t olerate d d ose 
of [ADDRESS_410703] of sel u meti ni b M E K i n hi biti o n u p o n 1 3 1I effic acy i n R AI A t hyr oi d 
c a ncers : We h y p ot hesize t hat t he li mite d efficac y of [ADDRESS_410704] t his h y p ot hesis, 
w e will perf or m a t w o -ar m, ra n d o mize d trial i n w hic h patie nts wit h R AI A, rec urre nt/ metastatic t h yr oi d 
 [ADDRESS_410705] u d y is a p pr o pr iate o nl y f or patie nts wit h rec urre nt/ metastatic 
t h yr oi d ca ncer f or w h o m [ADDRESS_410706] o verall res p o nse, pr o gressi o n -free s ur vi val 
( P F S), c ha n ges i n ser u m t h yr o gl o b uli n le vels, a n d safet y/t olera bilit y of eac h of t he treat me nt ar ms.  
 
1. [ADDRESS_410707] ore t he ge n o mic a n d tra nscri pt o mic la n dsca pe of R AI A t u m ors f or 
si g nat ures t hat c orrelate t o t hera pe utic be nefit ac hie ve d i n patie nts wit h R AI -a vi d 
rec urre nt a n d/ or metastatic t h yr oi d ca ncer treate d wit h [ADDRESS_410708] orat or y a nal ysis will i ncl u de c orrelati n g res p o nse t o 
t u m or ge n ot y pes. All t u m ors will be e val uate d f or c o m m o n t h yr oi d ca ncer ge ne 
m utati o ns ( B R A F, R A S, PI K 3 C A, A K T, R E T/ P T C, P A X 8/ P P A R γ). Descri pti ve 
statistics a n d gra p hical tec h ni q ues will be use d t o s u m marize t his data b y treat me nt 
ar m. Gi ve n t he s mall sa m ple size, all t hese a nal yses will be c o nsi dere d h y p ot he sis 
ge nerati n g a n d e x pl orat or y.  
 
2. [ADDRESS_410709] b o or sel u meti ni b f or R AI A rec urre nt a n d/ or metastatic t h yr oi d ca ncer . 
 
2. [ADDRESS_410710] b o or sel u meti ni b f or R AI A rec urre nt a n d/ or metastatic t h yr oi d ca ncer.  
 
2. 2 2  T o c o m pare t he  pr o gressi o n -free s ur vi val of patie nts wit h R AI A rec urre nt a n d/ or 
metastatic t h yr oi d ca ncer treate d wit h [ADDRESS_410711] b o or sel u meti nib.  
 
2. 2 3  T o c o m pare ser u m t h yr o gl o b uli n c ha n ges f or patie nts wit h R AI A rec urre nt a n d/ or 
metastatic t h yr oi d ca ncer treate d wit h [ADDRESS_410712] bo or 
sel u meti ni b f or patie nts wit h R AI-a vi d rec urre nt a n d/ or metastatic t h yr oi d ca ncer.  
 
2. [ADDRESS_410713] b o or 
 1 1   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
sel u meti ni b. 
 
 
 
 
3. 0  P atie nt Eli gi bilit y  
 
3. 1  I ncl usi o n Criteria  
 
3. 1 1  A ge ≥ 1 8 years . 
 
3. 1 2  Dia g n osis of rec urre nt a n d/ or metastatic t h yr oi d ca ncer.  
 
3. [ADDRESS_410714] ol o gical or c yt ol o gical  c o nfir mati o n of t h yr oi d carci n o ma of f ollic ular ori gi n 
(i ncl u di n g pa pi[INVESTIGATOR_5778] y, f ollic ular, or p o orl y differe ntiate d s u bt y pes a n d t heir res pecti ve 
varia nts) .  
 
N O T E : Me d ullar y a n d a na plastic t h yr oi d ca ncers are e xcl u de d. H urt hle cell carci n o ma s 
are e xcl u de d ( defi ne d as ha vi n g a n i n vasi ve t u m or c o m p ose d of  > 7 5 % o nc oc ytic 
( H urt hle) cells lac ki n g t he n uclear feat ures of pa pi[INVESTIGATOR_5778] y carci n o ma, t u m or necr osis, a n d 
mar ke d mit otic acti vit y ). Patie nts wit h o nc oc ytic ( H urt hle cell) varia nts of pa pi[INVESTIGATOR_5778] y 
t h yr oi d carci n o ma (de fi ne d as a t u m or c o m p ose d of a maj orit y of o nc oc ytic ( H urt hle) 
cells ha vi n g t he n uclear feat ures of pa pi[INVESTIGATOR_5778] y carci n o ma ) are eli gi ble t o partici pate.  
 
3. 1 4  R AI -a vi d lesi o n o n a ra di oi o di ne sca n (a dia g n ostic, p ost -t hera p y, or p ost-a blati o n 
sca ns) perf or me d ≤ [ADDRESS_410715] ural disease.   Patie nts wit h meas urea ble 
disease a n d t h ose wit h o nl y n o n -meas urea ble (“ n o n -tar get”) str uct ural disease 
(acc or di n g t o m o difie d R E CI S T v 1. 1 criteria, see Secti o n 1 1. 0) are eli gi ble. 
   
N O T E 1 : M o dificati o n of t he R E CI S T v 1. [ADDRESS_410716] y:  
 
1) it is n ote d t o be R AI -a vi d o n ra di oacti ve i o di ne i ma gi n g ( dia g n ostic or p ost-
t hera p y w h ole b o d y sca ns acce pta ble) a n d it meas ures > 1 c m i n t he l o n g a xis,  
 
2) it is pat h ol o gicall y  pr o ve n t o be i n v ol ve d wit h t h yr oi d ca ncer ( b y c yt ol o g y or 
pat h ol o g y) a n d it meas ures > 1 c m i n t he l o n g a xis,  
 
or  
 
3) its s h ort a xis is > 1. 5 c m w he n assesse d b y C T sca n .   
 
N O T E 2 : Patie nts o nl y wit h bi oc he mical e vi de nce of disease wit h o ut str uct ural 
e vi de nce of ca ncer are n ot  eli gi ble f or t his st u d y.  
 
3. [ADDRESS_410717] y:   
 
1)  u n detecta ble t h yr o gl o b uli n a nti b o d y  
 
A N D  
 1 2   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
 
2) a ser u m t h yr o gl o b uli n of 1 0 n g/ ml or greater i n t he c o nte xt of s u p presse d T S H ( T S H <  
0. 4 mc U/ ml) <  [ADDRESS_410718]  be c o n d ucte d wit h t he sa me t h yr o gl o b uli n assa y.  
 
 
3. 1 7  E C O G Perf or ma nce Stat us ( P S) 0, 1 or 2.  ( F or ms are a vaila ble o n t he A C C R U we b 
site) 
3. 1 8  A ble t o s wall o w a n d retai n orall y -a d mi nistere d me dicati o n wit h n o cli nicall y si g nifica nt 
gastr oi ntesti nal a b n or malities t hat ma y alter a bs or pti o n.  
 
3. 1 9a  T he f oll o wi n g la b orat or y val ues o btai ne d    2 8  d a ys pri or t o ra n d o mizati o n: 
 
•  A bs ol ute ne utr o p hil c o u nt ( A N C) ≥ 1 5 0 0/ m m3 
•  Platelet c o u nt  1 0 0, 0 0 0/ m m3 
•  He m o gl o bi n > 9. 0 g/ d L  
•  T otal bilir u bi n ≤ 1. 5 x u p per li mit of n or mal ( U L N)  
•  As partate tra nsa mi nase ( A S T)  2. 5 x U L N  ( or  5 x  U L N i n prese nce of li ver 
metastases)  
•  Creati ni ne  1. 5 m g/ d L O R calculate d creati ni ne cleara nce of ≥ 5 0  ml/ mi n b y eit her 
t he C oc kcr oft -Ga ult f or m ula  (see bel o w) or 2 4-h o urs uri ne c ollecti o n a nal ysis  
 
 
C oc kcr oft -G a ult E q u ati o n : 
 
Cre ati ni ne cle ar a nce f or m ales =  ( 1 4 0 - a ge)( wei g ht i n k g)  
     ( 7 2)(ser u m cre ati ni ne i n m g/ d L) 
 
Cre ati ni ne cle ar a nce f or fe m ales =  ( 1 4 0 - a ge)( wei g ht i n k g)( 0. 8 5)  
     ( 7 2)(ser u m cre ati ni ne i n m g/ d L) 
 
 
3. [ADDRESS_410719] perf or me d  ≤ 7 da ys pri or t o re gistrati o n  f or w o me n of 
c hil d beari n g p ote ntial o nl y.  
 
3. 1 9 c Pr o vi de i nf or me d writte n c o nse nt.  
 
3. 1 9 d  Willi n g t o ret ur n t o e nr olli n g i nstit uti o n f or f oll o w -u p ( d uri n g t he Acti ve M o nit ori n g 
P hase of t he st u d y).  
 
N ote: D uri n g t he Active M o nit ori n g  P h ase of a st u dy (i.e., active tre at me nt a n d o bserv ati o n), 
p artici p a nts m ust be willi n g t o ret ur n t o t he c o nse nti n g i nstit uti o n f or f oll o w-u p.  
 
 
3. 1 9 e Willi n g t o pr o vi de  ma n dat or y  arc hi val t u m or tiss ue ( bl oc k or mi ni m u m of 3 0 u nstai ne d 
sli des fr o m a pri mar y or rec urre nt/ metastatic t h yr oi d ca ncer) f or c orrelati ve researc h 
p ur p oses (see Secti o n 1 7. 0).  N O T E:  Patie nts wit h less arc hi val t u m or tiss ue a vaila ble 
ma y still be eli gi ble f or t he st u d y after disc ussi o n  wit h A C C R U (refer t o Pr ot oc ol 
Res o urce pa ge) .  Recei pt of arc hi val t u m or tiss ue is n ot re q uire d f or st u d y re gistrati o n 
a n d i nitiati o n of t hera p y.  
 
 1 3   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
3 .1 9 f Willi n g t o pr o vi de ma n dat or y  bl o o d sa m ple s f or c orrelati ve researc h p ur p oses (see 
Secti o n 1 4. 0 ). 
 
 
3. 2  E xcl usi o n Criteria  
 
3. 2 1  1 3 1I t hera p y < 6 m o nt hs pri or t o re gistrati o n. N ote: 1 3 1I a d mi nistere d s olel y f or dia g n ostic 
p ur p oses is n ot  c o nsi dere d 1 3 1I t hera p y. 
 
3. 2 2  E xter nal bea m ra diati o n t hera p y < 2 8 da ys pri or t o re gistrati o n. N ote: Pre vi o us treat me nt 
wit h ra diati o n is all o we d if t he i n vesti gat or j u d ges it will n ot c o m pr o mi se patie nt safet y 
o n t he st u d y.  
 
3. 2 3  Ha vi n g bee n treate d wit h a t otal c u m ulat i ve (lifeti me) 1 3 1I t hera pe utic acti vit y > 8 0 0 m Ci  
(e xcl u di n g 1 3 1I acti vit y a d mi nistere d f or dia g n ostic sca ns) . 
 
3. 2 4  Treat me nt wit h c he m ot hera p y or tar gete d t hera p y (e. g. t yr osi ne ki nase i n hi bit or) < 2 8 
da ys pri or t o re gistrati o n.  
 
3. 2 5  Pri or e x p os ure t o M E K, R A S, or R A F i n hi bit ors ( N ote: pre vi o us e x p os ure t o s orafe ni b 
is all o we d) O R hist or y of h y perse nsiti vit y t o sel u meti ni b, t h yr otr o pi n al p ha 
(T h yr o ge n ™ ), or a n y e xci pie nt a ge nts. 
 
3. 2 6  U nres ol ve d t o xicit y > C T C A E gra de 2 fr o m pre vi o us a nti -ca ncer t hera p y, e xce pt f or 
al o pecia. 
 
3. 2 7  Car diac c o n diti o ns as f oll o ws:  
 
•  U nc o ntr olle d h y perte nsi o n ( B P ≥ 1 5 0/ 9 5 m m H g des pi[INVESTIGATOR_55499] t hera p y)  
•  Left ve ntric ular ejecti o n fracti o n < 5 5 % meas ure d b y ec h ocar di o gra p h y  
•  Atrial fi brillati o n wit h a ve ntric ular rate > [ADDRESS_410720]  
•  S y m pt o matic heart fail ure ( N Y H A gra de II -I V) 
•  Pri or  or c urre nt car di o m y o pat h y  
•  Se vere val v ular heart disease  
•  U nc o ntr olle d a n gi na ( Ca na dia n Car di o vasc ular S ociet y gra de II -I V des pi[INVESTIGATOR_55499] 
t hera p y) 
•  Ac ute c or o nar y s y n dr o me ≤ 6 m o nt hs pri or t o re gistrati o n. 
 
3. 2 8  O p ht hal m ol o gical c o n diti o ns as f oll o ws:   
 
•  I ntra-oc ular press ure > 2 1 m m H g, or u nc o ntr olle d gla uc o ma (irres pecti ve of i ntra -
oc ular press ure)  
•  C urre nt or past hist or y of ce ntral ser o us reti n o pat h y or reti nal vei n occl usi o n  
 
3. 2 9 a S y m pt o matic or u ntreate d le pt o me ni n geal disease, brai n metastasis, or s pi [INVESTIGATOR_1304]  c or d 
c o m pressi o n. 
 
3. 2 9 b  U na ble t o f oll o w a l o w i o di ne diet or re q uiri n g me dicati o n wit h hi g h c o nte nt i n i o di de 
(e. g., a mi o dar o ne). 
 
3. [ADDRESS_410721] ≤ [ADDRESS_410722] u d y e nr oll me nt . 
N O T E: T h ose w h o  ha ve ha d i o di nate d i ntra ve n o us c o ntrast wit hi n t his ti me  fra me ma y 
still be eli gi ble if a uri nar y i o di ne a nal ysis re veals t hat e xcess i o di ne has bee n cleare d 
 1 4   R U 2 4 1 3 0 6 I 
  A d de n d u m 9  
( defi ne d as uri nar y i o di ne d oc u me nte d t o be < 3 0 0 mc g/ da y b y eit her a s p ot uri nar y 
i o di ne or 2 4-h o ur uri nar y i o di ne meas ure me nt).  
 
 
3. [ADDRESS_410723] u d y i n v ol ves a n i n vesti gati o nal a ge nt w h ose 
ge n ot o xic, m uta ge nic a n d terat o ge nic effects o n t he de vel o pi n g fet us a n d ne w b or n are 
u n k n o w n:  
 
•  Pre g na nt w o me n  
•  N ursi n g w o me n  
•  Me n or w o me n of c hil d beari n g p ote ntial w h o are u n willi n g t o e m pl o y a de q uate 
c o ntrace pti o n  
 
[ADDRESS_410724] u d y or 
i nterfere si g nifica ntl y wit h t he pr o per assess me nt of safet y a n d t o xicit y of t he 
prescri be d re gi me ns.  
 
3. 2 9f  I m m u n oc o m pr o mise d patie nts a n d patie nts k n o w n t o be HI V p ositi ve a n d c urre ntl y 
recei vi n g a ntiretr o viral t hera p y. N O T E: Patie nts k n o w n t o be HI V p ositi ve, b ut wit h o ut 
cli nical e vi de nce of a n i m m u n oc o m pr o mise d state, are eli gi ble f or t his trial.  
 
3. [ADDRESS_410725] oris, car diac arr h yt h mia, or ps yc hiatric ill ness/s ocial 
situati o ns t hat w o ul d li mit c o m plia nce wit h st u d y re q uire me nts.  
 
3.  2 9 h  Recei vi n g a n y ot her i n vesti gati o nal a ge nt w hic h w o ul d be c o nsi dere d as a treat me nt f or 
t he pri mar y ne o plas m. ( N O T E: Perf or ma nce of i n vesti gati o nal 1 2 4I P E T/ C T sca ns is 
all o we d pri or t o a n d d uri n g c o n d uct of t his st u d y.)  
 
3.  2 9i  Ot her acti ve mali g na nc y ≤ [ADDRESS_410726] of 
t his trial. E X C E P TI O N S: N o n-mela n otic s ki n ca ncer or carci n o ma -i n-sit u of t he cer vi x. 
N O T E: If t here is a hist or y o f pri or m ali g na nc y, patie nts  m ust n ot be recei vi n g ot her 
s pecific treat me nt (c he m ot hera p y, h or m o nal t hera p y, ra diati o n ) f or t heir ca ncer.  
 
3. [ADDRESS_410727] Sc he d ule  
( Wee k desi g nati o ns ma y c ha n ge if t here are i nterr u pti o ns i n st u d y treat me nts/assess me nts)  
Tests a n d pr oce d ures  ≤ 2 8 d a ys 
pri or t o 
re gistr ati o n
1 2  Pri or t o 
tre at m e nt 
i niti ati o n Wee k 
1  Wee k 
2  Wee k 
3  Wee k 
4  O bser v ati o n 
P h ase : 
[ADDRESS_410728] -
1 3 1I t her a p y  
( +/- 1 w k)  O bser v ati o n P h ase : 
•  [ADDRESS_410729] -1 3 1I t her a p y ( +/- 1 w k) t he n  
•  e ver y 3 m o nt hs ( ± 1 wee k)  u ntil 1 2 m o nt hs 
p ost1 3 1I t her a p y,  
f oll o we d by  
•  e ver y 6 m o nt hs ( ± 2 wee ks) u ntil 2 ye ars ( ± 
3 m o nt hs) p ost r a n d o miz ati o n  
Sel u meti ni b or place b o1    X  X  X  X    
A d here n ce t o l o w i o di ne 
diet2      X  X    
T h yr o ge n ™[ADDRESS_410730] or y a n d e x a m, wt, 
E C O G P S  X   X   X   X1 5  
Hei g ht  X         
P ulse a n d bl o o d press ure  X   X   X     
A d verse e v e nt assess me nt1 6 X   X4 X  X  X  X1 5 X  
He m at ol o g y: C B C/ 
differe ntial  X   X1 3  X  X1 5  
C he mistr y: S G O T ( A S T), 
S G P T ( A L T), al k p h os, T. 
bili, creati ni ne, calci u m, 
p h os, gl uc ose, Na, K  X   
X1 3   X   X1 5  
T S H, free T 4, ser u m 
t h yr o gl o b uli n, 
t h yr o gl o b uli n a nti b o d y1 8 X   
    X1 5  X  
Ra di ol o gic e v al uati o n f or 
disease assess me nt ( C T(s) 
a n d/ or M RI(s))6 
N O I O DI N A T E D 
C O N T R A S T I S 
A L L O W E D 
( R E Q UI R ED)[ADDRESS_410731] (ser u m beta 
H C G)8 X  
   X   
Ma n dat or y researc h  bl o o d 
sa m ple (see Secti o n 1 4. 0)9, 
R  X        
Ma n dat or y arc hi val tiss ue 
c ollecti o n1 0  (see Secti o n 
1 7. 0) X   
      
Patie nt Me dicati o n Diar y 
(A p pe n di x II )[ADDRESS_410732] b o or sel u meti ni b d osi n g/treat me nt s h o ul d be mai ntai ne d f or at least 7 da ys pri or t o a n d 
t hr o u g h o ut a d mi nistrati o n of t hera pe utic 1 3 1I (t his is n ot a re q uire me nt). E xte n din g t he ti me o n place b o or sel u meti ni b (i.e. e xte n di n g 
ti me o n treat me nt a n d/ or i nstit uti n g treat me nt i nterr u pti o ns) a n d/ or resc he d uli n g/re peati n g st u d y assess me nts/ pr oce d ures/treat me nts 
(t h o u g h t hera pe utic 1 3 1I s h o ul d be a d mi nistere d o nl y o nce ) is/are all owe d t o f ulfill t he criteria disc usse d a b o ve at t he i n vesti gat or’s 
discreti o n. T he peri o d of ti me o n place b o or sel u meti ni b (i.e. e xte n di n g ti me o n treat me nt a n d/ or i nstit uti n g treat me nt i nter r u pti o ns) is 
n ot t o e xcee d 8 wee ks.  
2.  Patie nts s h o ul d a d here t o a l o w i o di ne diet f or 5 da ys pri or t o t he start of T h yr o ge n ™ -sti m ulate d a d mi nistrati o n of t hera pe utic 1 3 1I 
pr ocesses. T he l o w i o di ne diet will be c o nti n ue d t hr o u g h 1 da y after 1 3 1I is gi ve n. Please see A p pe n di x III f or details of t he l o w i o di ne 
diet.  
3.  T h yr o ge n ™  0. [ADDRESS_410733] u g a d verse e ve nts s h o ul d be m o nit ore d t hr o u g h o ut t he 
treat me nt. N o f or mal visits are re q uire d f or t hese assess me nts, wit h t he e xce pti o n of Wee k 3 , w hic h is a ma n dat or y visit.  
5.  Patie nts < 7 0 years of a ge will be treate d wit h 1 5 0 m Ci 1 3 1I ( +/- 5 m Ci). Patie nts > 7 0 years of a ge ca n be treate d wit h a 1 3 1I acti vit y fr o m 
1 0 0 m Ci u p t o a n d i ncl u di n g 1 5 0 m Ci ( +/ - 5 m Ci f or 1 0 0 m Ci or 1 5 0 m Ci a d mi nistere d acti vities); f or t hese patie nts, t he acti vit y t o be 
 [ADDRESS_410734] u d y re gistrati o n.  T h o u g h perf or mi n g w h ole bl o o d a n d b o d y 
d osi metr y t o deter mi ne ma xi m u m t olerate d acti vit y ( M T A) is N O T re q uire d, f or ce nters at w hic h t his e val uati o n is d o ne pri or t o 
t hera pe utic [ADDRESS_410735] u d y a d mi nistrati o n ( Wee k 4), l o wer 1 3 1I acti vities t ha n w hat is rec o m men de d here ma y be a d mi nistere d if t he M T A is 
calc ulate d t o be l o wer t ha n t he l o wer li mit of w hat is all o we d per pr ot oc ol or w hat has bee n deter mi ne d t o be gi ve n (f or pati e nts > 7 0 
years of a ge). E x a m ples  (t hese are o nl y a p plica ble i n i nsta nces i n w hic h d osi metr y was perf or me d pri or t o t hera pe utic 1 3 1I 
a d mi nistrati o n): 1) P atie nts < 7 0 ye ars of a ge:  If t he d osi metr y-deter mi ne d M T A val ue is less t ha n 1 5 0 m Ci, t he n a R AI acti vit y less 
t ha n 1 5 0 m Ci ma y be a d mi nistere d; 2) P atie nts > 7 0 ye ars of a ge: If t he d osi metry -deter mi ne d M T A val ue is less t ha n t he acti vit y t hat 
was deter mi ne d t o be gi ve n at t he ti me of st u d y re gistrati o n, t he n a l o wer R AI acti vit y ma y be a d mi nistere d, e ve n acti vities less t ha n 1 0 0 
m Ci if t he M T A is bel o w t his t hres h ol d. D osi metr y ca n N O T be us e d t o j ustif y a d mi nisteri n g t hera pe utic 1 3 1I acti vities hi g her t ha n 
w hat has bee n rec o m me n de d per t his pr ot oc ol.  A d mi nistrati o n of T h yr o ge n ™  a n d/ or t hera pe utic 1 3 1I at a facilit y ot her t ha n t he 
partici pati n g site is all o we d if d oc u me ntati o n of t he dates a n d a m o u nt/acti vit y of dr u g /ra di ois ot o pe a d mi nistere d is pr o vi de d t o verif y 
a d here nce t o pr ot oc ol re q uire me nts. Perf or ma nce of p ost -t hera p y i o di ne sca ns is n ot re q uire d, b ut is all o we d per i nstit uti o nal practice. 
6.  C T(s) WI T H O U T C O N T R A S T (refer t o f o ot n ot e 1 4) a n d/ or M RI(s) f or t u m or(s) assess me nt is/are t o be d o ne pri or t o st u d y re gistrati o n, 
a b o ut 3 m o nt hs ( +/ - 1 wee k)  after 1 3 1I t hera p y, a n d t he n e ver y 3 m o nt hs ( +/ - 1 wee k) . After [ADDRESS_410736]-1 3 1I t hera p y, f oll o w u p sca ns 
are t o be d o ne e ver y 6 m o nt h s ( +/- 1 wee k) f or a ma xi m u m of 2 years ( +/ - 3 m o nt hs) fr o m st u d y ra n d o mizati o n. T he sc he d ule of 
ra di o gra p hic assess me nts ma y be altere d i n or der t o mai ntai n t he t u m or assess me nt i nter vals detaile d here i n t he e ve nt u nsc hed ule d 
assess me nts are perf or me d. E ver y eff ort m ust be ma de t o ha ve t he [ADDRESS_410737] -1 3 1I t hera p y assess me nt(s) perf or me d. 
7.  O p ht hal m ol o gical e xa mi nati o n s h o ul d be perf or me d b y a n o p ht hal m ol o gist a n d i ncl u de best c orrecte d vis ual ac uit y, i ntra oc ular press ure 
meas ure me nt, slit -la m p f u n d usc op y. O C T sca n s h o ul d be c o nsi dere d o nl y if dee me d cli nicall y a p pr o priate. It is rec o m me n de d t hat 
patie nts wit h o n g oi n g reti nal a b n or malit y at t he ti me of disc o nti n uati o n of Sel u meti ni b or place b o s h o ul d ha ve a f oll o w -u p 
o p ht hal m ol o gical assess me nt a p pr o xi ma tel y [ADDRESS_410738] u g/ place b o disc o nti n uati o n (t he p ur p ose of t his is t o d oc u me nt re versi bilit y, 
b ut s h o ul d o nl y be c o nsi dere d if t he patie nt is fit e n o u g h t o ha ve t he assess me nt d o ne).  
8.  F or w o me n of c hil d beari n g p ote ntial o nl y. M ust be d o ne  [ADDRESS_410739] will be perf or me d ≤ 2 da ys pri or t o a d mi nistrati o n of t he 1 3 1I. 
9.  C ollecti o n of 1 0 ml of bl o o d (i n la ve n der t o p t u be wit h E D T A) f or researc h p ur p oses s h o ul d n ot be c ollecte d a n d s u b mitte d u nt il after  
t he patie nt is re gistere d o nt o t he st u d y, b ut pri or  t o t he i nitiati o n of place b o or sel u meti ni b t hera p y (see Secti o n 1 4. 3). 
1 0.  ≤ 6 0 da ys fr o m re gistrati o n. N O T E: Recei pt of arc hi val t u m or tiss ue is n ot re q uire d f or st u d y re gistrati o n a n d i nitiati o n of t hera p y.  
[ADDRESS_410740] be d oc u me nte d i n t he me dical rec or d b y a n y me m ber of t he care tea m.  
1 2.  “ Pre-re gistrati o n assess me nts” nee d t o be c o m plete d ≤ [ADDRESS_410741] b o or sel u meti ni b. T hese tests d o n ot nee d t o be re pea te d if t he 
pre -re gistrati o n bl o o d w or k was perf or me d < [ADDRESS_410742] (e. g. O m ni pa q ue) be a v oi de d d uri n g scree ni n g a n d pri or t o R AI (alter nati ves s uc h as bari u m or 
ot her a ge nts ma y be use d), b ut t his is n ot  a re q uire me nt. I o di nate d i ntra ve n o us a n d oral c o ntrast f or ra di ol o gic e val uati o ns i n t he 
O bser vati o n P hase is all o we d.  
 [ADDRESS_410743] u g.  
 
 
1 7.  If a n o n g oi n g re d ucti o n i n left ve ntric ular ejecti o n fracti o n of > 1 0 % a n d t o be l o w 5 5 % at ti me of sel u meti ni b or place b o disc o nti n uati o n 
is n ote d, t he n a f oll o w-u p ec h ocar di o gra m, si n gle E C G, a n d vital si g n assess me nt s h o ul d be c o nsi dere d a p pr o xi matel y [ADDRESS_410744] u g/ place b o disc o nti n uati o n.  
1 8.  F or patie nts wit h n o n -meas urea ble/ n o n -tar get lesi o ns a n d l y m p h n o des, ser u m T G meas ure d i n t he c o nte xt of T S H s u p pressi o n ( T S H <  
0. 4 mc U/ ml) will be use d as part of disease res p o nse assess me nt.  F or t he pri mar y e n d p oi nt, ser u m T G m ust be assesse d wit h T S H <  0. 4 
mc U/ ml at baseli ne ( pre -treat me nt) a n d at t he 6-m o nt h assess me nt of res p o nse ( 6 m o nt hs s/ p R AI).  F or all ot her meas ure me nts of ser u m 
T G i n t hese patie nts, it is preferre d t hat t he T S H <  0. 4 mc U/ ml, b ut it is n ot a n a bs ol ute re q uire me nt.  If t he 6-m o nt h ser u m T G is 
i nitiall y meas ured i n t he c o nte xt of a T S H > 0. 4 mc U/ ml, t he n e ver y eff ort s h o ul d be ma de t o re peat t his assess me nt u ntil a ser u m T G 
val ue is o btai ne d i n t he c o nte xt of a T S H < 0. 4 mc U/ ml, e ve n if it re q uires o btai ni n g t he meas ure me nt o utsi de of t he pr ot oc ol -defi ne d +/ - 
1 wee k wi n d o w.  Ser u m T G val ues t hat ha ve t o be o btai ne d o utsi de t his pr ot oc ol -defi ne d wi n d o w t o e ns ure it is meas ure d i n t he c o nte xt 
of T S H < 0. 4 mc U/ ml will still be use d f or t he pri mar y assess me nt of res p o nse.  I M P O R T A N T: Use of a n y t h yr o gl o b uli n assa y is 
allo we d, t h o u g h all ser u m t h yr o gl o b uli n meas ure me nts f or st u d y p ur p oses m ust  be c o n d ucte d wit h t he sa me t h yr o gl o b uli n assa y.  T hese 
re q uire me nts d o n ot  a p pl y t o patie nts wit h meas urea ble disease.  
R  “ Researc h f u n de d” (see Secti o n 1 9. 0)  
 
* N ote:  O bserv ati o n P h as e: P art of t he Active M o nit ori n g P h ase of a st u dy. T he ti me peri o d f oll o wi n g t he active tre at me nt p h ase w he n 
t he p artici p a nt c o nti n ues t o receive cycles of ev al u ati o n i n c o m pli a nce wit h t he Test Sc he d ule a n d m ay be re q uire d t o ret ur n t o 
t he c o nse nti n g site. P artici p a nts will be re q uire d t o ret ur n t o t he c o nse nti n g site f or f oll o w -u p.  
 
 
  
 [ADDRESS_410745] ors:  
 
T his P hase [ADDRESS_410746] u d y will c o m pare ra di oacti ve i o di ne ( R AI) i n c o m bi nati o n wit h place b o or 
sel u meti ni b f or t he treat me nt of R AI-a vi d recurre nt/ metastatic t h yr oi d ca ncers. A 1: 1 ra n d o mizati o n will 
be use d, w here t he P oc oc k -Si m o n al g orit h m ( P oc oc k SJ et al, 1 9 7 5) will be use d t o bala nce t he ar ms 
wit h res pect t o t he f oll o wi n g stratificati o n fact ors, al o n g wit h t he re gisteri n g me m bers hi p:  
 
•  Pri or t h yr oi d ca ncer treat me nt wit h s yste mic c he m ot hera p y a n d/ or m olec ularl y tar gete d i n hi bit ors: 
Yes vs. N o  
•  A ge ≥ 7 0 years : Yes vs. N o 
•  B o ne Metastases prese nt: Yes vs. N o  
•  Pre vi o us [ADDRESS_410747] u d y: Yes vs. N o 
•  Meas urea ble disease (as defi ne d b y t his pr ot oc ol): Yes or N o  
 
6. 0  Re gistr ati o n/ R a n d o miz ati o n Pr oce d ures  
 
6. 1  Re gistrati o n Pr oce d ures  
 
6. 1 1  T o re gister a patie nt, access t he A C C R U we b pa ge at w w w.accr u. or g , g o t o t he 
A p plicati o n secti o n a n d clic k o n “re gistrati o n” a n d e nter t he re gistrati o n/ra n d o mizati o n 
a p plicati o n. T he re gistrati o n/ra n d o mizati o n a p plicati o n i s a vaila ble 2 4 h o urs a da y, 7 da ys 
a wee k. Bac k u p a n d/ or s yste m s u p p ort c o ntact i nf or mati o n is a vaila ble o n t he We b site. 
If u na ble t o access t he We b site, call t he Aca de mic a n d C o m m u nit y Ca ncer Researc h 
U nite d ( A C C R U) Re gistrati o n Office at  bet wee n t he h o urs of 8 a. m. a n d 
4: 3 0 p. m. Ce ntral Ti me ( M o n da y t hr o u g h Fri da y).  
 
Instr ucti o ns f or t he re gistrati o n/ra n d o mizati o n a p plicati o n are a vaila ble  o n t he a b o ve we b 
pa ge u n der t he St u d y Res o urces secti o n, “ A p plicati o n Trai ni n g.”   
 
Pri or t o i nitiat i o n of pr ot oc oli nter ve nti o n, t his pr ocess m ust be c o m plete d i n its e ntiret y 
a n d a n  A C C R U  s u bject I D n u m ber m ust be a vaila ble as n ote d i n t he i nstr ucti o ns. It is t he 
res p o nsi bilit y of t he i n di vi d ual a n d i nstit uti o n re gisteri n g t he patie nt t o c o nfir m t he 
pr o cess has bee n s uccessf ull y c o m plete d pri or t o release of t he st u d y a ge nt. Patie nt 
re gistrati o n via t he re gistrati o n/ra n d o mizati o n a p plicati o n ca n be c o nfir me d i n a n y of t he 
f oll o wi n g wa ys: 
 
•  C o ntact t he A C C R U  Re gistrati o n Office . If t he patient was f ull y 
re gistere d, t he A C C R U Re gistrati o n Office staff ca n access t he i nf or mati o n fr o m 
t he ce ntralize d data base a n d c o nfir m re gistrati o n. 
•  Refer t o w w w.accr u. or g; clic k o n “ Re gistrati o n, I nstallati o n & E ntr y I nstr ucti o ns.  
6. [ADDRESS_410748] u d y, t he patie nt will be 
a ut o maticall y re gistere d o nt o t his c o m p o ne nt (see Secti o ns 3. 1 9c, 3. 1 9 d , 1 4. 1  a n d 1 7.1 ). 
 
6. [ADDRESS_410749] oa de d t hr o u g h t he o nli ne A C C R U 
Re g ulat or y Ma na ge me nt S yste m ( A R M S).  
 
 
I n a d diti o n t o s u b mitti n g i nitial I R B a p pr o val d oc u me nts, o n g oi n g I R B a p pr o val 
  
 [ADDRESS_410750] oa de d t hr o u g h t he o nli ne A C C R U Re g ulat or y Ma na ge me nt S yste m ( A R M S). If t he 
necessar y d oc u me ntati o n is n ot s u b mitte d i n a d va nce of atte m pti n g patie nt re gistrati o n, 
t he re gistrati o n will n ot be acce pte d a n d t he patie nt ma y n ot be e nr olle d i n t he pr ot oc ol 
u ntil t he sit uati o n is res ol ve d.  
 
S u b missi o n of a n n ual I R B a p pr o vals t o A C C R U is re q uire d u ntil t he st u d y is cl ose d 
t hr o u g h y o ur I R B. 
 
6. 1 4  Pri or t o acce pti n g t he re gistrati o n/ra n d o mizati o n, t he re gistrati o n/ra n d o mizati o n 
a pplicati o n will verif y t he f oll o wi n g:  
 
•  I R B a p pr o val at t he re gisteri n g i nstit uti o n 
•  Patie nt eli gi bilit y  
•  E xiste nce of a si g ne d c o nse nt f or m  
•  E xiste nce of a si g ne d a ut h orizati o n f or use a n d discl os ure of pr otecte d healt h 
i nf or mati o n 
 
6. 1 5  At t he ti me of re gistr ati o n, t he f oll o wi n g will be rec or de d:  
 
•  Patie nt has/ has n ot gi ve n per missi o n t o st ore a n d use his/ her sa m ple(s) f or f ut ure 
researc h t o lear n a b o ut, pre ve nt, or treat ca ncer. 
•  Patie nt has/ has n ot gi ve n per missi o n t o st ore a n d use his/ her sa m ple(s) f or f ut ure  
researc h t o lear n, pre ve nt, or treat ot her healt h pr o ble ms (f or e xa m ple: dia betes, 
Alz hei mer’s disease, or heart disease).  
•  Patie nt has/ has n ot gi ve n per missi o n f or A C C R U  t o gi ve his/ her sa m ple(s) t o 
o utsi de researc hers.  
 
6. [ADDRESS_410751] be gi n  7  da ys after re gistrati o n.  
 
6. 1 7  Pretreat me nt tests/ pr oce d ures (see Secti o n 4. 0) m ust be c o m plete d wit hi n t he 
g ui deli nes s pecifie d o n t he test sc he d ule.  
 
6. 1 8  All re q uire d baseli ne s y m pt o ms (see Secti o n 1 0. 5 ) m ust be d oc u me nte d a n d gra de d. 
 
6. [ADDRESS_410752] c o m me nce at a n A C C R U /I T O G i nstit uti o n u n der t he 
s u per visi o n of a me dical o nc ol o gist  or e n d ocri n ol o gist  f or t he a d mi nistrati o n a n d 
ma na ge me nt of place b o/sel u meti ni b t hera p y . C olla b orati o n wit h a n uclear me dici ne 
p h ysicia n will als o be necessar y t o c o or di nate t he c o n d uct a n d a d mi nistrati o n of [ADDRESS_410753] ors bet wee n t he treat me nt 
  
 2 1  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
gr o u ps ( P oc oc k -Si m o n ref –  see bel o w). 
 
•  Ra di oacti ve i o di ne ( R AI) pl us place b o   
•  Ra di oacti ve i o di ne pl us sel u meti ni b  
 
6. [ADDRESS_410754] y will be la bele d wit h: 
 
•  T he st u d y pr ot oc ol n u m ber (i.e., A C C R U R U 2 4 1 3 0 6I)  
•  T he p atie nt st u d y I D n u m ber  
•  T he patie nt’s i nitials  
•  T he n u m ber of ca ps ules  
•  A d mi nistrati o n i nstr ucti o ns (i.e., ‘ A d mi nister as directe d per Pr ot oc ol A C C R U 
R U 2 4 1 3 0 6I’)  
•  Dr u g I de ntificati o n (i.e., Sel u meti ni b [ADDRESS_410755] b o)  
•  E x pi[INVESTIGATOR_1313] o n Date  
•  St ora ge i nstr ucti o ns (“ St ore at c o ntr olle d r o o m te m perat ure, 2 5° C ( 7 7° F)”)  
•  Date dis pe nse d  
•  I N D ca uti o n state me nt a n d/ or l ocal re g ulat or y state me nts 
•  E mer ge nc y c o ntact i nstr ucti o ns  
 
6. 3 3  Please see secti o n 1 5 . 1 8 f or m ore i nf or mati o n o n h o w t o re-or der m ore s u p plies, if 
nee de d.  
  
 2 2  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
7. 0  Pr ot oc ol Tre at me nt  
 
( Ple ase refer t o t he t a ble i n Secti o n 4. 0 f or sc he d ule of all pr ot oc ol tre at me nts a n d assess me nts) 
 
7. [ADDRESS_410756] b o *  7 5 m g  P O  BI D  N o ne  
T h yr o ge n ™  0. 9 m g  I M Dail y f or 2 da ys pri or 
t o R AI f or t hera p y  
R AI (1 3 1I) 1 0 0 -1 5 0 m Ci * *  P O  O nce  N o ne  
*  T he t wice dail y d oses of sel u meti ni b s h o ul d be sc he d ule d 1 2 h o urs a part ( +/ - 2 h o urs). 
If a partici pa nt misses a sc he d ule d d ose b y m ore t ha n [ADDRESS_410757] b o t o ma ke u p misse d d oses u nless 
e xte n di n g ti me (i.e. e xte n di n g ti me o n treat me nt a n d/ or i nstit uti n g treat me nt 
i nterr u pti o ns) is dee me d necessar y t o c o m pl y wit h i nstr ucti o ns detaile d bel o w. T he 
peri o d of ti me o n place b o or sel u meti ni b (i.e. t he ti me o n treat me nt i ncl u di n g 
treat me nt i nterr u pti o ns) is n ot t o e xcee d 8 wee ks. 
* *  Patie nts < 7 0 years of a ge will be treate d wit h 1 5 0 m Ci 1 3 1I ( +/- 5 m Ci). Patie nts ≥ 7 0 
years of a ge ca n be treate d wit h a 1 3 1I acti vit y fr o m 1 0 0 m Ci u p t o a n d i ncl u di n g 1 5 0 
m Ci ( +/ - 5 m Ci f or 1 0 0 m Ci or 1 5 0 m Ci a d mi nistere d acti vities); f or t hese patie nts, 
t he acti vit y t o be a d mi nistere d m ust be deter mi ne d b y t he i n vesti gat or at t he ti me of 
st u d y re gistrati o n. T h o u g h perf or mi n g w h ole bl o o d a n d b o d y d osi metr y t o deter mi ne 
ma xi m u m t olerate d acti vit y ( M T A) is N O T  re q uire d, f or ce nters at w hic h t his 
e val uati o n is d o ne pri or t o t hera pe utic [ADDRESS_410758] u d y a d mi nistrati o n ( Wee k 4), l o wer 
t hera pe utic 1 3 1I acti vities t ha n w hat is rec o m me n de d here ma y  be a d mi nistere d if t he 
M T A is calc ulate d t o be l o wer t ha n t he l o wer li mit of w hat is all o we d per pr ot oc ol or 
w hat has bee n deter mi ne d t o be gi ve n (f or patie nts >  7 0 years of a ge). E x a m ples  
(t hese are a p plica ble o nl y  i n i nsta nces i n w hic h d osi metr y was perf or me d pri or t o 
t hera pe utic 1 3 1I a d mi nistrati o n): 1) P atie nts < 7 0 ye ars of a ge: If t he d osi metr y-
deter mi ne d M T A val ue is less t ha n 1 5 0 m Ci, t he n a n R AI acti vit y less t ha n 1 5 0 m Ci 
ma y be a d mi nistere d; 2) P ati e nts > 7 0 ye ars of a ge: If t he d osi metr y-deter mi ne d M T A 
val ue is less t ha n t he acti vit y t hat was deter mi ne d t o be gi ve n at t he ti me of st u d y 
re gistrati o n, t he n a l o wer R AI acti vit y ma y be a d mi nistere d, e ve n acti vities less t ha n 
1 0 0 m Ci if t he M T A is bel o w t his t hres h ol d.  D osi metr y ca n N O T  be use d t o j ustif y 
a d mi nisteri n g t hera pe utic 1 3 1I acti vities hi g her t ha n w hat has bee n rec o m me n de d per 
t his pr ot oc ol.   
 
A d mi nistrati o n of T h yr o ge n ™  a n d/ or t hera pe utic 1 3 1I at a facilit y ot her t ha n t he 
partici pati n g site is all o we d if d oc u me ntati o n of t he dates a n d a m o u nt/acti vit y of dr u g 
/ra di ois ot o pe a d mi nistere d is pr o vi de d t o verif y a d here nce t o pr ot oc ol re q uire me nts. 
Perf or ma nce of p ost -t hera p y i o di ne sca ns is n ot re q uire d, b ut is all o we d per 
i nstit uti o nal practice. 
 
 
Pl ace b o or S el u meti ni b 
 
C o nti n u o us d osi n g of place b o or sel u meti ni b  [ADDRESS_410759] b o:  
 
Sel u meti ni b / place b o s h o ul d be ta ke n t wice a da y o n a n e m pt y st o mac h ( 1 h o ur bef ore or 2 h o urs 
after a meal), 1 2 h o urs  ( ± 2 h o urs) a part wit h a glass of water.  
 
•  Patie nts s h o ul d a v oi d e xcessi ve s u n e x p os ure a n d use a de q uate s u nscree n pr otecti o n if s u n 
e x p os ure is a ntici pate d . 
•  Patie nts s h o ul d n ot d o nate bl o o d d uri n g t he st u d y . 
•  U nless cli nicall y i n dicate d, patie nts s h o ul d a v oi d c ha n ges t o, or t he a d diti o n of, c o nc o mita nt 
me dicati o ns, i n partic ular a n y t hat ma y affect t he meta b olis m of sel u meti ni b (e .g ., C YP 1 A 2, 
C Y P 2 C 1 9 or 3 A 4 i n hi bit ors/i n d ucers) . 
 
T he p har mac o ki netics of Sel u meti ni b were i n vesti gate d i n st u d y D 1 5 3 2 C 0 0 0 8 6, c o n d ucte d i n 
t he U K i n v ol vi n g healt h y v ol u nteers of Asia n et h nicit y ( defi ne d as bei n g b or n i n a n Asia n 
c o u ntr y, a n d e x patriate f or n ot l o n ger t ha n 5 years, a n d wit h mater nal a n d pater nal gra n d pare nts 
of Asia n et h nicit y). T he s u bjects w h o recei ve d Sel u meti ni b i n St u d y D 1 5 3 2 C 0 0 0 8 6 were of t he 
f oll o wi n g et h nicities: Ja pa nese, C hi nese, Fili pi n o, Mala y, Mala ysia n, Mal di via n, Si n ga p orea n, 
T hai, I n dia n a n d Viet na mese, a n d it is n ot k n o w n i n t hese gr o u ps w het her Sel u meti ni b e x p os ure 
will be si milar t o Wester n s u bjects or t o s u bjects of t he s pecific Asia n et h nicities i ncl u de d i n 
St u d y D [ADDRESS_410760] u dies of Sel u meti ni b. H o we ver, as it is p ossi ble t hat Asia n s u bjects ma y 
e x perie nce hi g her Sel u meti ni b plas ma e x p os ure (t ha n w o ul d be e x pecte d i n Wester n s u b jects 
recei vi n g t he sa me d ose of sel u meti ni b), t here c o ul d be a p ote ntial f or a hi g her ris k of a d verse 
e ve nts. 
 
T he n u m ber of Asia n patie nts wit h a d va nce d ca ncer w h o ha ve recei ve d treat me nt wit h 
Sel u meti ni b is ver y l o w. E mer gi n g i nf or mati o n fr o m o n g oi n g st u d y D 1 5 3 2 C 0 0 0 6 7 of Ja pa nese 
patie nts recei vi n g sel u meti ni b + d oceta xel f or sec o n d -li ne treat me nt of N S C L C s u g gests t hat 
fe brile ne utr o pe nia ma y occ ur m ore c o m m o nl y i n Ja pa nese patie nts ( 3 of 8 patie nts treate d, 
alt h o u g h c o m parati ve data i n Ja pa nese patie nt s recei vi n g d oceta xel m o n ot hera p y is n ot 
a vaila ble) t ha n mi g ht be pre dicte d fr o m st u dies c o n d ucte d i n Wester n s u bjects.  
 
Patie nts of Asia n et h nicit y are n ot e xcl u de d fr o m st u dies e val uati n g Sel u meti ni b. H o we ver, 
w he n c o nsi deri n g e nr olli n g a n i n di vi d ual of Asia n et h nicit y t o a Sel u meti ni b cli nical st u d y, 
i n vesti gat ors s h o ul d ma ke a cli nical j u d g me nt as t o w het her t he p ote ntial ris k of e x perie nci n g 
hi g her Sel u meti ni b plas ma le vels o ut wei g hs t he p ote ntial be nefit of treat me nt wit h Sel u meti ni b. 
T he Patie nt I nf o r mati o n a n d C o nse nt f or m f or st u dies of Sel u meti ni b i ncl u des i nf or mati o n o n 
t he p ossi bilit y of hi g her Sel u meti ni b plas ma le vels a n d occ urre nce of a d verse e ve nts i n Asia n 
s u bjects t ha n i n s u bjects w h o are n ot of Asia n ori gi n. I n vesti gat ors s h o ul d be a ware o f t he 
p ote ntiall y hi g her ris k of a d verse e ve nts w he n m o nit ori n g patie nts of Asia n et h nicit y recei vi n g 
treat me nt i n cli nical st u dies of Sel u meti ni b. 
 
As re pr o d ucti ve t o xic ol o g y data i n dicate t hat sel u meti ni b has a d verse effects o n e m br y of oetal 
de vel o p me nt a n d s ur vi val at d ose le vels t hat d o n ot i n d uce mater nal t o xicit y i n mice, t he 
f oll o wi n g restricti o ns a p pl y: 
 
Sel u meti ni b / place b o s h o ul d n ot be a d mi nistere d t o pre g na nt or breast-fee di n g w o me n a n d 
c o nce pti o n w hile o n treat me nt m ust be a v oi de d. Fe male patie nt s of c hil d-beari n g p ote ntial will 
be re q uire d t o use relia ble met h o ds of c o ntrace pti o n f or t he d urati o n of t he st u d y a n d u ntil 
  
 [ADDRESS_410761] d ose of Sel u meti ni b . Of n ote, patie nts ma y be re q ueste d t o mai ntai n 
c o ntrace pti o n a n d a v oi d pre g na nc y f or a l o n ger peri o d of ti me after 1 3 1I a d mi nistrati o n 
acc or di n g t o i nstit uti o nal g ui deli nes.  
 
Male patie nts wit h se x ual part ners w h o are pre g na nt or w h o c o ul d bec o me pre g na nt (i .e., 
w o me n of c hil d -beari n g p ote ntial) s h o ul d use acce pta ble met h o ds of c o ntrace pti o n f or [ADDRESS_410762] d ose  of sel u meti ni b / place b o t o a v oi d pre g na nc y a n d/ or p ote ntial a d verse effects o n 
t he de vel o pi n g e m br y o. Of n ote, patie nts ma y be re q ueste d t o mai ntai n c o ntrace pti o n a n d a v oi d 
pre g na nc y f or a l o n ger peri o d of ti me after 1 3 1I a d mi nistrati o n acc or di n g t o i nstit uti o nal 
g ui deli nes.  
 
S el u meti ni b / place b o ca ps ules c o ntai n vita mi n E i n t he f or m of D -α - T oc o p her yl p ol yet h yle ne 
gl yc ol 1 0 0 0 s ucci nate ( T P G S ), a water-s ol u ble f or m of vita mi n E w hic h acts as a f or m ulati o n  
e xci pie nt . T he ma xi m u m dail y d ose of vita mi n E t hat a st u d y s u bject ma y recei ve fr o m 
sel u meti ni b/ place b o is a p pr o xi matel y 2 6 1. 6 m g/ da y. T heref ore:  
 
Patie nts s h o ul d n ot ta ke a n y s u p ple me ntal vita mi n E. Hi g h d oses of vita mi n E ha ve bee n 
re p orte d t o ca use blee di n g a n d i nterr u pt bl o o d c oa g ulati o n pr ocesses. 
 
Sel u meti ni b/ place b o s h o ul d be a d mi nistere d wit h ca uti o n i n patie nts w h o are als o rece i vi n g 
c o nc o mita nt C o u ma di n  a ntic oa g ula nt me dicati o ns, e. g. warfari n. T hese patie nts s h o ul d ha ve 
t heir I N R m o nit ore d/a ntic oa g ulati o n assess me nts c o n d ucte d m ore fre q ue ntl y a n d t he d ose of t he 
a ntic oa g ula nt s h o ul d be a dj uste d acc or di n gl y.  
 
1 3 1I T her a p y 
Patie n ts < 7 0 years of a ge will be treate d wit h 1 5 0 m Ci 1 3 1I ( +/- 5 m Ci). Patie nts > 7 0 years of 
a ge ca n be treate d wit h 1 3 1I acti vit y fr o m 1 0 0 m Ci u p t o a n d i ncl u di n g 1 5 0 m Ci ( +/ - 5 m Ci f or 
1 0 0 m Ci or 1 5 0 m Ci a d mi nistere d acti vities); f or t hese patie nts, t he acti vit y t o be a d mi nistere d 
m ust be deter mi ne d b y t he i n vesti gat or at t he ti me of st u d y re gistrati o n.  
 
T hese 1 3 1I acti vities are wit hi n t he 1 0 0 -2 0 0 m Ci ra n ge f or e m pi[INVESTIGATOR_29121]  R AI treat me nt of metastatic 
t h yr oi d ca ncer rec o m me n de d b y t he 2 0 1 5 A merica n T h yr oi d Ass oc iati o n ( A T A) g ui deli nes  
( Ha u ge n et al, 2 0 1 5) All o wi n g acti vities < 1 5 0 m Ci f or patie nts > 7 0  years of a ge  as detaile d 
a b o ve  ac k n o wle d ge s t hat t he 1 3 1I ma xi m u m t olera ble acti vit y ( M T A) te n ds t o decli ne a m o n g t he 
el derl y p o p ulati o n ( T uttle et. al., 2 0 0 6); (K ul kar ni et. al, 2 0 0 6).  
 
T h o u g h perf or mi n g w h ole bl o o d a n d b o d y d osi metr y t o deter mi ne ma xi m u m t olerate d acti vit y 
( M T A) is N O T  re q uire d, f or ce nters at w hic h t his e val uati o n is d o ne ( perf or me d d uri n g t he 
st u d y or wit hi n [ADDRESS_410763] u d y e nr oll me nt), l o wer t hera pe utic  1 3 1I acti vities t ha n w hat is 
rec o m me n de d here ma y  be a d mi nistere d if t he M T A is calc ulate d t o be l o wer t ha n t he l o wer 
li mit of w hat is all o we d per pr ot oc ol (i.e. f or patie nts wit h M T A val ues < 1 5 0 m Ci f or patie nts 
< 7 0 years of a ge or < 1 0 0 m Ci f or  patie nts >  7 0 years of a ge).  D osi metr y ca n N O T  be use d t o 
j ustif y a d mi nisteri n g t hera pe utic [ADDRESS_410764] -t hera p y i o di ne sca ns is n ot re q uire d, b ut certai nl y all o we d per 
i nstit uti o nal practice. 
 
A d mi nistrati o n of T h yr o ge n ™  a n d/ or t hera pe utic 1 3 1I at a facilit y ot her t ha n t he partici pati n g 
site is all o we d if d oc u me ntati o n of t he dates a n d a m o u nt/acti vit y of dr u g /ra di ois ot o pe 
a d mi nistere d is pr o vi de d t o verif y a d here nce t o pr ot oc ol re q uire me nts.  
 
A n y f or m of oral 1 3 1I (e. g., ca ps ule or li q ui d) is all o we d o n t he trial. 
 
  
 [ADDRESS_410765] ret ur n t o t he c o nse nti n g A C C R U i nstit uti o n f or  e val uati o n 
d uri n g treat me nt a n d d uri n g o bser vati o n ( Acti ve M o nit ori n g P hase)  acc or di n g t o t he ta ble i n 
Secti o n 4. [ADDRESS_410766] or : A d mi nistrati o n of T h yr o ge n ™ a n d/ or t hera pe utic 1 3 1I at a 
facilit y ot her t ha n t he partici pati n g site is all o we d if d oc u me ntati o n of t he dates a n d 
a m o u nt/acti vit y of dr u g /ra di ois ot o pe a d mi nistere d is pr o vi de d t o verif y a d here nce t o pr ot oc ol 
re q uire me nts. 
 
7. [ADDRESS_410767] u dies  
 
T he treat me nt c o de ca n n ot be br o ke n e xce pt i n t he e ve nt of a n e mer ge nc y f or a n i n di vi d ual 
patie nt.  
 
I n t he e ve nt of a n e mer ge nc y, call t he A C C R U Re gistrati o n Office at  t o brea k 
t he c o de o n M o n da y t hr o u g h Fri da y, 8: 0 0 a. m. t o 4: [ADDRESS_410768] u d y. T hat is, 
after t he patie nt has bee n f ull y e val uate d a n d all e val uati o n i nf or mati o n has bee n rec or de d b y 
t he atte n di n g p h ysicia n a n d t he patie nt (if a p pr o priate), t he A C C R U Re gistrati o n Office ma y be 
calle d t o fi n d o ut w hic h st u d y t hera p y t he patie nt was recei vi n g.  
 
 
 
 
8. [ADDRESS_410769] partl y ca usal t o t he a d mi nistrati o n of 
sel u meti ni b, t he f oll o wi n g d ose m o dificati o n g ui da nce s h o ul d be a p plie d. 
 
A L E R T : A D R re p orti n g m ay be re q uire d f or s o me a dverse eve nts ( See Secti o n 1 0) 
 
8. 1  D ose Le vels ( Base d o n A d verse E ve nts i n Secti o n 8. 2)  
 
D ose 
Le vel  Sel u meti ni b  
0 7 5 m g P O BI D  
-1  5 0 m g P O BI D  
D ose le vel 0 refers t o t he s tarti n g d ose. 
 
8. 2  G ui deli nes f or D ose M o dificati o ns/I nterr u pti o ns  
 
F or a d verse e ve nts ( A Es) t hat are c o nsi dere d at least partl y d ue t o a d mi nistrati o n of sel u meti ni b 
  
 2 6  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
t he f oll o wi n g d ose re d ucti o n/a dj ust me nt g ui da nce ma y be a p plie d: 
 
Treat me nt wit h sel u meti n i b/ place b o s h o ul d be te m p oraril y i nterr u pte d if o ne of t he f oll o wi n g 
a d verse e ve nts occ urs des pi[INVESTIGATOR_040] o pti m al s u p p orti ve c are : 
 
•  A n y i nt olera ble a d verse e ve nt re gar dless of gra de  
•  A n y a d verse e ve nts ≥ C T C A E Gra de 3 ( des pi[INVESTIGATOR_040] o pti mal s u p p orti ve care)  (e xce pti o n : 
patie nts wit h >  Gra de [ADDRESS_410770] u d y treat me nt at t he sa me d ose le vel wit h o ut 
i nterr u pti o n base d u p o n i n vesti gat or j u d g me nt).  
 
O n i m pr o ve me nt of t he a d verse e ve nt t o C T C A E gra de 1 ( or t o C T C A E gra de 2 f or ras h) or 
baseli ne, sel u meti ni b ma y be restarte d at t he sa me d ose or ma y be re d uce d  as descri be d i n  
 
secti o n 8. 1 at t he discreti o n of t he i n vesti ga t or.  O ne  d ose re d ucti o n is all o we d bef ore 
per ma ne nt disc o nti n uati o n of t hera p y.  
 
•  If a f urt her e pis o de of t he sa me A E s u bse q ue ntl y re q uires d ose i nterr u pti o n, sel u meti ni b 
ma y be restarte d at t he ne xt d ose le vel d o w n o n i m pr o ve me nt of t he A E . 
•  If a differe nt  A E  s u bse q ue ntl y re q uires d ose i nterr u pti o n, sel u meti ni b ma y be restarte d at 
t he sa me d ose or at t he ne xt d ose le vel d o w n o n i m pr ove me nt of t he A E . 
•  Sel u meti ni b s h o ul d n ot be re -escalate d t o a n earlier d ose le vel o n i m pr o ve me nt of a n A E.  
•  I deall y, place b o or sel u meti ni b d osi n g/treat me nt s h o ul d be mai ntai ne d f or at least 7 da ys 
pri or t o a n d t hr o u g h o ut a d mi nistrati o n of t hera pe utic 1 3 1I; h o we ver, t his is n ot a 
re q uire me nt. If necessar y, st u d y pr oce d ures a n d/ or 1 3 1I t hera p y ma y be resc he d ule d/re peate d 
(1 3 1I t hera p y s h o ul d be a d mi nistere d o nl y o nce ) at t he discreti o n of t he i n vesti gat or t o 
ac hie ve t his.  E xte n di n g t he ti me o n place b o or sel u meti ni b  (i.e. e xte n di n g ti me o n treat me nt 
a n d/ or i nstit uti n g treat me nt i nterr u pti o ns)  a n d/ or resc he d uli n g pr ot oc ol 
assess me nts /treat me nts is all o we d i n or der t o c o m pl y wit h t his a p pr oac h at t he 
i n vesti gat or’s discreti o n. 
•  T he peri o d of ti me o n  place b o or sel u meti ni b (i.e. e xte n di n g ti me o n treat me nt a n d/ or 
i nstit uti n g treat me nt i nterr u pti o ns) is n ot t o e xcee d 8 wee ks. 
•  N O T E: missi n g less t ha n [ADDRESS_410771] b o or sel u meti ni b f or reas o ns ot her t ha n t o xicit y 
will n ot be c o nsi dere d a vi olati o n of t he pr ot oc ol.  
 
9. 0  A ncill ar y Tre at me nt/ S u p p orti ve C are  
 
All ma na ge me nt of a d verse e ve nts is left t o t he I n vesti gat or’s discreti o n. A p pe n di x I V i ncl u des 
g ui deli nes f or t he ma na ge me nt of s o me c o m m o n sel u meti ni b -relate d a d verse e ve nts. C o m plia nce wit h 
t h ose g ui deli nes is rec o m me n de d, b ut n ot re q uire d. 
 
9. [ADDRESS_410772] ors: A n E vi de nce -Base d Cli nical Practice G ui deli ne. J 
Cli n O nc ol 2 0 0 6; 2 4: [ADDRESS_410773] 
s u p p ort, a nti bi otic treat me nt, a n d treat me nt of ot her ne wl y dia g n ose d or c o nc urre nt me dical 
  
 2 7  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
c o n diti o ns. All bl o o d pr o d ucts a n d c o nc o mita nt me dicati o ns s uc h as a nti diarr heals, 
a nal gesics, a n d/ or a ntie metics recei ve d fr o m t he first da y of st u d y treat me nt a d mi nistrati o n 
u ntil 3 0 da ys after t h e fi nal d ose will be rec or de d i n t he me dical rec or ds.  
 
9. 4  Ras h : earl y i nitiati o n of treat me nt f or ras h is str o n gl y rec o m me n de d t o mi ni mize  t he d urati o n 
a n d se verit y of t he a d verse e ve nt. All patie nts s h o ul d be gi ve n e m ollie nt crea m t o ta ke h o me f or 
pr o p h y lactic use o nce  st u d y treat me nt has bee n i nitiate d (see A p pe n di x I V). 
 
9. 5  Diarr hea : earl y i nitiati o n of treat me nt f or diarr hea is str o n gl y rec o m me n de d t o mi ni mize t he 
d urati o n a n d se verit y of t he a d verse e ve nt. Treat me nt pr o visi o n will be acc or di n g t o I n v esti gat or 
discreti o n acc or di n g t o l ocal practice a n d re g ulati o ns (see A p pe n di x I V). 
 
9. 6  D ys p nea : ne w or w orse ni n g d ys p nea has bee n re p orte d d uri n g treat me nt wit h sel u meti ni b; 
i n vesti gati o n t o deter mi ne t he u n derl yi n g ca use is rec o m me n de d (see A p pe n di x I V). 
 
9. 7  Re d ucti o n i n L V E F : as y m pt o matic re d ucti o ns i n L V E F ha ve bee n re p orte d i n s o me patie nts 
recei vi n g sel u meti ni b; treat me nt ma y be rec o m me n de d de pe n di n g o n t he ma g nit u de of t he 
L V E F re d ucti o n (see A p pe n di x I V). 
 
9. [ADDRESS_410774] ur ba nces : s y m pt o ms, i ncl u di n g bl urre d visi o n, occ ur c o m m o nl y d uri n g treat me nt 
wit h sel u meti ni b, a n d A Es of ce ntral ser o us reti n o pat h y a n d reti nal vei n occl usi o n ha ve bee n 
re p orte d i n st u dies of ot her M E K i n hi bit ors. I n vesti gati o n t o deter mi ne t he u n derl yi n g ca use of 
vis ual dist ur ba nce is rec o m me n de d, i ncl u di n g o p ht hal m ol o gical e xa mi nati o n. Patie nts wit h a n 
o n g oi n g reti nal a b n or malit y at t he ti me of sel u meti ni b disc o nti n uati o n s h o ul d ha ve a f oll o w-u p 
o p ht hal m ol o gical assess me nt a p pr o xi matel y 2 8 da ys after disc o nti n uati o n. T his assess me nt is 
rec o m me n de d t o d oc u me nt re versi bilit y, b ut s h o ul d be perf or me d o nl y if t he patie nt is fit 
e n o u g h t o ha ve t he assess me nt (see A p pe n di x I V). 
 
E xtra assess me nts are rec o m me n de d f or i n vesti gati o n of s pecific a d verse e ve nts t hat occ ur 
d uri n g treat me nt w it h sel u meti ni b: 
 
 
A d verse e ve nt  Assess me nt  
Cli nic all y si g nific a nt L V E F re d ucti o n 
( b y ≥ 1 0 perce nt a ge p oi nts a n d t o bel o w 
5 5 %)  Si n gle E C G  
Tr o p o ni n le vels (is of or m acc or di n g t o 
i nstit uti o n al n or m) 
C ar di o -res pir at or y A Es of n o n -o b vi o us 
c a use Si n gle E C G  
Tr o p o ni n le vels (is of or m acc or di n g t o 
i nstit uti o n al n or m) 
Ne w or w orse ni n g res pir at or y 
s y m pt o ms (s uc h as d ys p ne a , c o u g h) Si n gle E C G  
 
 
1 0. 0  A d verse E ve nt ( A E) Re p orti n g a n d M o nit ori n g  
 
1 0. 1  A d verse E ve nt C haracteristics  
 
C T C A E ter m ( A E descri pti o n) a n d gr a de:  T he descri pti o ns a n d gra di n g scales f o u n d i n t he 
re vise d N CI C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts ( C T C A E) versi o n 4. 0 will be 
  
 2 8  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
utilize d f or A E re p orti n g. All a p pr o priate treat me nt areas s h o ul d ha ve access t o a c o p y of t he 
C T C A E versi o n 4. 0. A c o p y of t he C T C A E versi o n 4. 0 ca n be d o w nl oa de d fr o m t he C T E P we b 
site: (htt p://cte p.ca ncer. g o v/ pr ot oc ol De vel o p me nt/electr o nic a p plicati o ns/ctc. ht m ) 
 
[ADDRESS_410775], 
i de ntif y a n d gra de t he se verit y of t he e ve nt usi n g t he C T C A E v ersi o n 4. 0 . Ne xt, 
deter mi ne w het her t he e ve nt is e x pecte d or u ne x pecte d (see Secti o n 1 0. 2 ) a n d if t he 
a d verse e ve nt is relate d t o t he me dical treat me nt or pr oce d ure (see Secti o n 1 0. 3).  
Wit h t his i nf or mati o n, deter mi ne w het her t he e ve nt m ust be re p orte d as a n e x pe dite d 
re p ort (see Secti o n 1 0. 4). E x pe dite d re p orts are t o be c o m plete d wit hi n t he 
ti mefra mes a n d via t he mec ha nis ms s pecifie d i n Secti o ns [ADDRESS_410776] als o be re p orte d via t he r o uti ne data re p orti n g 
mec ha nis ms defi ne d b y t he pr ot oc ol (see Secti o ns 1 0. 5 a n d 1 8. 0). 
 
[ADDRESS_410777] Le vel Ter m ( L L T).  
 
N O T E:  A se vere A E, as defi ne d b y t he a b o ve gra di n g scale, is N O T  t he sa me as 
seri o us A E w hic h is defi ne d i n t he ta ble i n Secti o n 1 0. 4.  
 
1 0. 2  E x pecte d vs. U ne x pecte d E ve nts  
 
•  T he deter mi nati o n of w het her a n A E is e x pecte d is base d o n a ge nt -s pecific i nf or mati o n 
pr o vi de d i n Secti o n 1 5. 0 of t he pr ot oc ol.  
•  U ne x pecte d A Es are t h ose n ot liste d i n t he a ge nt -s pecific i nf or mati o n pr o vi de d i n Secti o n 
1 5. 0 of t he pr ot oc ol.  
 
 
N O T E : “ U ne x pecte d a d verse e x perie nces” mea ns a n y a d verse e x perie nce t hat is neit her 
i de ntifie d i n nat ure, se verit y, or fre q ue nc y of ris k i n t he i nf or mati o n p r o vi de d f or I R B 
re vie w n or me nti o ne d i n t he c o nse nt f or m.  
 
1 0. 3  Assess me nt of Attri b uti o n  
 
W he n assessi n g w het her a n a dverse eve nt is rel ate d t o a me dic al tre at me nt or pr oce d ure, t he 
f oll o wi n g attri b uti o n c ate g ories are utilize d: 
 
Defi nite - T he a d verse e ve nt is cle arly rel ate d t o t he a ge nt(s). 
Pr o ba ble - T he a d v erse e ve nt is likely rel ate d t o t he a ge nt(s). 
P ossi ble - T he a d verse e ve nt m ay be rel ate d t o t he a ge nt(s). 
U nli kel y - T he a d verse e ve nt is d o u btf ully rel ate d t o t he a ge nt(s). 
U nrelate d - T he a d verse e ve nt is cle arly N O T rel ate d t o t he a ge nt(s). 
 
E ve nts det er mi ne d t o be p ossi bl y, pr o b a bl y or defi nitel y attri b ute d t o a me dic al 
tre at me nt s u g gest t here is e vi de nce t o i n dic ate a c a us al rel ati o ns hi p bet wee n t he 
dr u g a n d t he a d verse e ve nt.  
 
  
 2 9  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
1 0. 3 1  S p e ci al Sit u ati o ns f o r E x p e dit e d R e p o rti n g   
 
E xce pti o ns t o E x pe dit e d Re p orti n g: E X P E C T E D Seri o us A d verse E ve nts  
 
A n e x pe dite d re p ort ma y n ot be re q uire d f or s pecific Gra de 1, 2 a n d 3 Seri o us 
A d verse E ve nts w here t he A E is E X P E C T E D . A n y pr ot oc ol s pecific re p orti n g 
pr oce d ures M U S T B E S P E CI FI E D B E L O W a n d will s u perse de t he sta n dar d 
E x pe dite d A d verse E ve nt Re p orti n g Re q uire me nts:  
 
S yste m Or ga n Class 
( S O C) A d verse e ve nt/ 
S y m pt o ms  C T C A E Gra de at w hic h 
t he e ve nt will n ot be 
e x pe diti o usl y  re p orte d. 
Ge neral dis or ders a n d 
a d mi nistrati o n site 
c o n diti o ns E de ma face   
<  Gra de 3  E d e ma tr u n k 
Fati g ue  
Fe ver  
S ki n a n d s u bc uta ne o us 
tiss ue dis or ders D r y sk i n 
<  Gra de [ADDRESS_410778] o me 
Res pi[INVESTIGATOR_1305] y, t h oracic 
a n d me diasti nal 
dis or ders  D ys p nea  <  Gra de 3  
E ye dis or ders  Bl urre d visi o n  <  Gra de 3  
Vasc ular dis or ders  H y perte nsi o n  <  Gra de 3  
I n vesti gati o ns Ala ni ne 
a mi n otra nsferase 
i ncrease d <  Gra de 3  As partate 
a mi n otra nsferase 
i ncrease d 
Gastr oi ntesti nal 
dis or ders  Diarr hea  
<  Gra de 3  N a usea 
V o miti n g  
M uc ositis oral  
D r y m o ut h 
I nfecti o ns a n d  
i nfestati o ns Nail i nfecti o n  <  Gra de [ADDRESS_410779] be f oll o we d.  
 
  
 3 0  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
T he f oll o wi n g h os pi[INVESTIGATOR_1314] o ns are n ot c o nsi dere d t o be S A Es beca use t here is  n o 
“a d verse e ve nt” ( i.e., t here is n o u nt o war d me dical occ urre nce) ass ociate d wit h t he 
h os pi[INVESTIGATOR_1314] o n:  
 
•  H os pi[INVESTIGATOR_1314] o ns f or res pi[INVESTIGATOR_4594]  
•  Pla n ne d h os pi[INVESTIGATOR_1314] o ns re q uire d b y t he pr ot oc ol  or t o a d mi nister pr ot oc ol -
directe d treat me nt ( i.e. 1 3 1I t hera p y) 
•  H os pi[INVESTIGATOR_1314] o n pla n ne d bef ore i nf or me d c o nse nt ( w here t he c o n diti o n re q uiri n g 
t he h os pi[INVESTIGATOR_1314] o n has n ot c ha n ge d p ost st u d y dr u g a d mi nistrati o n) 
•  H os pi[INVESTIGATOR_1314] o n f or a d mi nistrati o n of st u d y dr u g or i nserti o n of access f or 
a d mi nistrati o n of st u d y dr u g  
•  H os pi [INVESTIGATOR_1314] o n f or r o uti ne mai nte na nce of a de vice (e. g., batter y re place me nt) 
t hat was i n place bef ore st u d y e ntr y 
 
1 0. 3 1 1  Persiste nt or Si g nific a nt Dis a bilities/I nc a p acities  
A n y A E t hat res ults i n persiste nt or si g nifica nt i nca pacit y or  s u bsta ntial 
disr u pti o n of t he a bilit y t o c o n d uct n or mal life f u ncti o ns (f or merl y referre d 
t o as disa bilities), c o n ge nital a b n or mities or birt h defects, m ust be re p orte d 
i m me diatel y if t he y occ ur at a n y ti me f oll o wi n g treat me nt wit h a n a ge nt 
u n der a n I N D/I D E si nce t he y are c o ns i dere d t o be a seri o us A E a n d m ust be 
re p orte d t o t he s p o ns or as s pecifie d i n 2 1 C F R 3 1 2. 6 4( b). 
 
1 0. 3 1 2  De at h  
 
•  A n y deat h occ urri n g wit hi n [ADDRESS_410780] d ose, re gar dless 
of attri b uti o n t o a n a ge nt/i nter ve nti o n u n der a n I N D/I D E 
re q uires e x pe dite d re p orti n g wit hi n 2 4-h o urs.  
•  A n y deat h occ urri n g greater t ha n 3 0 da ys wit h a n attri b uti o n of 
p ossi ble, pr o ba ble, or defi nite t o a n a ge nt/i nter ve nti o n u n der a n 
I N D/I D E re q uires e x pe dite d re p orti n g wit hi n 2 4-h o urs.  
 
•  Re p o rt a bl e c at e g o ri es of De at h   
 
•  De at h attri b ut a b l e t o a C T C A E t er m. 
•  De at h Ne o n at al: A dis or d er c h ar a ct eri z e d b y c ess ati o n of 
lif e d uri n g t h e first 2 8 d a ys of lif e. 
•  De at h N O S: A c ess ati o n of lif e t h at c a n n ot b e attri b ut e d 
t o a C T C A E t er m ass o ci ate d wit h Gr a d e 5. 
•  S u d d e n d e at h N O S: A s u d d e n ( d efi n e d as i ns t a nt or 
wit hi n o n e h o ur of t h e o ns et of s y m pt o ms) or a n 
u n o bs er v e d c ess ati o n of life t h at c a n n ot b e attri b ut e d t o a 
C T C A E t er m ass o ci at e d wit h Gr a d e 5.  
•  De at h d u e t o pr o gr essi v e dis e as e s h o ul d b e r e p ort e d as 
G r a d e 5 “ Ne o pl as ms b e ni g n , m ali g n a nt a n d 
u ns p e cif i e d (i n cl c ysts a n d p ol y ps) –  Ot h e r 
( P r o g r essi v e Dis e as e) ” u n d er t h e s yst e m or g a n cl ass 
( S O C) of t h e s a m e n a m e. E vi d e n c e t h at t h e d e at h was a 
m a nif est ati o n of u n d erl yi n g dis e as e ( e. g., r a di ol o gi c al 
c h a n g es s u g g esti n g t u m or gr o wt h or pr o gr essi o n: cli ni c al 
d et eri or ati o n ass o ci at e d wit h a dis e as e pr o c ess) s h o ul d b e 
s u b mitt e d. 
  
 3 1  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 
1 0. 3 1 3  Sec o n d ar y M ali g n a nc y  
 
• A sec o n d ary m ali g n a ncy is a ca ncer ca use d b y treat me nt f or a pre vi o us 
mali g na nc y (e. g., treat me nt wit h i n vesti gati o nal a ge nt/i nter ve nti o n, 
ra diati o n or c he m ot hera p y). A sec o n dar y mali g na nc y is n ot 
c o nsi dere d a metastasis of t he i nitial ne o plas m.  
• All sec o n dar y mali g na ncies t hat occ ur f oll o wi n g treat me nt wit h a n 
a ge nt u n der a n I N D/I D E t o be re p orte d. T hree o pti o ns are a vaila ble t o 
descri be t he e ve nt:  
 
o  Le u ke mia s ec o n dar y t o o nc ol o g y c he m ot hera p y (e. g., Ac ute 
M yel oct yic Le u ke mia [ A M L])  
o  M yel o d ys plastic s y n dr o me ( M D S)  
o  Treat me nt -relate d sec o n dar y mali g na nc y 
 
•  A n y mali g na nc y p ossi bl y relate d t o ca ncer treat me nt (i ncl u di n g 
A M L/ M D S) s h o ul d als o be re p orte d via t he r o uti ne re p orti n g 
mec ha nis ms o utli ne d i n eac h pr ot oc ol.  
 
1 0. 3 1 4  Sec o n d M ali g n a nc y  
 
• A sec o n d mali g na nc y is o ne u nrelate d t o t he treat me nt of a pri or 
mali g na nc y (a n d is N O T a metastasis fr o m t he i nitial mali g na nc y). 
Sec o n d mali g na ncies re q uire O N L Y r o uti ne re p orti ng.  
 
  
 3 3  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 
2.  Use t he A C C R U pr ot oc ol n u m ber a n d t he pr ot oc ol -s pecific patie nt I D pr o vi de d 
d uri n g trial re gistrati o n o n all re p or ts. 
 
T he a b o ve e x pe dite d re p orts ( 2 4 -h o ur a n d 3 or 7 da y) m ust be s u b mitte d via t he 
A C C R U A d verse E ve nt E x pe dite d Re p ort F or m . 
 
3.  Ma y o Cli nic Ca ncer Ce nter ( M C C C) I nstit uti o ns:  Pr o vi de c o pi[INVESTIGATOR_014], al o n g wit h t he 
U PI R T S O c o ver s heet, b y fa x t o t he M C C C Re g ulat or y Affairs 
U nit ( R A U) Re g ulat or y Affairs S pecialist , w h o will deter mi ne a n d c o m plete I R B 
re p orti n g. T he R A U will s u b mit t o t he A C C R U S A E C o or di nat or a n d t he 
A C C R U I N D C o or di nat or t o deter mi ne if F D A s u b missi o n is nee de d.  
 
4.  N o n -Ma y o A C C R U Sit es : S u b mit re p orts t o A C C R U Safet y via e mail at:  
   
 
O nce A C C R U Safet y r recei ves t he re p ort viae mail , A C C R U Safet y will f or war d 
a c o p y of t he a b o ve e x pe dite d re p orts t o  the  A C C R U I N D C o or di nat or , w h o will 
n otif y t he F D A as warra nte d b y t he e ve nt a n d sti p ulate d i n t he U. S. C o de of 
Fe deral Re g ulati o ns.   
 
Re p orti n g seri o us a d verse e ve nts t o Astra Ze neca  
 
All Seri o us a d verse e ve nts t hat meet t he criteria f or re g ulat or y re p orti n g s h o ul d be 
c o pie d t o Astra Ze neca at t he sa me ti me t hat t he y are re p orte d t o re g ulat or y a ut h orities. 
T he n otificati o n t o Astra Ze neca s h o ul d i ncl u de a c o p y of t he re g ulat or y s u b missi o n a n d 
a c o ver pa ge t hat i n dicates t he f oll o wi n g:  
 
•  “ N otificati o n fr o m a n I n vesti gat or -S p o ns ore d St u d y”  
•  St u d y title a n d refere nce n u m ber ( prefera bl y wit h I S SI S refere nce n u m ber)  
•  I n vesti gat or na me a n d a d dress 
•  I N D n u m ber or e q ui vale nt 
 
N otificati o n t o Astra Ze neca s h o ul d als o i ncl u de t he ca usalit y of e ve nts i n relati o n t o all 
st u d y me dicati o ns a n d if the S A E is relate d t o disease pr o gressi o n, as deter mi ne d b y t he 
pri nci pal i n vesti gat or. T he i n vesti gat or is res p o nsi ble f or i nf or mi n g t he I R B a n d/ or t he 
Re g ulat or y A ut h orit y of t he S A E per l ocal re q uire me nts.   
 
Se n d S A E re p ort a n d acc o m pa n yi n g c o ver pa ge b y wa y of fa x t o Astr a Ze nec a’s 
desi g n ate d f a x li ne:  . 
 
I n t he case of bli n de d trials, Astra Ze neca ma y re q uest t hat t he S p o ns or eit her pr o vi de a 
c o p y of t he ra n d o mizati o n c o de/ c o de brea k i nf or mati o n or u n bli n d t h ose S A Es w hic h 
re q uire e x pe dited re p orti n g.  
 
 
  
 [ADDRESS_410781] b o or Sel u meti ni b s h o ul d be disc o nti n ue d, a n d 
Astra Ze neca s h o ul d be i nf or me d of t he pre g na nc y wit hi n o ne b usi ness da y of t he 
i n vesti gat or or site pers o n nel bec o mi n g a ware of t he pre g na nc y.  
 
T he o utc o me (s p o nta ne o us miscarria ge, electi ve ter mi nati o n, n or mal birt h or c o n ge nital 
a b n or malit y) of all pre g na ncies occ urri n g d uri n g treat me nt wit h place b o or Sel u meti ni b 
m ust be f oll o we d u p a n d d oc u me nte d e ve n if t he p atie nt was disc o nti n ue d fr o m t he 
st u d y. 
 
N O T E: T he Gr a de 4 or 5 N o n -A E R Re p ort a ble E ve nts/ H os pit aliz ati o n F or m is 
n ot bei n g use d f or t his st u d y.  
 
[ADDRESS_410782] 
Sc he d ule ( Secti o n 4. 0 ).  T he C T C A E v 4. 0 gra di n g s h o ul d be use d u nless a n alter nate 
gra di n g met h o d is i n dicate d i n t he ta ble bel o w: 
 
S yste m Or ga n  Class 
( S O C) A d verse e ve nt/  
S y m pt o ms  Baseli ne  Eac h  
e val uati o n Gra di n g scale  
(if n ot C T C A E) 
Ge ne ral dis or ders 
a n d a d mi nistrati o ns  
site c o n diti o ns Fati g ue  X  X   
Wei g ht l oss  X  X   
L ocalize d e de ma  X  X   
Gastr oi ntesti nal 
Dis or ders  Diarr hea  # of st o ols 
per da y  X   
D ys p nea  X  X   
Na usea  X  X   
V o miti n g  X  X   
E ye Dis or ders  Bl urre d visi o n  X  X   
Vasc ular dis or ders  H y perte nsi o n  X  X   
I n vesti gati o ns Ala ni ne 
a mi n otra nsferase 
i ncrease 
 
As partate 
a mi n otra nsferase 
i ncrease X  X   
S ki n a n d 
s u bc uta ne o us tiss ue 
dis or ders  Ras h ac n eif or m  X  X   
Ras h 
mac ul o pa p ular  X  X   
 
 
  
 3 5  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
1 0. 5 2  S u b mit via a p pr o priate Aca de mic a n d C o m m u nit y Ca ncer Researc h U nite d ( A C C R U)  
Case Re p ort F or ms (i.e., pa per or electr o nic, as a p plica ble) t he f oll o wi n g A Es 
e x perie nce d b y a patie nt a n d n ot s pecifie d i n Secti o n 1 0. 5 : 
 
[ADDRESS_410783] u d y treat me nt or 
pr oce d ure.  
 
1 0. 5 2 3  Gra de  5 A Es ( Deat hs)  
 
1 0. 5 2 3 1  A n y deat h wit hi n 3 0 da ys of t he patie nt’s last st u d y treat me nt 
or pr oce d ure re gar dless of attri b uti o n  t o t he st u d y treat me nt or 
pr oce d ure.  
 
1 0. 5 2 3 2  A n y deat h m ore t ha n 3 0 da ys after t he patie nt’s last st u d y 
treat me nt or pr oce d ure t hat is felt t o be at least p ossi bl y 
treat me nt relate d m ust als o be s u b mitte d as a Gra de 5 A E, wit h 
a C T C A E t y pe a n d attri b uti o n assi g ne d.  
 
1 0. 5 3  Refer t o t he i nstr ucti o ns i n t he F or ms Pac ket ( or electr o nic data e ntr y scree ns, as 
a p plica ble) re gar di n g t he s u b missi o n of late occ urri n g A Es f oll o wi n g c o m pleti o n of t he 
Acti ve M o nit ori n g P hase (i.e., c o m plia nce wit h Test Sc he d ule i n Se cti o n 4. 0). 
 
 
1 1. 0  Tre at me nt E v al u ati o n Usi n g R E CI S T G ui deli ne  
 
N O T E: T his st u d y uses pr ot oc ol R E CI S T v 1. 1 te m plate date d 2/ 1 6/ [ADDRESS_410784] u d y usi n g t he ne w i nter nati o nal criteria pr o p ose d 
b y t he re vise d Res p o nse E val uati o n Criteria i n S oli d T u m ors ( R E CI S T) g ui deli nes ( versi o n 1. 1) 
(Eise n ha uer et al., 2 0 0 9 ) wit h s o me m o dificati o ns as detaile d bel o w . 
 
Patie nts wit h meas urea ble t u m ors a n d patie nts wit h o nl y n o n -meas urea ble t u m ors (“ n o n -tar get” disease 
o nl y) are eli gi ble f or e nr oll me nt a n d will ha ve res p o nse assesse d as detaile d bel o w (see Secti o ns 1 1. 4 3 
a n d 1 1. 4 4) . 
 
1 1. 1  Sc he d ule of E val uati o ns: F or t he p ur p oses of t his st u d y, patie nts s h o ul d be  ree val uate d a b o ut 3 
m o nt hs ( +/ - 1 wee k) after 1 3 1I t hera p y a n d the n e ver y 3 m o nt hs ( +/ - 1 wee k).  After [ADDRESS_410785] -treat me nt, sca ns s h o ul d be d o ne e ver y 6 m o nt hs ( +/- 2  wee k s) f or a ma xi m u m of 2 years 
( +/- 3 m o nt hs) fr o m st u d y ra n d o mizati o n.   
 
[ADDRESS_410786] dia meter ca n be 
acc uratel y meas ure d as   ≥ 1. [ADDRESS_410787] dia meter is ≥ 1. 0 
c m i n dia meter as assesse d usi n g cali pers (e. g. s ki n n o d ules) or i ma gi n g. I n 
t he case of s ki n lesi o ns, d oc u me ntati o n b y c ol or p h ot o gra p h y, i ncl u di n g a 
r uler t o esti mate t he size of t he lesi o n, is rec o m me n de d. 
 
1 1. 2 1 3  A mali g na nt l y m p h n o de is c o nsi dere d meas ura ble if  1) it is n ote d t o be R AI -
a vi d o n ra di oi o di ne i ma gi n g ( dia g n ostic or p ost -t hera p y w h ole b o d y sca ns 
acce pta ble) a n d it meas ures > 1 c m i n t he l o n g a xis, 2) it is pat h ol o gicall y 
pr o ve n t o be i n v ol ve d wit h t h yr oi d ca ncer ( b y c yt ol o g y or pat h ol o g y) a n d it 
meas ures > 1 c m i n t he l o n g a xis, or 3) its s h ort a xis is > 1. 5 c m w he n assesse d 
b y C T sca n ( C T sca n slice t hic k ness rec o m me n de d t o be n o greater t ha n 5 
m m).  
 
1 1. 2 1 4  T u m or lesi o ns i n a pre vi o usl y irra diate d area are c o nsi dere d meas ura ble 
disease u n der t he f oll o wi n g c o n diti o ns: t here has bee n e vi de nce of t u m or 
pr o gressi o n i n t he irra diate d area  pri or t o st u d y re gistrati o n . 
 
1 1. 2 2  N o n -Meas u ra ble Disease 
 
1 1. 2 2 1  All ot her lesi o ns ( or sites of disease  (e. g., visi ble p ul m o nar y n o d ules < [ADDRESS_410788] dia meter)) are c o nsi dere d n o n-meas ura ble disease. B o ne lesi o ns, 
le pt o me ni n geal disease, ascites, ple ural/ pericar dial eff usi o ns, l y m p ha n gitis 
c uti s/ p ul m o nis, i nfla m mat or y breast disease, a n d a b d o mi nal masses ( n ot 
f oll o we d b y C T or M RI), are c o nsi dere d as n o n-meas ura ble as well.  
 
N ote: ‘ C ystic lesi o ns’ t h o u g ht t o re prese nt c ystic metastases ca n be  
c o nsi dere d as meas ura ble lesi o ns, if t he y meet t he defi niti o n of meas ura bilit y 
descri be d a b o ve. H o we ver, if n o n -c ystic lesi o ns are prese nt i n t he sa me 
patie nt, t hese are preferre d f or se lecti o n as tar get lesi o ns. 
 
1 1. 3  G ui deli nes f or E val uati o n of Meas ura ble Disease  
 
1 1. 3 1  Meas ure me nt Met h o ds:  
 
•  All meas ure me nts s h o ul d be rec or de d i n metric n otati o n (i.e., deci mal fracti o ns of 
ce nti meters) usi n g a r uler or cali pers.  
 
•  T he sa me met h o d of assess me nt a n d t he sa me tec h ni q ue m ust be use d t o c haracterize 
eac h i de ntifie d a n d re p orte d lesi o n at baseli ne a n d d uri n g f oll o w -u p.  
 
•  I ma gi n g-base d e val uati o n is preferre d t o e val uati o n b y cli nical e xa mi nati o n w he n 
b ot h met h o ds ha ve bee n use d at t he sa me e val uati o n t o assess t he a ntit u m or effect of 
a treat me nt. 
 
1 1. 3 2  Acce pta ble M o dalities f or Meas ura ble Disease:  
 
•  C o n ve nti o nal C T a n d M RI:  T his g ui deli ne has defi ne d meas ura bilit y of lesi o ns o n 
C T sca n base d o n t he ass u m pti o n t hat C T slice t hic k ness is 5 m m or less. If C T sca ns 
ha ve slice t hic k ness greater t ha n 5 m m, t he mi ni m u m size f or a meas ura ble lesi o n 
s h o ul d be t wice t he slice t hic k ness. 
 
  
 3 7  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
•  As wit h C T, if a n M RI is perf or me d, t he tec h nical s pecificati o ns of t he sca n ni n g 
se q ue nces use d s h o ul d be o pti mize d f or t he e val uati o n of t he t y pe a n d site of 
disease. T he lesi o ns s h o ul d be meas ure d o n t he sa me p ulse se q ue nce. I deall y, t he 
same t y pe of sca n ner s h o ul d be use d a n d t he i ma ge ac q uisiti o n pr ot oc ol s h o ul d be 
f oll o we d as cl osel y as p ossi ble t o pri or sca ns. B o d y sca ns s h o ul d be perf or me d wit h 
breat h -h ol d sca n ni n g tec h ni q ues, if p ossi ble.  
 
•  F D G -P E T: F D G -P E T sca n ni n g is all o we d t o c o m ple me nt C T sca n ni n g i n 
assess me nt of pr o gressi ve disease [ P D] a n d partic ularl y p ossi ble ' ne w' disease. A 
‘ p ositi ve’ F D G-P E T sca n ne d lesi o n is defi ne d as o ne w hic h is F D G a vi d wit h a n 
u pta ke  greater t ha n t wice t hat of t he s urr o u n di n g tiss ue o n t he atte n uati o n c orrecte d 
i ma ge; ot her wise, a n F D G-P E T sca n ne d lesi o n is c o nsi dere d ‘ ne gati ve.’ Ne w lesi o ns 
o n t he basis of F D G -P E T i ma gi n g ca n be i de ntifie d acc or di n g t o t he f oll o wi n g 
al g orit h m: 
 
a. Ne gati ve F D G -P E T at baseli ne wit h a p ositi ve F D G -P E T at f oll o w -u p is a s i g n 
of P D base d o n a ne w lesi o n.  
 
b.  N o F D G -P E T at baseli ne a n d a p ositi ve F D G -P E T at f oll o w -u p:  
 
i. If t he p ositi ve F D G-P E T at f oll o w -u p c orres p o n ds t o a ne w site of disease 
c o nfir me d b y C T  or M RI , t his is P D.   
 
ii. If t he p ositi ve F D G-P E T at f oll o w -u p i s n ot c o nfir me d as a ne w site of 
disease o n C T at t he sa me e val uati o n, a d diti o nal f oll o w -u p C T sca ns (i.e., 
a d diti o nal f oll o w -u p sca ns at least 4 wee ks later) are nee de d t o deter mi ne if 
t here is tr ul y pr o gressi o n occ urri n g at t hat site. I n t his sit uati o n, t he date of 
P D will be t he date of t he i nitial a b n or mal P D G -P E T sca n.   
 
iii If t he p ositi ve F D G-P E T at f oll o w -u p c orres p o n ds t o a pre -e xisti n g site of 
disease o n C T t hat is n ot pr o gressi n g o n t he basis of t he a nat o mic i ma ges, it 
is n ot classifie d as P D. 
 
1 1. 3 3  Meas ure me nt at F oll o w -u p E val uati o n:  
 
•  C yt ol o gic a n d hist ol o gic tec h ni q ues ca n be use d t o differe ntiate bet wee n P R a n d C R 
i n rare cases (e. g., resi d ual lesi o ns i n t u m or t y pes s uc h as ger m cell t u m ors, w here 
k n o w n resi d ual be ni g n t u m ors ca n re mai n.)  
 
[ADDRESS_410789]  
 
1 1. 4 1  Tar get Lesi o ns & Tar get L y m p h N o des  
 
•  Meas ura ble lesi o ns (as defi ne d i n Secti o n 1 1. 2 1) u p t o a ma xi m u m of 5 lesi o ns, 
re prese ntati ve of all i n v ol ve d or ga ns, s h o ul d be i de ntifie d as “ Tar get Lesi o ns” a n d 
rec or de d a n d meas ure d at baseli ne. T hese lesi o ns ca n be n o n -n o dal or n o dal (as 
defi ne d i n 1 1. 2 1) , w here n o m ore t ha n 2 lesi o ns are fr o m t he sa me or ga n a n d n o 
m ore t ha n 2 mali g na nt n o dal lesi o ns are selecte d.  
 
N ote:  If fe wer t ha n 5 tar get lesi o ns a n d tar get l y m p h n o des are i de ntifie d (as t here 
ofte n will be), t here is n o reas o n t o perf or m a d diti o nal st u dies be y o n d t h ose 
s pecifie d i n t he pr ot oc ol t o disc o ver ne w lesi o ns. 
  
 3 8  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 
•  Tar get lesi o ns a n d tar get l y m p h n o des s h o ul d be selecte d o n t he basis of t heir size, 
be re prese ntati ve of all i n v ol ve d sites of disease, b ut i n a d diti o n s h o ul d be t h ose 
t hat le n d t he msel ves t o re pr o d uci ble re peate d meas ure me nts. It ma y be t he case 
t hat, o n occasi o n, t he lar gest lesi o n ( or mali g na nt l y m p h n o de) d oes n ot le n d itself 
t o re pr o d uci ble meas ure me nts i n w hic h circ u msta nce t he ne xt lar gest lesi o n ( or 
mali g na nt l y m p h n o de) w hic h ca n be meas ure d re pr o d uci bl y s h o ul d be selecte d.  
 
•  Baseli ne S u m of Di me nsi o ns ( B S D): A s u m of t he l o n gest dia meter f or all tar get 
lesi o ns pl us t he s u m of t he l o n g or s h ort a xis of all t he tar get l y m p h n o des (if t he 
l y m p h n o de q ualifie d as a tar get lesi o n base d u p o n a l o n g a xis of > [ADDRESS_410790]-baseli ne assess me nts; if t he l y m p h 
n o de q ualifie d as a tar get lesi o n base d u p o n a s h ort a xis o f > 1. [ADDRESS_410791] -baseli ne assess me nts)   will be calc ulate d 
a n d re p orte d as t he baseli ne s u m of di me nsi o ns ( B S D). T he B S D will be use d as 
refere nce t o f urt her c haracterize a n y o bjecti ve t u m or res p o nse i n t he meas ur a ble 
di me nsi o n of t he disease.  
 
•  P ost -Baseli ne S u m of t he Di me nsi o ns ( P B S D): A s u m of t he l o n gest dia meter f or 
all tar get lesi o ns pl us t he s u m of t he l o n g or s h ort a xis of all t he tar get l y m p h 
n o des (if t he l y m p h n o de q ualifie d as a tar get lesi o n based u p o n a l o n g a xis of > [ADDRESS_410792] -baseli ne assess me nts; if t he l y m p h 
n o de q ualifie d as a tar get lesi o n base d u p o n a s h ort a xis of > 1. [ADDRESS_410793] -baseli ne assess me nts)  will be calc ulate d a n d re p orte d as 
t he p ost-baseli ne s u m of di me nsi o ns ( P B S D). If t he ra di ol o gist is a ble t o pr o vi de 
a n act ual meas ure f or t he tar get lesi o n ( or tar get l y m p h n o de), t hat s h o ul d be 
rec or de d, e ve n if it is bel o w 0. 5 c m. If t he tar get lesi o n ( or tar get l y m p h no de) is 
belie ve d t o be prese nt a n d is fai ntl y see n b ut t o o s mall t o meas ure, a defa ult val ue 
of 0. [ADDRESS_410794] t hat t he tar get 
lesi o n or tar get l y m p h n o de has li kel y disa p peare d, t he meas ure me nt s h o ul d be 
rec or de d as 0 c m. 
 
•  T he mi ni m u m s u m of t he di me nsi o ns ( M S D) is t he mi ni m u m of t he B S D a n d t he 
P B S D.  
 
1 1. 4 2  N o n -Tar get Lesi o ns & N o n -Tar get L y m p h N o des  
 
N o n -meas ura ble sites of disease ( Secti o n 1 1. 2 2) are classifie d as n o n - tar get lesi o ns or 
n o n -tar get l y m ph n o des a n d s h o ul d als o be rec or de d at baseli ne. T hese lesi o ns a n d 
l y m p h n o des s h o ul d be part of t he res p o nse assess me nt as detaile d i n Secti o n 1 1. 4 3 3  or  
1 1. 4 4 2 . 
  
 3 9  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 
1 1. 4 3  R E S P O N S E C RI T E RI A F O R P A TI E N T S WI T H M E A S U R E A B L E T A R G E T 
L E SI O N S/ L Y M P H N O D E S  
 
[ADDRESS_410795] be 
meas ure d o n re -e val uati o n at e val uati o n ti me  p oi nt s s pecifie d i n Secti o n 1 1. 1. 
S pecificall y, a c ha n ge i n o bjecti ve stat us t o eit her a P R or C R ca n n ot be d o ne 
wit h o ut re -meas uri n g tar get l esi o ns a n d tar get l y m p h n o des.  
 
N ote: N o n -tar get lesi o ns a n d n o n-tar get l y m p h n o des s h o ul d be e val uate d at 
eac h assess me nt, es peciall y i n t he case of first res p o nse or c o nfir mati o n of 
res p o nse. I n selecte d circ u msta nces, certai n n o n-tar get or ga ns ma y be e val uate d 
less fre q ue ntl y. F or e xa m ple, b o ne sca ns ma y nee d t o be re peate d o nl y w he n 
c o m plete res p o nse is i de ntifie d i n tar get disease or w he n pr o gressi o n i n b o ne is 
s us pecte d. 
 
1 1. 4 3 2  E val uati o n of Tar get Lesi o ns  
 
•  C o m plete Res p o nse ( C R):  All of t he f oll o wi n g m ust be tr ue:  
 
a. Disa p peara nce of all tar get lesi o ns.  
 
b.  Eac h tar get l y m p h n o de m ust ha ve re d ucti o n i n s h ort a xis t o < 1. 0 c m  (if 
s h ort a xis bei n g use d f or meas ure me nt) or ha ve re d ucti o n i n l o n g a xis t o 
< 0. 7 c m (if l o n g a xis is bei n g use d f or meas ure me nt) . 
 
c. F or patie nts wit h o ut detecta ble t h yr o gl o b uli n a nti b o dies, ser u m 
t h yr o gl o b uli n o n s u p pressi o n  m ust be  meas ure d t o be < 0. 2 n g/ ml . If a 
ce nter d oes n ot ha ve a t h yr o gl o b uli n assa y t hat rea ds t o < 2 n g/ ml, t he n a 
T S H -sti m ulate d T g < 1 n g/ ml w o ul d be re q uire d t o c o nfir m c o m plete 
res p o nse. F or patie nts wit h detecta ble t h yr o gl o b uli n a nti b o dies, 
assess me nt of t h yr o gl o b uli n will n ot be necessar y f or assess me nt of 
c o m plete res p o nse.  
 
•  Partial Re s p o nse ( P R): At least a 3 0 % decrease i n P B S D (s u m of t he l o n gest 
dia meter f or all tar get lesi o ns pl us t he s u m of t he  l o n g or s h ort a xis of all t he 
tar get l y m p h n o des ( de pe n di n g o n w hic h a xis is bei n g use d f or assess me nts) 
at c urre nt e val uati o n) ta ki n g as refere nce t he B S D ( see Secti o n 1 1. 4 1).  
 
•  Pr o gressi o n ( P D):  At least o n e of t he f oll o wi n g m ust be tr ue:  
 
a. At least o ne ne w mali g na nt lesi o n, w hic h als o i ncl u des a n y l y m p h n o de 
t hat was n or mal at baseli ne ( < 1. 0 c m s h ort a xis) a n d i ncrease d t o ≥ 1. [ADDRESS_410796] a 2 0 % i ncrease i n P B S D (s u m of t he l o n g est dia meter f or all 
tar get lesi o ns pl us t he s u m of t he l o n g or s h ort a xis of all t he tar get l y m p h 
n o des ( de pe n di n g o n w hic h a xis is bei n g use d f or assess me nts) at c urre nt 
e val uati o n) ta ki n g as refere nce t he M S D ( Secti o n 1 1. 4 1). I n a d diti o n, t he 
P B S D m ust als o de m o nstrate a n a bs ol ute i ncrease of at least 0. 5 c m fr o m 
t he M S D. 
 
  
 4 0  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
c. See Secti o n 1 1. 3 2 f or details i n re gar ds t o t he re q uire me nts f or P D via 
F D G -P E T i ma gi n g.  
 
•  Sta ble Disease ( S D): Neit her s ufficie nt s hri n ka ge t o q ualif y f or P R, n or 
s ufficie nt i ncrease t o q ualif y f or P D ta ki n g as refere nce t he M S D.  
 
1 1. 4 3 3  E val uati o n of N o n -Tar get Lesi o ns & N o n -tar get L y m p h N o des 
 
•  C o m plete Res p o nse ( C R):  All of t he f oll o wi n g m ust be tr ue:  
 
a. Disa p peara nce of all n o n -tar get lesi o ns.  
 
b.  Eac h n o n -tar get l y m p h n o de m ust ha ve a re d ucti o n i n s h ort a xis t o < 1. [ADDRESS_410797] be  meas ure d t o be u n detecta ble. F or patie nts 
wit h detecta ble t h yr o gl o b uli n a nti b o dies, assess me nt of t h yr o gl o b uli n  
will n ot be necessar y f or assess me nt of c o m plete res p o nse.  
 
•  N o n -C R/ N o n -P D: Persiste nce of o ne or m ore n o n -tar get lesi o ns or n o n-tar get 
l y m p h n o des. 
 
•  Pr o gres si o n ( P D): At least o ne of t he f oll o wi n g m ust be tr ue:  
 
a. At least o ne ne w mali g na nt lesi o n, w hic h  als o i ncl u des a n y l y m p h n o de 
t hat was n or mal at baseli ne ( < 1. 0 c m  s h ort a xis) a n d i ncrease d t o ≥ 1. 0 c m 
s h ort a xis a n d is dee me d t o be mali g na nt d uri n g f oll o w -u p.  
 
b.  U ne q ui v ocal pr o gressi o n of e xisti n g n o n -tar get lesi o ns a n d n o n-tar get 
l y m p h n o des. ( N O T E: U ne q ui v ocal pr o gressi o n s h o ul d n ot n or mall y 
tr u m p tar get lesi o n a n d tar get l y m p h n o de stat us. It m ust be 
re prese ntati ve of o verall disease stat us c ha n ge.) 
 
c. See Secti o n [ADDRESS_410798] at us  f or P atie nts wit h Me as ure a ble T ar get 
Lesi o ns/ L y m p h N o des  
 
T he o veral l o bjecti ve stat us f or a n e val uati o n is deter mi ne d b y c o m bi ni n g t he 
patie nt’s stat us o n tar get lesi o ns, tar get l y m p h n o des, n o n -tar get lesi o ns, n o n-
tar get l y m p h n o des, a n d ne w disease as defi ne d i n t he f oll o wi n g ta bles. Ser u m 
t h yr o gl o b uli n meas ure me nts will n ot  be use d i n deter mi ni n g o verall res p o nse, 
e xce pt  f or desi g nati n g a c o m plete res p o nse (as detaile d i n Secti o n 1 1. 4 3 2 a n d i n 
t he ta ble bel o w): 
 
 
  
 4 2  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
If a ce nter d oes n ot ha ve a t h yr o gl o b uli n assa y t hat rea ds t o <  2 
n g/ ml, t he n a T S H -sti m ulate d T G < 1 n g/ ml w o ul d be re q uire d t o 
c o nfir m c o m plete res p o nse.  F or patie nts wit h detecta ble 
t h yr o gl o b uli n a nti b o dies, assess me nt of t h yr o glo b uli n will n ot be 
necessar y f or assess me nt of c o m plete res p o nse.  
 
•  N o n -C R/ N o n -P D: Persiste nce of o ne or m ore n o n -tar get lesi o ns or n o n-
tar get l y m p h n o des.   
  
•  Pr o gres si o n ( P D): At least o ne of t he f oll o wi n g m ust be tr ue:  
 
a.    At least o ne ne w mali g na nt l esi o n, w hic h als o i ncl u des a n y l y m p h 
n o de t hat was n or mal at baseli ne ( < 1. 0 c m  s h ort a xis) a n d i ncrease d 
t o ≥ 1. 0 c m s h ort a xis a n d is dee me d t o be mali g na nt d uri n g f oll o w -
u p.  
 
b . U ne q ui v ocal pr o gressi o n of e xisti n g n o n -tar get lesi o ns a n d n o n-
tar get l y m p h n o des. ( N O T E: U ne q ui v ocal pr o gressi o n s h o ul d n ot 
n or mall y tr u m p tar get lesi o n a n d tar get l y m p h n o de stat us. It m ust 
be re prese ntati ve of o verall disease stat us c ha n ge.)  
 
c. See Secti o n [ADDRESS_410799] at us f or P atie nts wit h N o n -Me as ure a ble, N o n -
T ar get Lesi o ns/ L y m p h n o des  
 
T he  o verall o bjecti ve stat us f or  a n e val uati o n is deter mi ne d b y:  
•  Str uct ural assess me nt of lesi o ns/l y m p h n o des as detaile d i n Secti o n 
1 1. 4 4 2.  
•  F or t he “ n o n-C R/ n o n -P D” str uct ural  cate g or y, meas ure me nt of t he ser u m 
T G i n t he c o nte xt of s u p presse d T S H  (a n d ne gati ve T G a nti b o d y) will be 
use d  t o deter mi ne t he  fi nal res p o nse desi g nati o n (t he e xce pti o n is f or t he 
assess me nt of c o m plete res p o nse, w hic h re q uires meas ure me nt of a 
sti m ulate d T G, see c hart bel o w).  
  
 4 5  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
u p o n a c o m paris o n bet wee n t he 6 m o nt h ra di ol o gic sca n(s)/e val uati o ns a n d t he 
baseli ne, pre -treat me nt ra di ol o gic sca ns  (a n d ser u m t h yr o gl o b uli n meas ure me nts if 
a p plica ble) . 
 
1 1. 4 6  S y m pt o matic Deteri orati o n: Patie nts wit h gl o bal deteri orati o n of healt h stat us 
re q uiri n g disc o nti n uati o n of treat me nt wit h o ut o bjecti ve e vi de nce of disease 
pr o gressi o n at t hat ti me, a n d n ot eit her relate d t o s t u d y treat me nt or ot her me dical 
c o n diti o ns, s h o ul d be re p orte d as P D d ue t o “s y m pt o matic deteri orati o n.” E ver y eff ort 
s h o ul d be ma de t o d oc u me nt t he o bjecti ve pr o gressi o n e ve n after disc o nti n uati o n of 
treat me nt d ue t o s y m pt o matic deteri orati o n. A patie nt is classifie d as ha vi n g P D d ue 
t o “s y m pt o matic deteri orati o n” if a n y of t he f oll o wi n g occ ur t hat are n ot eit her relate d 
t o st u d y treat me nt or ot her me dical c o n diti o ns: 
 
•  Wei g ht l oss > 1 0 % of b o d y wei g ht.  
•  W orse ni n g of t u m or -relate d s y m pt o ms. 
•  Decli ne i n perf or m a nce stat us of > [ADDRESS_410800] ors   
 
1 2. 1  N u m ber of pri or 1 3 1I treat me nts: 0 vs. 1 vs. 2 vs. 3 vs. 4 or m ore . 
 
1 2. 2  P re vi o us c he m ot hera p y/tar gete d t hera p y f or t h yr oi d ca ncer: Yes vs. N o . 
 
1 2. 3  P ri or R T: Yes vs. N o . 
 
[ADDRESS_410801] ol o g y: ( pa pi[INVESTIGATOR_5778] y, f ollic ular, p o orl y differe ntiate d, a n d ot her res pecti ve varia nts). 
 
 
1 3. 0  Tre at me nt/ F oll o w – u p Decisi o n at E v al u ati o n of P atie nt  
 
1 3. 1  Patie nts w h o are C R, P R, or S D will c o nti n ue treat me nt/assess me nt per pr ot oc ol.  Patie nts t hat 
are n o n-P D after c o m pleti n g treat me nt will be f oll o we d d uri n g t he o bser vati o n p hase as 
o utli ne d i n Secti o n 4. 0: [ADDRESS_410802] -treat me nt w he n patie nts will be  f oll o we d e ver y 6 m o nt hs f or a 
ma xi m u m of 2 years  ( +/- 3 m o nt hs)  fr o m ra n d o mizati o n. 
 
1 3. 2  Patie nts w h o de vel o p P D w hile recei vi n g t hera p y or u n der g oi n g pr ot oc ol  assess me nt  will be 
f oll o we d i n t he e ve nt m o nit ori n g p hase (see secti o n 1 8). H o we ver, it is p ossi ble t hat patients 
will ha ve P D  earl y i n t he st u d y a n d still de m o nstrate be nefit fr o m t he st u d y treat me nt later i n 
t he st u d y f or se veral reas o ns: 1) sel u meti ni b al o ne pri or t o R AI ma y n ot ha ve si g nifica nt cli nical 
efficac y, 2) T h yr o ge n ™  sti m ulati o n ca n tra nsie ntl y i ncrease t u m or size w hic h ca n be mista ke n 
f or disease pr o gressi o n; 3) t he t hera pe utic effects of R AI ca n be dela ye d; a n d 4) e vi de nce of 
pr o gressi o n ma y be e vi de nt pri or t o a d mi nistrati o n of R AI.  He nce, patie nts wit h e vi de nce of 
ra di o gra p hic, cli nical or bi oc he m ical (i.e. t h yr o gl o b uli n, if a p plica ble) P D n ote d pri or t o t he 6 -
m o nt h disease e val uati o n (i.e. t he sca ns a n d e val uati o ns perf or me d 6 m o nt hs after t hera pe utic 
1 3 1I is a d mi nistere d) ma y re mai n o n treat me nt/assess me nt at t he discreti o n of t he treati n g 
p h ysic ia n. If, i n t he o pi [INVESTIGATOR_9384] o n of t he treati n g p h ysicia n, t hese patie nts are u nli kel y t o de m o nstrate 
be nefit wit h s u bse q ue nt cli nical assess me nts, t he patie nts will be classifie d as ha vi n g P D a n d 
will be f oll o we d i n t he e ve nt m o nit ori n g p hase (see S ecti o n 1 8. 0). 
  
 4 6  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 
1 3. 3  Patie nts w h o g o off pr ot oc ol treat me nt f or reas o ns ot her t ha n P D will g o t o t he  e ve nt -
m o nit ori n g p hase per Secti o n 1 8. 0.  
 
1 3. 4  Patie nts w h o de vel o p C N S P D at a n y ti me s h o ul d g o t o e ve nt m o nit ori n g.  
 
T hese patie nts s h o ul d recei ve treat me nt if dee me d cli nicall y i n dicate d b y t he treati n g 
p h ysicia n(s) . 
 
[ADDRESS_410803] u d y ( or off st u d y, if a p plica ble).  
 
•  If t he patie nt recei ve d treat me nt, all data u p u ntil t he p oi nt of c o nfir mati o n of i neli gi bilit y 
m ust be s u b mitte d. E ve nt m o nit ori n g will be re q uire d per Secti o n 1 8. 0 of t he pr ot oc ol.  
•  If t he patie nt ne ver recei ve d treat me nt, o n-st u d y material m ust be s u b mitte d. E ve nt 
m o nit ori n g will be re q uire d per Secti o n [ADDRESS_410804] u d y. T he 
patie nt ma y c o nti n ue treat me nt off -pr ot oc ol at t he dis creti o n of t he p h ysicia n as l o n g as t here 
are n o safet y c o ncer ns, a n d t he patie nt was pr o perl y re gistere d. E ve nt m o nit ori n g will be 
re q uire d per Secti o n 1 8. 0 of t he pr ot oc ol. 
 
1 3. 5 c A patie nt is dee me d a ca ncel if he/s he is re m o ve d fr o m t he st u d y f or a n y r eas o n  bef ore a n y 
st u d y treat me nt is gi ve n. O n-st u d y material a n d t he E n d of Acti ve Treat me nt/ Ca ncel 
N otificati o n F or m m ust be s u b mitte d. N o f urt her data s u b missi o n is necessar y.  
 
 
  
 4 7  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
1 4. 0  B o d y Fl ui d Bi os peci me ns   
 
1 4. 1  S u m mar y Ta ble of Researc h Bl o o d/ Bl o o d Pr o d ucts t o Be C ollecte d f or T his  Pr ot oc ol  
I n dic ate if 
s peci m e n is 
m a n d at or y 
or o pti o n al  C ollecti o n t u be 
descri pti o n 
a n d/ or a d diti ve 
(c ol or of t u be 
t o p) V ol u m e t o 
c ollect per 
t u be ( n u m ber 
of  t u bes t o be 
c ollecte d)  Bl o o d pr o d uct 
bei n g pr ocesse d 
a n d s u b mitt e d 
b y p artici p ati n g 
site Pre -
Tre at m e nt 
( pri or t o 
st arti n g pl ace b o 
or sel u meti ni b)  A d diti o n al 
pr ocessi n g 
re q uire d at 
site after 
bl o o d dr a w ?  St o r a ge  
/s hi p pi n g 
c o n diti o ns1 
Ma n dat or y  La v e n der  1 0 ml ( 1)  Bl o o d  X  N o  Refri gerate d  
(R e q uisiti o n f or m  l ocate d o n t he A C C R U we b site .) 
 
[ADDRESS_410805] s peci me ns t he da y bef ore a fe deral 
h oli da y.  N O T E: R esearc h bl o o d sa m ples s h o ul d n ot be c ollecte d a n d s u b mitte d u ntil after  t he 
patie nt is re gistere d o nt o t he st u d y, b ut pri or  t o t he i nitiati o n of place b o/sel u meti ni b t hera p y. 
 
[ADDRESS_410806] I D n u m ber, a n d ti me 
a n d date bl o o d is dra w n . 
 
1 4. 3 2  S hi p t he E D T A t u be wit h  a pr o perl y pre pare d c ol d pac k.  
 
1 4. 3 3  S hi p s peci me ns via Fe d E x Pri orit y O ver ni g ht ser vice.  
 
1 4. 3 4  S hi p sa m ples t o : 
B A P Freezer  
 
 
 
 
[ADDRESS_410807] ora ge I nf or mati o n  
 
1 4. 4 1  Bl o o d/ bl o o d pr o d uct sa m ples will be c ollecte d f or t he f oll o wi n g researc h :  
 
[ADDRESS_410808] ore d fr oze n at -7 0º C b y B A P, acc or di n g t o patie nt c o nse nt 
i nf or mati o n u ntil s pecific a nal yses are i de ntifie d. As pr ot oc ols are 
de vel o pe d, t he y will be prese nte d f or  A C C R U , I R B, a n d I T O G re vie w a n d 
a p pr o val.  ( T his c ollecti o n is part of a ge neral strate g y of i n vesti gati o n f or 
t he maj orit y of A C C R U/I T O G st u dies.) 
 
  
 4 8  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
1 4. 4 1 2  As part of o n g oi n g A C C R U /I T O G researc h, we will c ollect w hite bl o o d 
cells/ plas ma f or f ut ure researc h st u dies, acc or di n g t o patie nt c o nse nt 
i nf or mati o n. Sa m ples will be st ore d fr oze n at − [ADDRESS_410809] u g I nf or m ati o n  
 
I n vesti g at or Br oc h ure: T he m ost c urre nt versi o n of t he I n vesti gat or Br oc h ure will be mai ntai ne d i n t he 
st u d y f ol der o n t he A C C R U we bsite. U p date d I n vesti gat or’s Br oc h ures s h o ul d be o btai ne d fr o m t he 
st u d y f ol der as t he y bec o me a vaila ble.  
 
Eac h i n vesti gat or s h o ul d o btai n a c o p y of t he I n vesti gat or’s Br oc h ure pri or t o i nitiati o n of t he st u d y.  
 
1 5. 1  Sel u meti ni b ( A Z D 6 2 4 4   K osel u g o ™ ) or sel u meti ni b-matc he d place b o  
 
1 5. 1 1  B ac k gr o u n d : T he R A S/ R A F/ M E K/ E R K pat h wa y is a n i m p orta nt me diat or of ma n y 
cell ular pr ocesses i ncl u di n g pr oliferati o n, s ur vi val, differe ntiati o n, a p o pt osis, m otilit y 
a n d meta b olis m. T his pat h wa y is ofte n a berra ntl y acti vate d i n h u ma n t u m ors d ue t o 
t he o verex pressi o n of acti vate d K -R A S, m uta nt b -Raf, or ot her gr o wt h fact or 
rece pt ors. Sel u meti ni b is a selecti ve mit o ge n-acti vate d pr otei n ki nase ( M E K) 
i n hi bit or. B y i n hi biti n g M E K, sel u meti ni b i n hi bits E R K p h os p h or ylati o n. T h us, 
sel u meti ni b ma y i n hi bit o nc o ge nic gr o wt h si g nali n g i n t u m or cells b y tar geti n g t he 
R A S/ R A F/ M E K/ E R K pat h wa y.  
 
1 5. 1 2  F or m ul ati o n:  
    T he dr u g pr o d uct c o nsists of a series of plai n, H P M C  
ca ps ules c o ntai ni n g 1 0 m g ( w hite) a n d 2 5 m g ( bl ue) sel u meti ni b (e x presse d as free -
base) f or oral a d mi nis trati o n. Sel u meti ni b ca ps ules are s u p plie d i n w hite, H D P E 
b ottles wit h desicca nt, a ta m per e vi de nt i n d ucti o n seal me m bra ne a n d c hil d resista nt 
scre w cl os ure. 
 
 T he 1 0 m g ca ps ule is prese nte d as eit her a plai n w hite ca ps ule wit h a ce nter ba n d, or 
w hite t o o ff-w hite ca ps ule wit h a ce nter ba n d mar ke d wit h ‘ S E L 1 0’ pri nte d i n blac k 
i n k. 
 
 T he 2 5 m g ca ps ule is prese nte d as eit her a plai n bl ue ca ps ule wit h a ce nter ba n d, or 
bl ue ca ps ule wit h a ce nter ba n d mar ke d wit h ‘ S E L 2 5’ pri nte d i n blac k i n k.  
 
 A part fr o m t h e mar ki n gs, plai n a n d mar ke d ca ps ules are i de ntical i n all ot her as pects.  
 
  
 4 9  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 T he ca ps ules c o ntai n sel u meti ni b H y d -S ulfate a n d Vita mi n E p ol yet h yle ne 
gl yc ol s ucci nate (als o k n o w n as T P G S - a water s ol u ble f or m of vita mi n E) Place b o 
c o m p ositi o n is c o nsiste nt w it h t he c o m p ositi o n of dr u g pr o d uct, wit h t he a bse nt dr u g 
s u bsta nce bei n g re place d b y Vita mi n E p ol yet h yle ne gl yc ol s ucci nate . T he sa me 
H P M C ca ps ule s hells are use d f or b ot h place b o a n d acti ve dr u g pr o d ucts.  
 
B ot h sel u meti ni b a n d place b o are s u p plie d i n [ADDRESS_410810] or a ge:  St ore t he sel u meti ni b or place b o ca ps ules i n t he ori gi nal 
pac ka gi n g u ntil use at r o o m te m perat ure ( 2 0° C -2 5° C). Brief e xc ursi o ns are 
per mitte d bet wee n 1 5° C a n d 3 0° C. F o r f urt her i nf or mati o n refer t o t he 
i n vesti gati o nal pr o d uct la bel. 
 
1 5. 1 4  A d mi nistr ati o n:  Sel u meti ni b  s h o ul d be ta ke n o n a n e m pt y st o mac h, 1 h o ur bef ore or 
2 h o urs after a meal. Ta ke ca ps ules wit h water o nl y.  
1 5. 1 5  P h ar m ac o ki netic i nf or m ati o n :  
A bs or pti o n  - Sel u meti ni b was a bs or be d relati vel y q uic kl y acr oss all d ose 
le vels, wit h a me dia n t ma x of  1 t o  1. 5 h o urs acr oss t he d ose ra n ge ( 2 5 t o 1 0 0 m g).    
Distri b uti o n  - F oll o wi n g t he pea k, sel u meti ni b c o nce ntrati o ns decli ne d m ulti -
e x p o ne ntiall y, wit h a mea n t 1/ 2 ra n gi n g fr o m 5 t o 7 h, w hic h is c o nsiste nt acr oss 
d ose le vels. C L/ F a n d V ss/ F als o re mai ne d lar gel y c o nsiste nt acr oss t he d ose 
ra n ge, wit h mea n val ues ra n gi n g fr o m 1 2 t o 2 3 L/ h a n d 8 7 t o 1 2 6 L 
res pecti vel y. Plas ma N-des met h yl sel u meti ni b c o nce ntrati o ns f oll o we d a 
si milar p har mac o ki netic pr ofile t o sel u meti ni b, alt h o u g h e x p os ure was m uc h 
l o wer, wit h C ma x a n d A U C val ues ge nerall y < 1 5 % of pare nt, wit hi n eac h 
patie nt. T he me dia n t ma x was ar o u n d 1. 5 hrs a n d t 1/ 2 was ar o u n d 9 t o 1 3 h o urs.  
 
Met a b olis m  -  
C yt oc hr o me  P 4 5 0 3 A 4 is t he pre d o mi na nt is of or m res p o nsi ble f or  sel u meti ni b 
o xi dati ve meta b olis m wit h C Y P 2 C 1 9, C Y P 1 A 2, C Y P 2 C 9, C Y P 2 E 1, a n d  C Y P 3 A 5 
i n v ol ve d t o a lesser e xte nt.  Its acti ve meta b olite, N-des met h yl sel u meti ni b is 
a p pr o xi matel y 3 -5 ti mes m ore p ote nt t ha n sel u meti ni b, a n d ge nerate d pri maril y b y 
C Y P 1 A 2, C Y P 2 C 1 9, C Y P 2 C 9 a n d C Y P 2 C 8 a n d meta b olize d t hr o u g h t he sa me 
r o utes as sel u meti ni b. 
S peci al P o p ul ati o ns –  Re nal i m pair me nt is e x pecte d  t o ha ve mi ni mal effect o n 
e x p os ure t o sel u meti ni b. Patie nts wit h m o derate a n d se vere he patic i m pair me nt ma y 
e x perie nce hi g her e x p os ures of a p pr o xi matel y 1. [ADDRESS_410811] u g I nter acti o ns : Hi g h vita mi n E d oses ma y p ote ntiate t he a nticoa g ula nt 
acti vit y of warfari n. M o nit or P T/I N R m ore fre q ue ntl y i n patie nts recei vi n g b ot h 
sel u meti ni b a n d warfari n.  
 
T he c o nc o mita nt i nta ke of s u p ple me ntal  vita mi n E s h o ul d be a v oi de d i n all 
s u bjects recei vi n g sel u meti ni b. 
 
A v oi d c o -a d mi nisteri n g sel u meti ni b wit h me dici nal pr o d ucts t hat are str o n g 
i n hi bit ors of C Y P 3 A 4 (e g, clarit hr o m yci n, gra pefr uit j uice, oral ket oc o naz ole) 
a n d C Y P 2 C 1 9 (e g, ticl o pi [INVESTIGATOR_271545]). If  c o-a d mi nistrati o n is u na v oi da ble, patie nts 
s h o ul d be caref ull y m o nit ore d f or A Es.  N o d ose a dj ust me nt is necessar y f or 
  
 5 0  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
use of sel u meti ni b wit h m o derate C Y P 3 A 4 or C Y P 2 C 1 9 i n hi bit ors. Patie nts 
s h o ul d be caref ull y m o nit ore d f or A Es w he n c o-a d mi nistere d wit h m o derate 
C Y P 3 A 4 or C Y P 2 C 1 9 i n hi bit ors.  
 
A v oi d c o nc o mita nt use of str o n g C Y P 3 A 4 i n d ucers (e g, p he n yt oi n, rifa m pi[INVESTIGATOR_37180] n, 
car ba maze pi [INVESTIGATOR_050], St. J o h n’s W ort) or m o derate C Y P [ADDRESS_410812] u g i nteracti o n via i n hi b iti o n or 
i n d ucti o n of C Y P e nz y mes 
 
1 5. 1 7  K n o w n p ote nti al t o xicities : 
 
Ver y C o m m o n A d verse E ve nts, ( > 1 0 %) 
Car di o vasc ular:  Peri p heral e de ma  
Ce ntral ner v o us s yste m: Fati g ue , hea dac he 
Der mat ol o gic:  Ras h ac neif or m, ras h mac ul o -pa p ular  
E n d ocri ne & meta b olic: Cr eati ne p h os p h o ki nase ( C K) i ncrease d  
Gastr oi ntesti nal:  Diarr hea, na usea, v o miti n g , a b d o mi nal pai n, c o nsti pati o n. 
Res pi[INVESTIGATOR_1305] y: E xerti o nal d ys p nea  
 
C o m m o n A d verse E ve nts, ( 1 t o < 1 0 %) 
Car di o vasc ular: H y perte nsi o n  
Ce ntral ner v o us s yste m: Fe ver, dizzi ness, i ns o m nia, de pressi o n  
Der mat ol o gic: Dr y s ki n, pr urit us , ras h 
E n d ocri ne & meta b olic: H y p oal b u mi ne mia, h y p o ma g nese mia , 
h y per p h os p hate mia  
E ye: Peri or bital e de ma, bl urre d visi o n  
Gastr oi ntesti nal: u p per a b d o mi nal pai n, a b d o mi nal diste nsi o n, st o matitis, 
a n ore xia, decr ease d a p petite,  dr y m o ut h  
He mat ol o gic: T hr o m b oc yt o pe nia, a ne mia  
He patic: A S T i ncrease d, A L T i ncrease d  
Ne ur o m usc ular & s keletal: Bac k pai n, art hral gia, ast he nia  
Res pi[INVESTIGATOR_1305] y: D ys p nea, c o u g h  
Miscella ne o us: Al o pecia , L o w bl o o d p otassi u m  
 
R are A d verse E ve nts ( I m p ort a nt or life-t hre ate ni n g), < 1 %  
Left ve ntric ular s yst olic d ysf u ncti o n , Li ver i nj ur y/fail ure 
 
[ADDRESS_410813] u g pr oc ure me nt:  
Astra Ze neca will s u p pl y sel u meti ni b or place b o t o Cli nical Researc h Ser vices, a 
di visi o n of R x Cr ossr oa ds b y Mc Kess o n f or distri b uti o n t o partici pati n g sites. N o 
bli n de d starter s u p plies will be a vaila ble f or t his st u d y. Bli n de d, patie nt -s pecific 
cli nical s u p plies will be se nt t o t he re gisteri n g i n vesti gat or at t he ti me of 
ra n d o mizati o n a n d s h o ul d arri ve wit hi n [ADDRESS_410814] a me m ber of t he Cli nical Researc h Ser vices 
tea m:  
  
Cli nical Researc h Ser vices, a di visi o n of R x Cr ossr oa ds b y Mc Kess o n  
Cli nical Researc h Ser vices  
 
 
 
O ut d ate d or re m ai ni n g dr u g is t o be destr oye d o n -site as per pr oce d ures i n pl ace at 
e ac h i nstit uti o n. 
 
[ADDRESS_410815] c o m m o nl y re p orte d si de effects 
wit h t his a ge nt (i ncl u di n g na usea, diarr hea, c o nsti pati o n, d ys pe psia a n d 
v o miti n g). Ma na ge s y m pt o maticall y a n d assess f or effecti ve ness of 
i nter ve nti o n. 
 
[ADDRESS_410816] patie nts t o re p ort a n y li m b s welli n g ( us uall y le gs) t o t he st u d y 
tea m. Rarel y L V E F d ysf u ncti o n has bee n see n.  
 
1 5. 1 9 7  M o nit or L F T’s.  
 
1 5. 1 9 8  M o nit or C B C w/ di ff. I nstr uct patie nts t o re p ort a n y u n us ual br uisi n g or 
blee di n g t o t he st u d y tea m.  
 
[ADDRESS_410817] u d y tea m. 
1 5. 1 9 9 d    Assess patie nt’s c o nc o mita nt me dicati o ns as t here are n u mer o us dr u g t o 
dr u g i nteracti o ns.  
 
1 5. 2  T h yr o ge n ™  (r h T S H, t h yr otr o pi n alfa f or i njecti o n) 
 
Effecti ve c o n d uct of R AI t hera p y re q uires sti m ulati o n b y T S H i n or der t o ma xi mize  R AI u pta ke 
b y  t h yr oi d cells. Rec o m bi na nt h u ma n T S H (r h T S H or T h yr o ge n ™ ) will be use d t o sti m ulate 
i o di de u pta ke acc or di n g t o t he ma n ufact urer’s rec o m me n dati o n ( 0. 9 m g i ntra -m usc ular i njecti o n 
f or 2 da y s pri or t o t he R AI a d mi nistrati o n  acc or di n g t o t he Secti o n 4. 0 ). T his all o ws patie nts t o 
a v oi d t he h y p ot h yr oi dis m state, si nce t he y ca n mai ntai n t heir r o uti ne  t h yr oi d h or m o ne 
s u p ple me ntati o n. Patie nts or cli nicia ns c h o osi n g wit h dra wal of t h yr oi d  h or m o ne tr eat me nt f or 
t his p ur p ose will be i neli gi ble f or t his st u d y.  
 
[ADDRESS_410818] u g pr oc ure me nt:  C o m mercial s u p plies. P har macies or cli nics s hall o btai n 
s u p plies fr o m n or mal c o m mercial s u p pl y c hai n or w h olesaler.  
 
1 5. 3  Ra di oacti ve i o di ne ( R AI)  
 
1 5. 3 1  T hera pe utic R AI  d ose (1 3 1I) 
 
Patie nts < 7 0 years of a ge will be treate d wit h 1 5 0 m Ci 1 3 1I ( +/- 5 m Ci). Patie nts > 7 0 
years of a ge ca n be treate d wit h a 1 3 1I acti vit y fr o m 1 0 0 m Ci u p t o a n d i ncl u di n g 1 5 0 
m Ci ( +/ - 5 m Ci f or 1 0 0 m Ci or 1 5 0 m Ci a d mi nistere d acti vities); f or t h ese patie nts, 
t he acti vit y t o be a d mi nistere d m ust be deter mi ne d b y t he i n vesti gat or at t he ti me of 
st u d y re gistrati o n. 
 
T h o u g h perf or mi n g w h ole bl o o d a n d b o d y d osi metr y t o deter mi ne ma xi m u m 
t olerate d acti vit y ( M T A) is N O T  re q uire d, f or ce nters at w hic h t his e val uati o n is d o ne 
pri or t o t hera pe utic [ADDRESS_410819] u d y a d mi nistrati o n ( Wee k 4), l o wer 1 3 1I acti vities t ha n w hat 
is rec o m me n de d here ma y  be a d mi nistere d if t he M T A is calc ulate d t o be l o wer t ha n 
t he l o wer li mit of w hat is all o we d per pr ot oc ol or w hat has bee n deter mi ne d t o be 
gi ve n  (f or patie nts > 7 0 years of a ge).  E x a m ples (t hese are a p plica ble o nl y i n 
i nsta nces i n w hic h d osi metr y was perf or me d pri or t o t hera pe utic 1 3 1I a d mi nistrati o n): 
1) P atie nts < 7 0 ye ars of a ge: If t he d osi metr y-deter mi ne d M T A val ue is l ess t ha n 1 5 0 
m Ci, t he n a R AI acti vit y less t ha n 1 5 0 m Ci ma y be a d mi nistere d; 2) P atie nts > 7 0 
ye ars of a ge: If t he d osi metr y-deter mi ne d M T A val ue is less t ha n t he acti vit y t hat was 
deter mi ne d t o be gi ve n at t he ti me of st u d y re gistrati o n, t he n a l o wer R AI a cti vit y 
ma y be a d mi nistere d, e ve n acti vities less t ha n 1 0 0 m Ci if t he M T A is bel o w t his 
t hres h ol d. D osi metr y ca n N O T  be use d t o j ustif y a d mi nisteri n g t hera pe utic 1 3 1I 
acti vities hi g her t ha n w hat has bee n rec o m me n de d per t his pr ot oc ol.  
 
A d mi nistrati o n of T h yr o ge n ™ a n d/ or t hera pe utic 1 3 1I at a facilit y ot her t ha n t he 
partici pati n g site is all o we d if d oc u me ntati o n of t he dates a n d a m o u nt/acti vit y of dr u g 
/ra di ois ot o pe a d mi nistere d is pr o vi de d t o verif y a d here nce t o pr ot oc ol re q uire me nts. 
 
A n y f or m of oral 1 3 1I (e. g., ca ps ule or li q ui d) is all o we d. 
 
[ADDRESS_410820] u g pr oc ure me nt: C o m mercial s u p plies. P har macies or cli nics s hall o btai n s u p plies 
fr o m n or mal c o m mercial s u p pl y c hai n or w h olesaler.  
 
[ADDRESS_410821] b o or sel u meti ni b f or t he treat me nt of patie nts wit h 
R AI A  rec urre nt a n d/ or metastatic t h yr oi d ca ncer. Hist orical res p o nse  rate t o a si n gle d ose of 
R AI ca n be diffic ult t o esti mate fr o m retr os pecti ve data t hat i ncl u de heter o ge neit y wit h re gar ds 
t o t he e xte nt of disease treate d, R AI d oses a d mi nistere d, patie nt pre parati o n, res p o nse 
assess me nts etc. N o net heless, a  retr os pecti ve a nal ysis has de m o nstrate d t hat t he  res p o nse rate 
f or first-li ne 1 3 1I t hera p y al o ne f or rec urre nt/ metastatic R AI A t h yr oi d ca ncer wit h meas ura ble 
disease is ge nerall y ar o u n d 2 0 % (Sa bra et al., 2 0 1 3 ). We esti mate t hat patie nts wit h n o n -
meas urea ble disease a n d wit h t he ser u m t h yr o gl o b uli n criteria descri be d i n t his pr ot oc ol will 
ha ve a res p o nse rate of a p pr o xi matel y 5 0 %.  A ntici pati n g t hat 4 0 % of t he patie nts accr ue d wi ll 
ha ve meas urea ble disease a n d 6 0 % wit h n o n -meas urea ble disease o nl y (re q uiri n g ser u m T G 
meas ure me nts t o be use d i n res p o nse assess me nt), t he pre dicte d res p o nse rate f or t his 
p o p ulati o n w o ul d be 4 0 %. It is h o pe d t hat t he c o m bi nati o n of sel u meti ni b a n d 1 3 1I ca n i ncrease 
t he res p o nse rate t o 6 5 % .  
 
T his  trial will als o c o m pare t he best o verall res p o nse rate, pr o gressi o n -free s ur vi val ( P F S), 
c ha n ges i n ser u m t h yr o gl o b uli n le vels  a n d a d verse e ve nt rates  bet wee n t he t w o treat me nt ar ms. 
I n a d diti o n, we will e x pl ore t he ge n o mic a n d tra nscri pt o mic la n dsca pe of R AI A t u m ors f or 
si g nat ures t hat c orrelate t o t hera pe utic be nefit ac hie ve d i n patie nts wit h R AI -a vi d rec urre nt 
a n d/ or metastatic t h yr oi d ca ncer treate d wit h [ADDRESS_410822] b o or sel u meti ni b f or t he treat me nt of patie nts wit h R AI A  rec urre nt a n d/ or metastatic 
t h yr oi d ca ncer at t he 6 -m o nt h ti me p oi nt  (“ 6-m o nt h ti me p oi nt” refers t o t he assess me nts 
desi g nate d t o occ ur a p pr o xi matel y [ADDRESS_410823] b o or 
sel u meti ni b has bee n a d mi nistere d , w hic h ma y be 6 m o nt hs +/- 1  wee k fr o m  t he ti me 
t hera pe utic R AI is a d mi nistere d. F or patie nts wit h n o n -meas urea ble disease, T G val ues o btai ne d 
o utsi de t his wi n d o w ma y be all o we d if re peat meas ure me nts were re q uire d t o e ns ure t he t his 
val ue was o btai ne d i n t he c o nte xt of a T S H <  0. 4 .).  
 
A patie nt will be classifie d as a res p o n der if t he y ha ve a partial or c o m plete res p o nse at t he 6-
m o nt h ti me p oi nt w he n c o m pare d t o t he baseli ne, pre -st u d y ra di ol o gic sca n(s) acc or di n g t o t he 
criteria o utli ne d i n Secti o n 1 1. 0  (c o nfir mati o n of res p o nse is n ot re q uire d) . T he pr o p orti o n of 
patie nts wit h a res p o ns e will be calc ulate d a n d c o m pare d bet wee n t he 2 ar ms usi n g a C hi -s q uare 
or Fis her’s E xact test.  All eli gi ble patie nts w h o are ra n d o mize d a n d be gi n treat me nt will be 
e val ua ble f or t he pri mar y e n d p oi nt.  
 
It is p ossi ble t hat patie nts will ha ve cli nical, ra di ol o gic, or bi oc he mical e vi de nce of disease 
pr o gressi o n earl y i n t he st u d y a n d still de m o nstrate be nefit fr o m t he st u d y treat me nt later i n t he 
st u d y f or se veral reas o ns: 1) sel u meti ni b al o ne pri or t o R AI ma y n ot ha ve si g nifica nt cli nical 
efficac y, 2) T h yr o ge n ™  sti m ulati o n ca n tra nsie ntl y i ncrease t u m or size w hic h ca n be mista ke n 
f or disease pr o gressi o n; 3) t he t hera pe utic effects of R AI ca n be dela ye d; a n d 4) e vi de nce of 
pr o gressi o n ma y be e vi de nt pri or t o a d mi nistrati o n of R AI. He nce, patie nts wit h e vi de nce of 
ra di o gra p hic or cli nical P D n ote d pri or t o t he [ADDRESS_410824] u d y a n d c o nti n ue t o recei ve treat me nt a n d/ or be e val uate d f or res p o nse at t he discreti o n of t he 
treati n g p h ysicia n. T he fi nal o bjecti ve res p o nse assess me nt  at 6 m o nt hs f or t hese patie nts will 
be base d u p o n a c o m paris o n bet wee n t he 6 -m o nt h ra di ol o gic sca n(s) (a n d ser u m t h yr o gl o b uli n, 
  
 5 4  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
if a p plica ble) a n d t he baseli ne, pre -st u d y ra di ol o gic sca ns (a n d ser u m t h yr o gl o b uli n, if 
a p plica ble). H o we ver, if i n t he o pi [INVESTIGATOR_9384] o n of t he treati n g p h ysicia n t hese patie nts are u nli kel y t o 
de m o nstrate be nefit at t he 6 -m o nt h ti me p oi nt, t he patie nts will be c o nsi dere d t o ha ve ha d a 
pr o gressi o n/ deat h e ve nt, cate g orize d as n o n -res p o n ders, a n d ta ke n off t he st u d y. 
 
Patie nts w h o recei ve a d diti o nal treat me nt f or t heir t h yr oi d ca ncer o utsi de of t his pr ot oc ol pri or 
t o t he 6-m o nt h ti me p oi nt (e xce pt f or t h yr oi d h or m o ne T S H s u p pressi o n, palliati ve ra diati o n t o 
a n o n-tar get lesi o n, or t hera p y t o pre ve nt pat h ol o gic fract ures ca use d b y b o ne metastases (e. g. 
z ole dr o nic aci d a n d de n os u ma b)) will be c o nsi dere d n o n -res p o n ders. 
 
Fi n al A n al ysis f or Pri m ar y E n d p oi nt : T he pri mar y g oal is t o c o m pare [ADDRESS_410825] a si g nifica nt differe nce bet wee n a res p o nse rate of 4 0 % i n t he c o ntr ol 
gr o u p vs. 6 5 % i n t he e x peri me ntal gr o u p  ( o d ds rati o f or res p o nse of 2. 7 8 6, wit h 1-si de d t y pe I 
err or = 0. 1 5 a n d p o wer = 8 0 % ). All patie nts w h o meet t he eli gi bilit y criteria, si g n t he c o nse nt 
f or m, are ra n d o mize d, a n d start treat me nt will be e val ua ble.  
 
1 6. 3  Sec o n dar y E n d p oi nts  
 
T he f oll o wi n g e n d p oi nts will be c o m pare d bet wee n t he 2 ar ms: best o verall res p o nse , 6- m o nt h 
pr o gressi o n -free s ur vi val, c ha n ge s i n ser u m t h yr o gl o b uli n le vels, a n d a d verse e ve nt rates 
bet wee n t he [ADDRESS_410826] o ver all res p o nse : T he best o verall res p o nse will be c o m pare d bet wee n t he t w o acc or di n g 
t o t he criteria o utli ne d i n Secti o n [ADDRESS_410827] u d y.  
 
Pr o gressi o n -Free S ur vi v al : Pr o gressi o n -free s ur vi val ( P F S) is defi ne d as t he ti me fr o m st u d y 
e ntr y t o t he first of eit her disease pr o gressi o n or deat h fr o m a n y ca use, w here disease 
pr o gressi o n will be deter mi ne d base d o n criteria o utli ne d i n Secti o n [ADDRESS_410828] will be use d t o c o m pare t he 2 treat me nt 
ar ms. E vi de nce of pr o gressi o n n ote d  fr o m t he ti me of re gistrati o n t o wit hi n 6 m o nt hs after 1 3 1I 
t hera p y ma y be disre gar de d as a pr o gressi o n e ve nt if t he treati n g p h ysicia n feels it is reas o na ble 
acc or di n g t o t he rati o nale detaile d i n Secti o n 1 6. 2 . T he res p o nse assess me nt at 6 m o nt hs f or 
t hese patie nts will be base d u p o n a c o m paris o n bet wee n t he 6-m o nt h  ra di ol o gic sca n(s) a n d t he 
baseli ne,  pre -st u d y ra di ol o gic sca ns. I n a d diti o n, t he 6-m o nt h P F S rate will als o be c o m pare d 
bet wee n t he ar ms.  
 
Ser u m T h yr o gl o b uli n Le vels : C ha n ges i n t h yr o gl o b uli n will be assesse d. T he  Wilc o x o n Ra n k -
S u m test will be use d t o c o m pare t he c ha n ge s i n t h yr o gl o b uli n (pre -R AI a n d p ost -R AI) bet wee n 
t he t w o treat me nt ar ms. ( T his a nal ysis will n ot be p ossi ble f or patie nts wit h detecta ble 
t h yr o gl o b uli n a nti b o dies.) 
 
A d verse e ve nts : T he ma xi m u m gra de f or eac h t y pe of a d verse e ve nt will be s u m marize d usi n g 
C T C A E versi o n 4. 0. T he fre q ue nc y a n d perce nta ge of gra de 3 + a d verse e ve nts will be 
c o m pare d bet wee n t he 2 treat me nt ar ms. C o m paris o ns bet wee n ar ms will be ma de b y usi n g 
eit her t he C hi -s q uare or Fis her’s E xact test. 
  
 [ADDRESS_410829] ore t he ge n o mic a n d  tra nscri pt o mic la n dsca pe of R AI A t u m ors f or si g nat ures t hat 
c orrelate t o t hera pe utic be nefit ac hie ve d i n patie nts wit h R AI -a vi d rec urre nt a n d/ or metastatic 
t h yr oi d ca ncer treate d wit h [ADDRESS_410830] orat or y 
a nal ysis will i ncl u de c orrelati n g res p o nse t o t u m or ge n ot y pes. All t u m ors will be e val uate d f or 
c o m m o n t h yr oi d ca ncer ge ne m utati o ns ( B R A F, R A S, PI K 3 C A, A K T, R E T/ P T C, 
P A X 8/ P P A R γ). Descri pti ve statistics a n d gra p hical tec h ni q ues will be use d t o s u m marize t his 
data b y  treat me nt ar m.  Gi ve n t he s mall sa m ple size, all t hese a nal yses will be c o nsi dere d 
h y p ot hesis ge nerati n g a n d e x pl orat or y.  
 
1 6. 5  T otal Sa m ple Size  
 
A ma xi m u m of 5 6 e val ua ble patie nts ( 2 8  per ar m) will be accr ue d o nt o t his ra n d o mize d p hase II 
st u d y u nless the st u d y is cl ose d earl y f or e xcessi ve t o xicit y. We a nti ci pate accr ui n g a n 
a d diti o nal 5 % of patie nts t o acc o u nt f or i neli gi bilit y, ca ncellati o n, maj or treat me nt vi olati o n, or 
ot her reas o ns. T heref ore, ma xi m u m accr ual is 6 0 patie nts ( 3 0  per ar m).  
 
 
[ADDRESS_410831] u d y will ta ke a p pr o xi matel y 3 years t o c o m plete . T his all o ws a 6 m o nt h 
f oll o w-u p f or t he fi nal patie nt e nr olle d, al o n g wit h data e ntr y, data clea n -u p, a n d a nal ysis.  
1 6. 8  Data & Safet y M o nit ori n g  
 
T he pri nci pal i n ve sti gat or(s) a n d t he st u d y statisticia n will re vie w t he st u d y at  least t wice a year 
t o i de ntif y accr ual, a d verse e ve nt, a n d a n y e n d p oi nt pr o ble ms t hat mi g ht be de vel o pi n g. T he 
trial is m o nit ore d c o nti n uall y b y t he st u d y tea m w h o are n otifie d of e ver y gra de 4 a n d 5 e ve nt i n 
real ti me. T he Ma y o Cli nic Ca ncer Ce nter ( M C C C) Data Safet y M o nit ori n g B oar d ( D S M B) is 
res p o nsi ble f or re vie wi n g accr ual a n d safet y data f or t his trial at least t wice a year, base d o n 
re p orts pr o vi de d b y t he M C C C Statistical Office.  
 
T he st o p pi n g r ule s pecifie d bel o w is base d o n t he k n o wle d ge a vaila ble at st u d y de vel o p me nt. 
We n ote t hat t he A d verse E ve nt St o p pi n g R ule ma y be a dj uste d i n t he e ve nt of eit her ( 1) t he 
st u d y re-o pe ni n g t o accr ual after a n y te m p orar y s us pe nsi o n or ( 2) at a n y ti m e d uri n g t he 
c o n d uct of t he trial a n d i n c o nsi derati o n of ne wl y ac q uire d i nf or mati o n re gar di n g t he a d verse 
e ve nt pr ofile of t he treat me nt(s) u n der i n vesti gati o n. T he st u d y tea m ma y als o c h o ose t o 
s us pe n d accr ual beca use of u ne x pecte d a d verse e ve nt pr ofiles  t hat ha ve n ot cr osse d t he 
s pecifie d r ule bel o w. 
 
Accr ual will be te m p oraril y s us pe n de d t o t his st u d y if at a n y ti me we o bser ve e ve nts c o nsi dere d 
at least p ossi bl y relate d t o st u d y treat me nt (i.e., a n a d verse e ve nt wit h attri b ute s pecifie d as 
" p ossi ble", "pr o ba ble", or " defi nite") t hat satisf y a n y of t he f oll o wi n g criteria f or eac h ar m 
se paratel y: 
 
  
 5 6  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
•  If at a n y ti me, 6 of t he i nitial 2 0 treate d patie nts or 3 0 % or m ore of all patie nts (i.e. w he n 
accr ual is greater t ha n 2 0 patie nts) ha ve e x perie nce d a gra de 4 n o n -he mat ol o gic a d verse 
e ve nt. 
•  If at a n y ti me, 2 of t he i nitial 2 0 treate d patie nts  or 1 0 % or m ore of all patie nts (i.e. w he n 
accr ual is greater t ha n 2 0 patie nts)  ha ve e x perie nc e d a gra de 5 a d verse e ve nt ( n o n -
pr o gressi ve disease).  
•  I n a d diti o n, eac h gra de [ADDRESS_410832] year (after st u d y acti vati o n), we will 
c o nsi der st o p pi n g t he trial f or sl o w accr ual . 
 
1 6. 9 b  Pri mar y E n d p oi nt C o m pleti o n Ti me Esti mati o n ( F or cli nicaltrails. g o v re p orti n g):  
 
T he pri mar y e n d p oi nt is a c o m paris o n of t he c o nfir me d res p o nse rate  bet wee n t he [ADDRESS_410833] a b o ut 2 5% of patie nts 
will be classifie d as  mi n orities b y race a n d a b o ut 5 5 % of patie nts t o be w o me n. E x pecte d sizes 
of racial b y ge n der s u bse ts are s h o w n i n t he f oll o wi n g ta ble: 
 
Accr u al T ar gets  
Et h nic C ate g or y  Se x/ Ge n der  
Fe m ales  M ales  T ot al  
His pa nic or Lati n o   6  5  1 1  
N ot His pa nic or Lati n o  2 7  2 2  4 9  
Et h nic C ate g or y: T ot al of all s u bjects  3 3  2 7  6 0  
R aci al C ate g or y  
A merica n I n dia n or Ala s ka n Nati ve  0   0   0  
Asia n  2  1  3  
Blac k or Africa n A merica n  6  5  1 1  
Nati ve Ha waiia n or ot her Pacific Isla n der   1   0   1  
W hite  2 4  2 1  4 5  
R aci al C ate g or y: T ot al of all s u bjects  3 3  2 7  6 0  
 
  
 5 7  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
Et h nic 
C ate g ories:  His p a nic or L ati n o –  a pers o n of C u ba n, Me xica n, P uert o Rica n, S o ut h or 
Ce ntral A merica n, or ot her S pa nis h c ult ure or ori gi n, re gar dless of race. 
T he ter m “ S pa nis h ori gi n” ca n als o be use d i n a d diti o n t o “ His pa nic or 
Lati n o.”  
 
N ot His p a nic or L ati n o  
 
R aci al 
C ate g ories:  A meric a n I n di a n or Al as k a n N ati ve –  a pers o n ha vi n g ori gi ns i n a n y of 
t he ori ginal pe o ples of N ort h, Ce ntral, or S o ut h A merica, a n d w h o 
mai ntai ns tri bal affili ati o ns or c o m m u nit y attac h me nt. 
Asi a n –  a pers o n ha vi n g ori gi ns i n a n y of t he ori gi nal pe o ples of t he Far 
East, S o ut heast Asia, or t he I n dia n s u bc o nti ne nt i ncl u di n g, f or e xa m ple, 
Ca m b o dia, C hi na, I n dia, Ja pa n, K orea, Mala ysia, Pa kista n, t he P hili p pi [INVESTIGATOR_332057] n ds, T haila n d, a n d Viet na m. ( N ote: I n di vi d uals fr o m t he P hili p pi [INVESTIGATOR_332057] n ds ha ve bee n rec or de d as Pacific Isla n ders i n pre vi o us data c ollecti o n 
strate gies.)  
Bl ac k or Afric a n A meric a n –  a pers o n ha vi n g ori gi ns i n a n y of t he blac k 
racial gr o u ps of Africa. Ter ms s uc h as “ Haitia n” or “ Ne gr o” ca n be use d i n 
a d diti o n t o “ Blac k or Africa n A merica n.”  
N ati ve H a w aii a n or ot her P acific Isl a n der –  a pers o n ha vi n g ori gi ns i n 
a n y of t he ori gi nal pe o ples of Ha waii, G ua m, Sa m oa, or ot her Pacific 
Isla n ds. 
W hite –  a pers o n ha vi n g ori gi ns i n a n y of t he ori gi nal pe o ples of E ur o pe, 
t he Mi d dle East, or N ort h Africa. 
 
 
 
  
 5 8  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
1 7. 0  P at h ol o g y C o nsi der ati o ns/ Tiss ue Bi os peci me ns  
 
1 7. 1  Tiss ue Bi os peci me n S u b missi o n  
 
1 7. 1 1  S u m mar y Ta ble of Tiss ue Bi os peci me ns f or T his Pr ot oc ol  
 
T y pe of tiss ue 
bi os peci me n t o s u b mit  M a n d at or y 
or o pti o n al  W he n t o 
s u b mit Re as o n f or 
s u b missi o n 
( b ac k gr o u n d/ 
met h o d ol o g y 
secti o n) W her e t o 
fi nd s pecific 
det ails f or 
bi os peci me n 
s u b missi o n 
F or mali n -fi xe d paraffi n-
e m be d de d ( F F P E) tiss ue 
bl oc ks wit h c orres p o n di n g 
H & E ( O R  ( 2 0) 5  micr o n - 
a n d ( 1 0)  1 0 -micr o n 
u nstai ne d sli des wit h 
c orres p o n di n g H & E) Ma n dat or y  ≤ [ADDRESS_410834] u dies 
( Secti o n 1 7.3 ) Secti o n 1 7. 2  
If a n i nstit uti o n is n ot a ble t o pr o vi de t he tiss ue, it d oes n ot ca use t he patie nt t o be i neli gi ble; 
h o we ver, t he c ollecti o n of t hese tiss ues is str o n gl y rec o m me n de d . 
 
1 7. 2  Paraff i n E m be d de d Tiss ue Bl oc ks/ Sli des ( ma n dat or y f or researc h tiss ue) 
 
1 7. 2 1  S u b mit o ne f or mali n fi xe d paraffi n -e m be d de d ( F F P E) t u m or tiss ue bl oc k fr o m t he 
p ri mar y or rec urre nt/ metastatic t h yr oi d ca ncer. A c orres p o n di n g H & E sli de fr o m t he 
s u b mitte d bl oc k m ust be pr o vi de d t o per mit q ualit y assess me nt ( Q A) of tiss ue bl oc k.  
 
1 7. 2 2  T he F F P E tiss ue bl oc k is preferre d; h o we ver, if a n i nstit uti o n is u na ble t o pr o vi de a 
tiss ue bl oc k, c ut 2 0 fi ve-micr o n u nstai ne d sli des a n d m o u nt o n c har ge d glass sli des 
a n d 1 0 te n -micr o n  u nstai ne d sli des m o u nte d o n u nc har ge d sli des. L a bel t he sli des 
wit h t he A C C R U p atie nt I D n u m ber, accessi o n n u m ber, a n d or der of secti o ns 
(i.e., 1-1 1) .  D o n ot use stic k y l a bels o n t he sli des. H & E st ai n t he first c ut sli de 
(i.e., sli de l a bele d 1). F or sa m p les c o ntai ni n g less t ha n 7s q uare milli meters of t u m or 
tiss ue, m ulti ple secti o ns s h o ul d be m o u nte d o nt o eac h sli de t o e ns ure t hat t he 
a p pr o priate a m o u nt of t u m or tiss ue is a vaila ble. I deall y, eac h sli de m ust ha ve a 
mi ni m u m of 7 5 % t u m or tiss ue o n t he sli de t o be dee me d a de q uate f or st u d y. D o n ot 
b a ke or pl ace c o ver sli ps o n t he sli des.   
 
1 7. 2 3  T he f oll o wi n g materials bel o w are ma n dat or y ( u nless i n dicate d ot her wise) a n d 
re q uire d f or s hi p me nt: 
 
•  Paraffi n e m be d de d tiss ue bl oc ks wit h c orres p o n di n g H & E ( or 3 0 sli de s per 
i nstr ucti o ns i n secti o n 1 7. 2 2) 
•  Researc h Tiss ue S peci me n S u b missi o n F or m  
•  S ur gical Pat h ol o g y Re p ort  ( D o n ot re dact t he accessi o n n u m ber(s)) 
•  O perati ve Re p ort -O pti o nal  
  
 5 9  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
1 7. 2 4  S hi p all bl oc k/sli de tiss ue s peci me ns a n d acc o m pa n yi n g materials t o t he f oll o wi n g:  
 
A C C R U O perati o ns Office  
Att n: P C Office ( St u d y R U 2 4 1 3 0 6 I) 
 
 
 
 
[ADDRESS_410835] ora ge  I nf or mati o n 
 
1 7. 3 1  S u b mitte d tiss ue sa m ples will be a nal yze d as f oll o ws:  
 
1 7. 3 1 1  F F P E t u m or  tiss ue bl oc ks/ u nstai ne d sli des will be c ollecte d i n searc h of 
bi o mar kers t hat ma y c orrelate t o cli nical res p o nses t o eit her  [ADDRESS_410836] o m-
desi g ne d Na n ostri n g platf or m f or t w o p ur p oses: a) Detecti o n of f usi o n 
o nc o ge nic tr a nscri pts (t hat ca n n ot be detecte d b y a n e x o n -ca pt ure met h o d), 
a n d b) T o meas ure m R N A le vels of t hree maj or classes of tra nscri pts: 1) 
Mar kers of t he M A P K pat h wa y tra nscri pti o nal o ut p ut (e. g. Et v 1, Et v 4, 
Et v 5, S pr y 2, S pr y 4, D us p 6); 2) Ge nes re q uire d f or t h yr oi d h or m o ne 
bi os y nt hesis (e. g. N k x 2. 1, Pa x 8, F o xe 1, T g, T p o, Ts h R, Nis, Pe n dri n, 
Di o 2); a n d 3) P ossi ble deter mi na nts of i ntri nsic resista nce t o t hera p y, 
i ncl u di n g a da pti ve res p o nses t o M A P K pat h wa y i n hi biti o n t hat ha ve 
alrea d y  bee n  f o u n d t o be rele va nt for B R A F M U T t u m ors (i.e. ne ure g uli n 
me diate d acti vati o n of H E R 3 ki nase) : e. g. Nrg 1 (a n d ot her R T K li ga n ds), 
Her 2, Her 3, T G F β R 2). T he  assa y will i nterr o gate ~ [ADDRESS_410837] u d y are a vaila ble 
f or a nal ysis, m ore a d va nce d D N A a n d R N A a nal ytic tec h ni q ues f or F F P E 
tiss ues (e. g., w h ole e x o me, w h ole ge n o me, R N Ase q, etc.) ma y be a vaila ble 
a n d preferre d o ver t he a p pr oac h detaile d a b o ve.  If s o, t he st u dies disc usse d 
  
 [ADDRESS_410838]. Ja mes 
Fa gi n, Me m orial Sl oa n -Ketteri n g Ca ncer Ce nter ( Ne w Y or k, Ne w Y or k) . 
 
[ADDRESS_410839] u d y, a n y u n use d/re mai ni n g material will be st ore d i n t he 
A C C R U Ce ntral O perati o ns Office (att n: Pat h ol o g y C o or di nat or) f or f ut u re researc h 
acc or di n g t o  t he patie nt c o nse nt per missi o n. P ote ntial f ut ure researc h ma y i ncl u de 
i m m u n o hist oc he mistr y (I H C) a nal yses, D N A e xtracti o n, R N A e xtracti o n, a n d/ or 
tiss ue micr oarra y ( T M A) c o nstr ucti o n t o a nal yze pre dicti ve bi o mar kers, c ha n ges i n 
e x p ressi o n patter n wit h t hera p y, a n d c orrelati o n wit h res p o nse a n d/ or a d verse e ve nts. 
F or T M As, t he d o n or bl oc k re mai ns i ntact e xce pt f or 6 s mall ( 0. 6 m m) h oles w here 
t he c ores were ta ke n. T his pr ocess has mi ni mal i m pact o n t he utilit y of t he bl oc k f or 
f ut ure cli nical dia g n ostic nee ds. W he n a pr ot oc ol is de vel o pe d, it will be prese nte d f or  
A C C R U,  I R B a n d I T O G re vie w a n d a p pr o val. (T hese s peci me ns ma y o nl y be use d 
s u bse q ue ntl y f or I T O G-a p pr o ve d researc h pr ot oc ols .) 
 
[ADDRESS_410840] will be n o tifie d b y t he A C C R U O perati o ns Office 
( Pat h ol o g y C o or di nat or) if t he bl oc k ma y be de plete d. 
 
[ADDRESS_410841] be e ntere d b y Re m ote Date E ntr y ( R D E) a n d c o m plete d b y q ualifie d a n d a ut h orize d 
pers o n nel. Access t he R A V E R D E s yste m t hr o u g h t he i Me di data p ortal at htt ps://l o gi n.i me di data.c o m . 
All data o n t he C R F m ust reflect t he c orres p o n di n g s o urce d oc u me nt. Please refer t o t he A C C R U 
we bsite f or i nstr ucti o ns N O T E: All re p orts m ust be de -i de ntifie d a n d la bele d 
wit h t he st u d y n u m ber, A C C R U patie nt I D n u m ber a n d i nitials.  
 
1 8. 1  S u b missi o n Ti meta ble  
 
I niti al M ateri al(s)  
C R F  Acti ve -M o nit ori n g P h ase  
( C o m plia nce wit h Test Sc he d ule Secti o n 4. 0) 
O n -St u d y  
 2 wee ks  after re gistrati o n  Baseli ne A d verse E ve nt  
R E CI S T Meas ure me nt –  Baseli ne  
Researc h Bl o o d S u b missi o n –  Baseli ne (see 
Secti o n 1 4. 0)  
Rese arc h Tiss ue S u b missi o n - Baseli ne  (see 
Secti o n 1 7. 0)2  
E n d ocri ne La b orat or y - Baseli ne   
O P a n d Pat h Re p orts (see Secti o n 1 7. 0)1 
E n d of Acti ve Treat me nt/ Ca ncel N otificati o n F or m S u b mit  2 w ee ks  after re gistrati o n if 
wit h dra wal/ref usal occ urs pri or t o b e gi n ni n g 
pr ot oc ol t hera p y  
1.  Attac h  a c o p y of O P a n d pat h re p orts i n R A V E usi n g t he S u p p orti n g D oc u me ntati o n F or m f or 
d oc u me ntati o n of disease.  T his is i n a d diti o n t o t he pat h ol o g y material re q uire me nts f or tiss ue 
s u b missi o n ( Secti o n 1 7. 0). 
2.  As per Sec ti o n 1 7. 0, researc h tiss ue bi os peci me n s h o ul d be s u b mitte d ≤ [ADDRESS_410842] Sc he d ule M ateri al(s)  
C R F  Acti ve -M o nit ori n g P h ase  
( C o m plia nce wit h Test Sc he d ule Secti o n 4. 0) 
At eac h e val uati o n 
d uri n g treat me nt  At e n d of 
treat me nt O bser va ti o n 
E val uati o n/ Treat me nt  X3  X   
E val uati o n/ O bser vati o n    X 
Na dir/ A d verse E ve nt  X  X  X2 
R E CI S T  Meas ure me nt    X1 
E n d ocri ne La b orat or y     X  
R T Material  X   
E n d of Acti ve Treat me nt/ Ca ncel N otificati o n   X   
N otificati o n  –  Gra de 4 or 5 N o n -A E R 
Re p ort a ble E ve nts/ H os pi[INVESTIGATOR_1314] o n  At eac h occ urre nce  
(see Secti o n 1 0. 0)   
A D R/ A E R  At eac h occ urre nce  
(see Secti o n 1 0. 0)   
1.  Attac h a c o p y i n R A V E f or d oc u me ntati o n of res p o nse or pr o gressi o n o n t he S u p p orti n g 
D oc u me ntati o n F or m . 
2.  C o m plete o nl y at [ADDRESS_410843] I -1 3 1 e val uati o n d uri n g O bser vati o n (see Secti o n 4. 0).  
3.  C o m plete at eac h e val uati o n d uri n g Acti ve Treat me nt (see Secti o n 4. 0).  
 
 
 
F oll o w -u p M ateri al(s)   
C R F  E ve nt M o nit ori n g P h ase1 
q. [ADDRESS_410844] -I1 3 1 
t hera p y a n d 
e ver y 6 m o nt hs 
after t hat2  At P D After P D  
q.  6  m os. Deat h  Ne w Pri mar y  
E ve nt M o nit ori n g2  X  X X  X  At eac h 
occ urre nce  
1.  If a patie nt is still ali ve 2  years after r a n d o mizati o n , n o f urt her f oll o w-u p is re q uire d.  
2.  A ttac h a c o p y i n R A V E f or d oc u me ntati o n o f pr o gressi o n o n t he S u p p orti n g D oc u me ntati o n F or m. 
 
 
  
 6 3  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
1 9. 0  B u d get  
 
1 9. 1  C osts c har ge d t o patie nt:  
 
Eac h site s h o ul d re vie w t he test sc he d ule ( Secti o n 4. 0) ta ki n g i nt o acc o u nt l ocal a n d re gi o nal 
c o vera ge p olicies t o deter m i ne w hic h ite ms are sta n dar d of ca re a n d w hic h are researc h at t heir 
site. Refer t o t he pa y me nt s y n o psis f or f u n di n g pr o vi de d per accr ual f or c o veri n g st u d y c osts, as 
well as a n y a d diti o nal  i n v oicea bles t hat ma y be all o we d.  
 
1 9. 2  Tests t o be researc h f u n de d:   Bl o o d a n d tiss ue c orrelati ve c ollecti o n a n d a nal ysis.  
 
1 9. 3  Ot her b u d get c o ncer ns:  Place b o/sel u meti ni b pr o vi de d b y Astra Ze neca.  
 
 
[ADDRESS_410845], B. L., B olla g, G., K oles nic k, R., 
T hi n, T. H., R os e n, N., et al. ( 2 0 1 1). S mall-m olec ule M A P K i n hi bit ors rest ore ra di oi o di ne i nc or p orati o n 
i n m o use t h yr oi d ca ncers wit h c o n diti o nal B R A F acti vati o n. J Cli n I n vest 1 2 1 , 4 7 0 0-4 7 1 1.  
 
C o he n, Y., Xi n g, M., Ma m b o, E., G u o, Z., W u, G., Tri n k, B., Beller, U., Westra , W. H., La de ns o n, P. W., 
a n d Si dra ns k y, D. ( 2 0 0 3). B R A F m ut ati o n i n pa pi[INVESTIGATOR_5778] y t h yr oi d carci n o ma. J Natl Ca ncer I nst  9 5 , 6 2 5-
6 2 7.  
 
De Vita, G., Ba uer, L., da C osta, V. M., De Felice, M., Baratta, M. G., De Me n na, M., a n d Di La ur o, R. 
( 2 0 0 5). D ose-de pe n de nt i n h i biti o n of t h yr oi d differe ntiati o n b y R A S o nc o ge nes. M ol E n d ocri n ol 1 9 , 7 6-
8 9.  
 
D or n, R., K o p p, J., V o gt, H., Hei de nreic h, P., Carr oll, R. G., a n d G ulec, S. A. ( 2 0 0 3). D osi metr y -g ui de d 
ra di oacti ve i o di ne treat me nt i n patie nts wit h metastatic differe ntiate d th yr oi d ca ncer: lar gest safe d ose 
usi n g a ris k -a da pte d a p pr oac h. J N ucl Me d  4 4 , 4 5 1-4 5 6.  
 
D ura nte, C., Ha d d y, N., Ba u di n, E., Le b o ulle u x, S., Hartl, D., Tra va gli, J. P., Caill o u, B., Ricar d, M., 
L u m br os o, J. D., De Vat haire, F. , et al. ( 2 0 0 6). L o n g-ter m o utc ome of 4 4 4 patie nts wit h dista nt 
metastases fr o m pa pi[INVESTIGATOR_5778] y a n d f ollic ular t h yr oi d carci n o ma: be nefits a n d li mits of ra di oi o di ne t hera p y. J 
Cli n E n d ocri n ol Meta b  9 1 , 2 8 9 2-2 8 9 9.  
 
D ura nte, C., P u xe d d u, E., Ferretti, E., M orisi, R., M oretti, S., Br u n o, R., Bar b i, F., A ve nia, N., Sci pi o ni, 
A., Verrie nti, A. , et al. ( 2 0 0 7). B R A F m utati o ns i n pa pi[INVESTIGATOR_5778] y t h yr oi d carci n o mas i n hi bit ge nes i n v ol ve d 
i n i o di ne meta b olis m. J Cli n E n d ocri n ol Meta b 9 2 , 2 8 4 0-2 8 4 3.  
 
Eise n ha uer, E. A., T herasse, P., B o gaerts, J., Sc h wartz, L. H.,  Sar ge nt, D., F or d, R., Da nce y, J., Ar b uc k, 
S., G w yt her, S., M o o ne y, M. , et al. ( 2 0 0 9). Ne w res p o nse e val uati o n criteria i n s oli d t u m o urs: re vise d 
R E CI S T g ui deli ne ( versi o n 1. 1). E ur o pea n j o ur nal of ca ncer  4 5 , 2 2 8-2 4 7.  
 
Elisei, R., U g oli ni, C., Vi ola, D., L u pi, C., Bia gi ni, A., Gia n ni ni, R., R o mei, C., Micc oli, P., Pi [INVESTIGATOR_332058], 
A., a n d Bas ol o, F. ( 2 0 0 8). B R A F( V 6 0 0 E) m utati o n a n d o utc o me of patie nts wit h pa pi[INVESTIGATOR_5778] y t h yr oi d 
carci n o ma: a [ADDRESS_410846] u d y. J Cli n E n d ocri n ol Meta b  9 3 , 3 9 4 3-3 9 4 9.  
 
Ha u ge n, B., Ale xa n der, E., Bi ble, K., D o hert y, G., Ma n del, S., Ni kif or o v, Y., et al. ( 2 0 1 5). 2 0 1 5 
A merica n T h yr oi d Ass ociati o n Ma na ge me nt G ui deli nes f or A d ult Patie nts wit h T h yr oi d N o d ules a n d 
Differe ntiate d T h yr oi d Ca ncer. T h yr oi d . E p u b a he a d of pri nt. 
  
 6 4  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 
Ha yes, D. N., L ucas, A. S., Ta n vet ya n o n, T., Krz yza n o ws ka, M. K., C h u n g, C. H., M ur p h y, B. A., Gil bert, 
J., Me hra, R., M o ore, D. T., S hei k h, A., et al. ( 2 0 1 2). P hase II efficac y a n d p har mac o ge n o mic st u d y of 
Sel u meti ni b ( A Z D 6 2 4 4; A R R Y -1 4 2 8 8 6) i n i o di ne -[ADDRESS_410847] or y pa pi[INVESTIGATOR_5778] y t h yr oi d carci n o ma wit h or 
wit h o ut f ollic ular ele me nts. Cli nical ca ncer researc h : a n official j o ur nal of t he A merica n Ass ociati o n 
f or Ca ncer Researc h 1 8 , 2 0 5 6-2 0 6 5.  
 
H o, A. L., Gre wal, R. K., Le b oe uf, R., S her ma n, E.J., Pfister, D. G., Dea n dreis, D., Pe ntl o w, K. S., 
Za nz o nic o, P. B., Ha q ue, S., Ga va ne, S. , et al. ( 2 0 1 3). Sel u meti ni b-e n ha nce d ra di oi o di ne u pta ke i n 
a d va nce d t h yr oi d ca ncer. T he Ne w E n gla n d j o ur nal of me dici ne  3 6 8 , 6 2 3-6 3 2.  
 
Ki m ura, E. T., Ni kif or o va, M. N., Z h u, Z., K na uf, J. A., Ni kif or o v, Y. E., a n d Fa gi n, J. A. ( 2 0 0 3). Hi g h 
pre vale nce of B R A F m utati o ns i n t h yr oi d ca ncer: ge netic e vi de nce f or c o nstit uti ve acti vati o n of t he 
R E T/ P T C -R A S -B R A F si g nali n g pat h wa y i n pa pi[INVESTIGATOR_5778] y t h yr oi d carci n o ma. Ca ncer Res  [ADDRESS_410848] h olt, L., R o bert, C., S os ma n, J. A., Lar ki n, J., Herse y, P., Mi d dlet o n, M. R., 
Ca ntari ni, M. V., Zaz uli na, V., Ke msle y, K. , et al. ( 2 0 1 1). P hase II, O pe n-La bel, Ra n d o mize d Trial of 
t he M E K 1/ 2 I n hi bit or Sel u meti ni b as M o n ot hera p y vers us Te m oz ol o mi de i n Patie nts wit h A dva nce d 
Mela n o ma. Cli nical ca ncer researc h : a n official j o ur nal of t he A merica n Ass ociati o n f or Ca ncer 
Researc h.  
 
Kl u b o -G wiez dzi ns ka, J., B ur ma n, K. D., Va n N ostra n d, D., Mete, M., J o n klaas, J., a n d Wart ofs k y, L. 
( 2 0 1 1a). Ra di oi o di ne Treat me nt of Metastatic T h yr oi d Ca ncer: Relati ve Efficac y a n d Si de Effect Pr ofile 
after Pre parati o n b y T h yr oi d H or m o ne Wit h dra wal Vs. Rec o m bi na nt H u ma n Ts h. T h yr oi d : official 
j o ur nal of t he A merica n T h yr oi d Ass ociati o n. 
 
Kl u b o -G wiez dzi ns ka, J., Va n N ostra n d, D., At ki ns, F., B ur ma n, K., J o n klaas, J., Mete, M., a n d 
Wart ofs k y, L. ( 2 0 1 1 b). Efficac y of d osi metric vers us e m pi[INVESTIGATOR_332059] d acti vit y of 1 3 1I f or t hera p y of 
differe ntiate d t h yr oi d ca ncer. J Cli n E n d ocri n ol Meta b  9 6 , 3 2 1 7-3 2 2 5.  
 
K na uf, J. A., a n d Fa gi n, J. A. ( 2 0 0 9). R ole of  M A P K pat h wa y o nc o pr otei ns i n t h yr oi d ca ncer 
pat h o ge nesis a n d as dr u g tar gets. C urr O pi n Cell Bi ol  2 1 , 2 9 6-3 0 3.  
 
K na uf, J. A., K ur o da, H., Bas u, S., a n d Fa gi n, J. A. ( 2 0 0 3). R E T/ P T C -i n d uce d de differe ntiati o n of 
t h yr oi d cells is me diate d t hr o u g h Y 1 0 6 2 si g nalin g t hr o u g h S H C -R A S -M A P ki nase. O nc o ge ne  2 2 , 4 4 0 6-
4 4 1 2.  
 
K ul kar ni, K., N ostra n d, D., At ki ns, F., Ai ke n, M., B ur ma n, K., & Wart ofs k y, L. ( 2 0 0 6). T he Relati ve 
Fre q ue nc y i n W hic h E m pi[INVESTIGATOR_29121] D osa ges of Ra di oi o di ne W o ul d P ote ntiall y O vertreat or U n dertreat 
Patie nts  W h o Ha ve Metastatic Well -Differe ntiate d T h yr oi d Ca ncer. T h yr oi d  1 6 , 1 0 1 9-1 0 2 3.  
 
Lee, J. H., Lee, E. S., a n d Ki m, Y. S. ( 2 0 0 7). Cli nic o pat h ol o gic si g nifica nce of B R A F V 6 0 0 E m utati o n i n 
pa pi[INVESTIGATOR_5778] y carci n o mas of t he t h yr oi d: a meta -a nal ysis. Ca ncer  1 1 0 , 3 8-4 6.  
 
Li u, D., H u, S., H o u, P., Jia n g, D., C o n d o uris, S., a n d Xi n g, M. ( 2 0 0 7). S u p pressi o n of 
B R A F/ M E K/ M A P ki nase pat h wa y rest ores e x pressi o n of i o di de -meta b olizi n g ge nes i n t h yr oi d cells 
e x pressi n g t he V 6 0 0 E B R A F m uta nt. Cli nical ca ncer researc h : a n official j o ur nal of t he A merica n 
Ass ociati o n f or Ca ncer Researc h  1 3 , 1 3 4 1-1 3 4 9.  
 
Ma x o n, H. R., 3r d, E n glar o, E. E., T h o mas, S. R., Hertz ber g, V. S., Hi n nefel d, J. D., C he n, L. S., S mit h, H., 
C u m mi n gs, D., a n d A de n, M. D. ( 1 9 9 2). Ra di oi o di ne -1 3 1 t hera p y f or well -differe nti ate d t h yr oi d ca ncer -
-a q ua ntitati ve ra diati o n d osi metric a p pr oac h: o utc o me a n d vali dati o n i n 8 5 patie nts. J N ucl Me d  3 3 , 
1 1 3 2 -1 1 3 6.  
  
 6 5  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
 
Ma x o n, H. R., T h o mas, S. R., Hertz ber g, V. S., Kereia kes, J. G., C he n, I. W., S perli n g, M.I., a n d Sae n ger, 
E. L. ( 1 9 8 3). Relati o n  bet wee n effecti ve ra diati o n d ose a n d o utc o me of ra di oi o di ne t hera p y f or t h yr oi d 
ca ncer. T he Ne w E n gla n d j o ur nal of me dici ne  3 0 9 , 9 3 7-9 4 1.  
 
Mazzaferri, E. L., a n d Kl o os, R. T. ( 2 0 0 1). Cli nical re vie w 1 2 8: C urre nt a p pr oac hes t o pri mar y t hera p y 
f or pa pi[INVESTIGATOR_5778] y an d f ollic ular t h yr oi d ca ncer. J Cli n E n d ocri n ol Meta b  8 6 , 1 4 4 7-1 4 6 3.  
 
Ni kif or o v, Y. E., a n d Ni kif or o va, M. N. ( 2 0 1 1). M olec ular ge netics a n d dia g n osis of t h yr oi d ca ncer. Nat 
Re v E n d ocri n ol  7 , 5 6 9-5 8 0.  
 
Pe ntl o w, K. S., Gra ha m, M. C., La m brec ht, R. M., Da g hi g hia n , F., Bac harac h, S. L., Be n drie m, B., Fi n n, 
R. D., J or da n, K., Kalai gia n, H., Kar p, J. S. , et al. ( 1 9 9 6). Q ua ntitati ve i ma gi n g of i o di ne-[ADDRESS_410849] ors i n t he 
C o ntr olle d Cli nical Trial. Bi o metrics 1 9 7 5; 3 1( 1): 1 0 3 -1 1 5.  
 
Ricarte -Fil h o, J. C., R y der, M., C hitale, D. A., Ri vera, M., He g u y, A., La da n yi, M., Ja na kira ma n, M., 
S olit, D., K na uf, J. A., T uttle, R. M. , et al. ( 2 0 0 9). M utati o nal pr ofile of a d va nce d pri mar y a n d metastatic 
ra di oacti ve i o di ne-refract or y t h yr oi d ca ncers re veals disti nct pat h o ge netic r oles f or B R A F, PI K [ADDRESS_410850] e ba n, P. 
( 2 0 0 6). T he o nc o ge ne B R A F V 6 0 0 E is ass ociate d wit h a hi g h ris k of rec urre nce a n d less differe ntiate d 
pa pi[INVESTIGATOR_5778] y t h yr oi d carci n o ma d ue t o t he i m pair me nt of Na +/I - tar geti n g t o t he me m bra ne. E n d ocr Relat 
Ca ncer  1 3 , 2 5 7-2 6 9.  
 
Sa bra, M. M., D o mi n g uez, J . M., Gre wal, R. K., Lars o n, S. M., G h ossei n, R. A., T uttle, R. M., a n d Fa gi n, 
J. A. ( 2 0 1 3). Cli nical o utc o mes a n d m olec ular pr ofile of differe ntiate d t h yr oi d ca ncers wit h ra di oi o di ne -
a vi d dista nt metastases. J Cli n E n d ocri n ol Meta b  9 8 , E 8 2 9-8 3 6.  
 
S g o ur os, G., K ol bert, K. S., S hei k h, A., Pe ntl o w, K. S., M u n, E. F., Bart h, A., R o b bi ns, R.J., a n d Lars o n, 
S. M. ( 2 0 0 4). Patie nt -s pecific d osi metr y f or 1 3 1I t h yr oi d ca ncer t hera p y usi n g 1 2 4I P E T a n d 3 -
di me nsi o nal -i nter nal d osi metr y ( 3 D-I D) s oft ware. J N ucl Me d 4 5 , 1 3 6 6-1 3 7 2 . 
 
S oares, P., Tr o visc o, V., R oc ha, A. S., Li ma, J., Castr o, P., Pret o, A., Ma xi m o, V., B otel h o, T., Ser uca, 
R., a n d S o bri n h o -Si m oes, M. ( 2 0 0 3). B R A F m utati o ns a n d R E T/ P T C rearra n ge me nts are alter nati ve 
e ve nts i n t he eti o pat h o ge nesis of P T C. O nc o ge ne  2 2 , 4 57 8 -4 5 8 0.  
 
Tala, H., R o b bi ns, R., Fa gi n, J. A., Lars o n, S. M., a n d T uttle, R. M. ( 2 0 1 1). Fi ve -year s ur vi val is si milar 
i n t h yr oi d ca ncer patie nts wit h dista nt metastases pre pare d f or ra di oacti ve i o di ne t hera p y wit h eit her 
t h yr oi d h or m o ne wit h dra wal or rec o m bi na nt h u ma n T S H. J Cli n E n d ocri n ol Meta b  9 6 , 2 1 0 5-2 1 1 1.  
 
T h o mas, S. R., Ma x o n, H. R., a n d Kereia kes, J. G. ( 1 9 7 6). I n vi v o q ua ntitati o n of lesi o n ra di oacti vit y 
usi n g e xter nal c o u nti n g met h o ds. Me dical p h ysics  0 3 , 2 5 3-2 5 5.  
 
T uttle, R., Le b oe uf, R., R o b bi ns, R., Q uale y, R., Pe ntl o w, K., Lars o n, S., & C ha n, C. ( 2 0 0 6). E m pi[INVESTIGATOR_332060] i o di ne d osi n g re gi me ns fre q ue ntl y e xcee d ma xi m u m t olerate d acti vit y le vels i n el derl y 
patie nts wit h t h yr oi d ca ncer. J o ur nal of N uclear Me dici ne, 4 7 , 1 5 8 7-9 1.  
 
 
  
 6 6  R U 2 4 1 3 0 6I  
  A d de n d u m 9  
Z h u, Z., Cia m pi, R. , Ni kif or o va, M. N., Ga n d hi, M., a n d Ni kif or o v, Y. E. ( 2 0 0 6). Pre vale nce of 
R E T/ P T C rearra n ge me nts i n t h yr oi d pa pi[INVESTIGATOR_5778] y carci n o mas: effects of t he detecti o n met h o ds a n d ge netic 
heter o ge neit y. J Cli n E n d ocri n ol Meta b  [ADDRESS_410851] ate f or C a ncer Tre at m e nt T ri als  
( E n glis h L a n g u a ge) 
 
* N O T E S F O R L O C A L I N V E S TI G A T O R S  
 
•  T he g oal of t he i nf or me d c o nse nt pr ocess is t o pr o vi de pe o ple wit h s ufficie nt i nf or mati o n f or 
ma ki n g i nf or me d c h oices. T he i nf or me d c o nse nt f or m pr o vi des a s u m mar y of t he cli nical st u d y 
a n d t he i n di vi d ual's ri g hts as a researc h partici pa nt. It ser ves as a starti n g p oi nt f or t he necessar y 
e xc ha n ge of i nf or mati o n bet wee n t he i n vesti gat or a n d p ote ntial researc h partici pa nt. T his 
te m plate f or t he i nf or me d c o nse nt f or m is o nly o ne part of t he lar ger pr ocess of i nf or me d c o nse nt. 
F or m ore i nf or mati o n a b o ut i nf or me d c o nse nt, re vie w t he " Rec o m me n dati o ns f or t he 
De vel o p me nt of I nf or me d C o nse nt D oc u me nts f or Ca ncer Cli nical Trials" pre pare d b y t he 
C o m pre he nsi ve W or ki n g Gr o u p o n I nf o r me d C o nse nt i n Ca ncer Cli nical Trials f or t he Nati o nal 
Ca ncer I nstit ute.  T he We b site a d dress f or t his d oc u me nt is 
 
 
•  A bla n k li ne, _ _ _ _ _ _ _ _ _ _, i n dicates t hat t he l ocal i n vesti gat or s h o ul d pr o vi de t he a p pr o priate 
i nf or mati o n bef ore t he d oc u me nt is re vie we d wit h t he pr os pecti ve researc h partici pa nt.  
 
•  S u g gesti o n f or L oc al I n vesti gat ors: A n N CI pa m p hlet e x plai ni n g cli nical trials is a vaila ble f or 
y o ur patie nts.  T he pa m p hlet is e ntitle d: "If Y o u Ha ve Ca ncer … W hat Y o u S h o ul d K n o w a b o ut 
Cli nical Trials".  T his pa m p hlet ma y be or dere d o n t he N CI We b site at  
htt ps://cissec ure. nci. ni h. g ov/ nci p u bs/  or call 1 -8 0 0 -4 -C A N C E R ( 1 -8 0 0 -4 2 2 -6 2 3 7) t o re q uest a 
free c o p y.  
 
•  O pti o nal feat ure f or L ocal I n vesti gat ors: Refere nce a n d attac h dr u g s heets, p har mace utical 
i nf or mati o n f or t he p u blic, or ot her material o n ris ks. C hec k wit h y o ur l ocal I R B re gar di n g re vie w 
of a d diti o nal materials.  
 
* T hese n otes f or i n vesti gat ors are i nstr ucti o nal a n d s h o ul d n ot be i ncl u de d i n t he i nf or me d c o nse nt 
f or m gi ve n t o t he pr os pecti ve researc h partici pa nt.  
 
  A p pe n di x I  
A d de n d u m [ADDRESS_410852] u d y of R a di o acti ve I o di ne ( R AI)  i n C o m bi n ati o n wit h 
Pl ace b o or Sel u meti ni b  f or t he Tre at me nt of R AI-A vi d Rec urre nt/ Met ast atic T h yr oi d C a ncers  
 
T his is a n i m p ort a nt f or m. Ple ase re a d it c ar ef ully. It tells y o u w h at y o u need t o k n o w a b o ut t his 
rese arc h st u dy.  If y o u a gree t o t a ke p art i n t his st udy, y o u nee d t o si g n t his f or m.  Y o ur si g n at ure 
me a ns t h at y o u h ave bee n t ol d a b o ut t he  st u dy a n d w h at t he ris ks are. Y o ur si g n at ure o n t his f or m als o 
me a ns t h at y o u w a nt t o t a ke p ar t i n t his st u dy. 
 
T his is a cli nical tr ial, a t y pe of researc h st u d y. Y o ur st u d y d oct or will e x pla i n t he cli nical trial t o y o u. 
Cli nical trials i ncl u de o nl y pe o ple w h o c h o ose t o ta ke part. Please ta ke y o ur ti me t o ma ke y o ur decisi o n 
a b o ut ta ki n g part. Y o u ma y disc uss y o ur decisi o n  wit h y o ur frie n ds a n d fa mil y. Y o u ca n als o disc uss it 
wit h y o ur healt h care tea m. If y o u ha ve a n y q uesti o ns, y o u ca n as k y o ur st u d y d oct or f or m ore 
e x pla nati o n.  
 
Y o u are bei n g as ke d t o ta ke part i n t his researc h st u d y beca use y o u  ha ve t h yr oi d ca ncer t hat has s prea d 
a n d c o ul d p ote ntiall y be treate d wit h ra di oacti ve i o di ne.   
 
 
W h y is t his rese arc h st u d y bei n g d o ne ?  
 
T he p ur p ose of t his researc h st u d y is t o fi n d o ut if ra di oacti ve i o di ne is m ore effecti ve w he n use d i n 
c o m bi nati o n wit h t he st u d y dr u g, sel u meti ni b, f or t he treat me nt of t h yr oi d ca ncer t hat has s prea d.  
 
Ma n y t h yr oi d ca ncers a bs or b i o di ne. Beca use of t his, d oct ors ofte n gi ve ra di oacti ve i o di ne al o ne t o treat 
t h yr oi d ca ncer as part of sta n dar d practice. It is t h o u g ht t hat the m ore t h yr oi d t u m ors are a ble t o a bs or b 
ra di oacti ve i o di ne, t he m ore li kel y it is t hat t he ra di oacti ve i o di ne will ca use t h ose t u m ors t o s hri n k.   
 
T he g oal of t his st u d y is t o fi n d o ut if sel u meti ni b ca n hel p ra di oacti ve i o di ne w or k better i n patie nts 
w h ose t u m ors st ill a bs or b ra di oacti ve i o di ne. T o fi g ure t his o ut, treat me nt wit h ra di oacti ve i o di ne pl us a 
place b o i n o ne gr o u p of patie nts will be c o m pare d t o treat me nt wit h ra di oacti ve i o di ne pl us sel u meti ni b  i n 
a n ot her gr o u p of patie nts. A place b o is a n i nacti ve s u bsta nce t hat l o o ks t he sa me as, a n d is gi ve n t he sa me 
wa y as, t he acti ve st u d y dr u g bei n g teste d (sel u meti ni b, i n t his case).    
 
I n t his st u d y, y o u will get eit her t he ra di oacti ve i o di ne a n d a place b o, or t he ra di oacti ve i o di ne a n d 
sel u meti ni b. Y o u will n ot get b ot h. T he effects, g o o d a n d/ or ba d, of ra di oacti ve i o di ne pl us place b o or 
ra di oacti ve i o di ne pl us sel u meti ni b o n y o u a n d y o ur t h yr oi d ca ncer will be st u die d. 
 
 
H o w m a n y pe o ple will t a ke p art i n t he rese arc h st u d y ?  
 
A b o ut [ADDRESS_410853] us sel u meti ni b; t he ot her gr o u p will recei ve 
ra di oacti ve i o di ne pl us a place b o. 
 
  A p pe n di x I  
A d de n d u m [ADDRESS_410854] u d y ? 
 
 
Bef ore y o u be gi n t he st u d y …   
 
Y o u will nee d t o ha ve t he f oll o wi n g e xa ms, tests or pr oce d ures t o fi n d o ut if y o u ca n be i n t he st u d y. 
T hese e xa ms, t ests or pr oce d ures are part of re g ular ca ncer care a n d ma y be d o ne e ve n  if y o u do n ot j oi n 
t he st u d y. If y o u ha ve ha d s o me of t he m rece ntl y, t hey ma y n ot nee d t o be re peate d. T his will be u p t o 
y o ur st u d y d oct or.  
 
•  Me dical hist or y a n d p h ysical e xa m, i ncl u di n g  p ulse, bl o o d press ure, hei g ht, wei g ht a n d a n 
assess me nt of h o w well y o u perf or m acti vities of dail y li vi n g.  
•  R o uti ne bl o o d tests. A b o ut 2 teas p o o ns of bl o o d will be dra w n.  
•  E ye e xa m.  
•  A pre g na nc y test d o ne b y ta ki n g a bl o o d sa m ple fr o m a vei n i n y o ur ar m wit hi n [ADDRESS_410855] u d y (if y o u are a w o ma n of c hil d beari n g p ote ntial). 
•  A meas ure me nt a n d e val uati o n of y o ur t u m or b y M RI a n d/ or C T sca n.  
•  A n ec h ocar di o gra m a n d electr ocar di o gra m t o l o o k at y o ur heart a n d heart val ves t o see h o w well 
t he y are w or ki n g. 
•  A c hec k t o see if a n y of t he si de effects t hat ma y be ca use d  b y t he st u d y dr u gs are alrea d y prese nt.  
 
 
D uri n g t he st u d y   
 
If t he e x a ms, tests a n d pr oce d ures s h o w t h at y o u c a n be i n t he st u d y, a n d y o u c h o ose t o t a ke p art, 
t he n y o u will nee d t he f oll o wi n g tests a n d proce d ures. T he y are p art of re g ul ar c a ncer c are. T h e y 
are bei n g d o ne m ore ofte n bec a use y o u are i n t his st u d y.  
 
•  P h ysical e xa m, w hic h ma y i ncl u de p ulse, bl o o d press ure, wei g ht a n d a test of h o w well y o u 
perf or m acti vities of dail y li vi n g.  
•  R o uti ne bl o o d tests. A b o ut 2 teas p o o ns of bl o o d will be dra w n.  
•  Pre g na nc y test (if a p plica ble).  
 
 
Y o u will nee d t hese tests a n d pr oce d ures t h at are eit her bei n g teste d i n t his st u d y or bei n g d o ne t o 
see h o w t he st u d y is affecti n g y o ur b o d y. 
 
•  P h ysical e xa m, w hic h ma y i ncl u de  p ulse, bl o o d press ure, wei g ht a n d a test of h o w we ll y o u 
perf or m acti vities of dail y li vi n g.  
•  R o uti ne bl o o d tests. A b o ut 2 teas p o o ns of bl o o d will be dra w n.  
•  A meas ure me nt a n d e val uati o n of y o ur t u m or b y M RI a n d/ or C T sca n.  
•  Pre g na nc y test (if a p plica ble).  
 
 
  A p pe n di x I  
A d de n d u m 9  
  Pa ge 4  of 1 7  
 
 Rese arc h Tests  
 
•  A bl o o d sa m ple f or researc h tes ts is re q uire d f or t his st u d y. Bef ore treat me nt starts, t he researc h 
bl o o d sa m ple will be ta ke n at t he sa me ti me as t he r o uti ne bl o o d sa m ples b y dra wi n g s o me bl o o d 
fr o m a vei n. A b o ut 2 a d diti o nal teas p o o ns of bl o o d will be dra w n. 
•  Ma n dat or y t u m or tiss ue s u b m issi o n: T his st u d y als o i ncl u des researc h tests t hat will be perf or me d 
o n t u m or tiss ue sa m ples t hat y o u will pr o vi de. T hese sa m ples s h o ul d be tiss ues t hat were o btai ne d 
fr o m previ o us  s ur geries or bi o psies; n o a d diti o n al t u m or tiss ue will be t ake n fr o m y o u d uri n g t his 
st u dy.  
 
S o me of t he researc h tests d o ne o n t he researc h bl o o d a n d tiss ue sa m ples are ge netic tests. Beca use t hese 
ge netic tests are n ot use d f or re g ular me dical care, neit her y o u n or y o ur d oct or will be t ol d t he res ults of 
t he test(s).  T he test res ults will n ot be p ut i n y o ur me dical rec or d eit her. 
 
T here is m ore i nf or mati o n a b o ut t hese researc h tests at t he e n d of t his f or m.  
 
 
Y o u will be "r a n d o mize d " i nt o o ne of t he st u d y gr o u ps descri be d bel o w.  
 
Ra n d o mizati o n mea ns t hat y o u are p ut i nt o a gr o u p b y c ha nce, as i n t he fli p of a c oi n. A c o m p uter 
pr o gra m will place y o u i n o ne of t he st u d y gr o u ps.  Neit her y o u n or y o ur d oct or ca n c h o ose t he gr o u p y o u 
will be i n. Y o u will ha ve a n e q ual  c ha nce of  bei n g place d i n eit her gr o u p. I n t he e ve nt of a n e mer ge nc y, 
y o ur d oct or ma y c o ntact t he s p o ns or t o lear n w hic h gr o u p y o u ha ve bee n place d i n. T his is calle d 
“ u n bli n di n g”. 
 
Y o u will ta ke t he st u d y dr u g (sel u meti ni b  or place b o ) i n pi[INVESTIGATOR_4382] f or m, b y m o ut h, t w o ti mes e ver y da y 
be gi n ni n g o n da y o ne of t he first wee k , a n d c o nti n ue ta ki n g t his u ntil 2 da ys after y o u recei ve t he 
ra di oacti ve i o di ne (1 3 1I) t hera p y.  
 
After a b o ut  t w o wee k s of  treat me nt wit h sel u meti ni b or place b o , y o u will be as ke d t o start a l o w-
i o di ne diet f or t he [ADDRESS_410856] b o , y o u will recei ve t w o i njecti o ns of 
T h yr o ge n ™  t o hel p t he t h yr oi d ca ncer cells  t o ta ke u p ra di oacti ve i o di ne. Y o u  will n ot nee d t o  st o p 
y o ur t h yr oi d h or m o ne re place me nt,  s o y o u s h o ul d n ot s uffer fr o m s y m pt o ms of h y p ot h yr oi dis m. 
After t he T h yr o ge n ™  i njecti o ns, y o u will be treate d wit h [ADDRESS_410857] u d y me dicati o n ( Patie nt Me dicati o n 
Diar y), a n d e ver y da y write d o w n t he da y a n d ti me y o u ta ke t he me dicati o n. If y o u n otice a n y si de effects , 
y o u ca n i ncl u de t his i nf or mati o n i n t he C o m me nts secti o n of t he diar y.  
 
T hi n gs t o a v oi d w hile partici pati n g i n t his st u d y:  
 
•  D o n ot s pe n d ti me i n t he s u n; if y o u d o s pe n d ti me i n t he s u n, o nl y sta y o ut f or a s h ort peri o d of 
ti me a n d be s ure t o use s u nscree n pr otecti o n. 
  A p pe n di x I  
A d de n d u m 9  
  Pa ge 5  of 1 7  
 
 •  D o n ot d o nate bl o o d.  
•  D o n ot use a vita mi n E s u p ple me nt.  
•  D o n ot bec o me pre g na nt; b ot h males a n d fe males s h o ul d use c o ntr ace pti o n  w he n e n ga gi n g i n 
se x ual acti vit y w hile partici pati n g i n t his st u d y a n d f or u p t o [ADDRESS_410858] u d y me dicati o n. 
•  D o n ot breastfee d.  
 
St u d y C ale n d ar  
Y o u will t ake sel u meti ni b or pl ace b o ( 7 5 m g by m o ut h) t wice every d ay be gi n ni n g o n d ay 1 of week 1 
t hr o u g h 2 d ays f oll o wi n g 1 3 1I t her a py, ( a t ot al of a p pr oxi m ately 3 0 d ays) d uri n g t his st u dy. T he c h art 
bel o w s h o ws w h at will h a p pe n t o y o u d uri n g t he tre at me nt peri o d a n d f ut ure f oll o w -u p v isits as 
previ o usly ex pl ai ne d. T he left -h a n d c ol u m n s h o ws t he d ay i n t he st u dy peri o d a n d t he ri g ht -h a n d c ol u m n 
tells y o u w h at t o d o o n t h at d ay. 
 
Sel u meti ni b or Pl ace b o  
All P atie nts i n B ot h Gr o u ps [ADDRESS_410859] u d y •  Me dical hist or y a n d p h ysical e xa m, i ncl u di n g p ulse, bl o o d press ure, hei g ht, wei g ht 
a n d a n assess me nt of h o w well y o u perf or m acti vities of dail y li vi n g.  
•  R o uti n e bl o o d tests.  
•  Ma n dat or y researc h bl o o d sa m ple.  
•  Pre g na nc y test (if a p plica ble).  
•  E ye e xa m.  
•  M RI a n d/ or C T sca n f or t u m or meas ure me nt.  
•  Ec h ocar di o gra m a n d electr ocar di o gra m.  
•  Ma n dat or y arc hi val tiss ue c ollecti o n. ( N O T E: Recei pt of arc hi val t u m or tiss ue is 
n ot  re q uire d f or st u d y re gistrati o n a n d i nitiati o n of t hera p y.) 
 
Wee k 1  •  Me dical hist or y a n d p h ysical e xa m, i ncl u di n g  bl o o d press ure, wei g ht a n d a n 
assess me nt of h o w well y o u perf or m acti vities of dail y li vi n g.  
•  R o uti ne bl o o d tests. N O T E: t his d oes n ot nee d t o be re peate d if t he pre -re gistrati o n 
bl o o d w or k was d o ne wit hi n [ADDRESS_410860] u g 
(sel u meti ni b or place b o).  
•  Be gi n ta ki n g sel u meti ni b or place b o t wice eac h da y o n a n e m pt y st o mac h ( 1 h o ur 
bef ore or 2 h o urs after a meal), a p pr o x i matel y [ADDRESS_410861] o p b y y o ur healt h care tea m. 
•  Eac h da y, i n t he Patie nt Me dicati o n Diar y, write d o w n w he n y o u ta ke t he st u d y 
me dicati o n a n d a n y si de effects y o u n otice.  
  A p pe n di x I  
A d de n d u m 9  
  Pa ge 6  of 1 7  
 
 Wee k 2  •  C o nti n ue ta ki n g sel u meti ni b or place b o t wice eac h da y o n a n e m pt y st o mac h ( 1 
h o ur bef ore or 2 h o urs after a meal), a p pr o xi matel y [ADDRESS_410862] o p b y y o ur healt h care tea m.  
•  Eac h da y, i n t he Patie nt Me dicati o n Diar y, write d o w n w he n y o u ta ke t he st u d y 
me dicati o n a n d a n y si de effects y o u n otice.  
Wee k 3  •  Be gi n l o w i o di ne diet ( 5 da ys bef ore treat me nt wit h T h y r o ge n™).  
•  Me dical hist or y a n d p h ysical e xa m, i ncl u di n g bl o o d press ure, wei g ht a n d a n 
assess me nt of h o w well y o u perf or m acti vities of dail y li vi n g.  
•  R o uti ne bl o o d tests.  
•  C o nti n ue ta ki n g sel u meti ni b or place b o t wice eac h da y o n a n e m pt y st o mac h ( 1 
h o ur bef ore  or 2 h o urs after a meal), a p pr o xi matel y [ADDRESS_410863] o p b y y o ur healt h care tea m.  
•  Eac h da y, i n t he Patie nt Me dicati o n Diar y, write d o w n w he n y o u ta ke t he st u d y 
me dicati o n a n d a n y si de effects y o u n otice.  
Wee k 4  •  Pre g na nc y test (if a p plica ble).  
•  Recei ve t w o i njecti o ns of T h yr o ge nT M o ver t w o da ys.  
•  Recei ve ra di oacti ve i o di ne t hera p y (1 3 1I t hera p y).  
•  C o nti n ue ta ki n g sel u meti ni b or place b o t wice eac h da y o n a n e m pt y st o mac h ( 1 
h o ur bef ore or 2 h o urs after a meal), a p pr o xi matel y [ADDRESS_410864] b o t wice eac h da y u ntil 2 da ys after y o u 
recei ve t he ra di oacti ve i o di ne t hera p y (1 3 1I t hera p y), u nless tol d t o st o p b y y o ur 
healt h care tea m.  
•  Eac h da y, i n t he Patie nt Me dicati o n Diar y, write d o w n w he n y o u ta ke t he st u d y 
me dicati o n a n d a n y si de effects y o u n otice.  
•  C o nti n ue t he l o w -i o di ne diet f or 1 da y after y o u recei ve t he ra di oacti ve i o di ne 
t hera p y (1 3 1I t hera p y).  
 
W he n I a m fi nis he d wit h tre at me nt  
 
W he n y o u fi nis h treat me nt, y o u will nee d t he f oll o wi n g tests a n d pr oce d ures t hat ar e part of re g ular 
ca ncer care. T he y are bei n g d o ne m ore ofte n beca use y o u are i n t his st u d y.   
 
 
  A p pe n di x I  
A d de n d u m [ADDRESS_410865] u d y C ale n d ar F oll o wi n g C o m p leti o n of T her a p y 
 
W he n  W h at y o u d o  
O ne m o nt h after 
recei vi n g 1 3 1I •  Me dical hist or y a n d p h ysical e xa m, i ncl u di n g  p ulse, bl o o d press ure, hei g ht, 
wei g ht a n d a n assess me nt of h o w well y o u perf or m acti vities of dail y li vi n g.  
•  R o uti ne bl o o d tests.  
•  Assess me nt o f si de effects. 
E ver y 3 m o nt hs 
after recei vi n g 
1 3 1I •  M RI a n d/ or C T sca n f or t u m or meas ure me nt.  
•  T h yr oi d tests, i ncl u di n g t h yr o gl o b uli n.  
 
[ADDRESS_410866] u d y •  M RI a n d/ or C T sca n f or t u m or meas ure me n t. 
•  T h yr oi d tests, i ncl u di n g t h yr o gl o b uli n.  
 
 
 
H o w l o n g will I be i n t he rese arc h st u d y ?   
 
We will c o nti n ue t o f oll o w y o u f or u p t o [ADDRESS_410867] u d y ?  
 
Yes. Y o u c a n deci de t o s t o p at a n y ti me. Tell t he st u d y d oct or if y o u are t hi n ki n g a b o ut st o p pi n g or deci de 
t o st o p.  He or s he will tell y o u h o w t o st o p safel y.  
 
It is i m p orta nt t o tell t he st u d y d oct or if y o u are t hi n ki n g a b o ut st o p pi n g s o a n y ris ks fr o m t he sel u meti ni b 
can be  e val uate d b y y o ur d oct or. A n ot her reas o n t o tell y o ur d oct or t hat y o u are t hi n ki n g a b o ut st o p pi n g is 
t o disc uss w hat f oll o w-u p care a n d testi n g c o ul d be m ost hel pf ul f or y o u.  
 
T he st u d y d oct or ma y st o p y o u fr o m ta ki n g part i n t his st u d y at a n y ti me if he/ s he belie ves it is i n y o ur 
best i nterest; if y o u d o n ot f oll o w t he st u d y r ules; or if t he st u d y is st o p pe d.  
 
 
W h at si de effects or ris ks c a n I e x pect fr o m bei n g i n t he rese arc h st u d y ?  
 
Y o u ma y ha ve si de effects w hile o n t he st u d y. E ver y o ne ta ki n g part i n t he st u d y will be watc he d c aref ull y 
f or a n y si de effects. H o we ver, d oct ors d o n’t k n o w all t he  si de effects t hat ma y ha p pe n. Si de effect s ma y 
be mil d or ver y seri o us. Y o ur healt h care tea m ma y gi ve y o u me dici ne s t o hel p lesse n si de effects. Ma n y 
si de effects g o a wa y s o o n after y o u st o p ta ki n g t he sel u meti ni b. I n s o me cases, si de effects ca n be seri o us, 
l o n g lasti n g, or ma y ne ver g o a wa y. T here als o is a ris k of deat h.  
 
Y o u s h o ul d t al k t o y o ur st u dy d oct or a b o ut a ny si de effects t h at y o u h ave w h ile t a ki n g p art i n t he st u dy. 
 
 
 
 
 
  A p pe n di x I  
A d de n d u m 9  
  Pa ge 8  of 1 7  
 
 Ris ks a n d si de effects rel ate d t o sel u meti ni b i ncl u de t h ose w hic h are:  
 
Li kel y ris ks of Sel u meti ni b  (e ve nts occ urri n g gre ater t h a n 2 0 % of t he ti me) 
•  L o ose st o ols ( Diarr hea)  
•  Ur ge t o v o mit ( Na usea)  
•  T hr o wi n g u p ( V o miti n g)  
•  S welli n g of t he e x tre mities (ar ms a n d/ or le gs) 
•  Feeli n g tire d ( Fati g ue)  
•  Ac ne /s ki n ras h 
 
Less li kel y ris ks of Sel u meti ni b  (eve nts occ urri n g less t h a n or e q u al t o 2 0 % of t he ti me) 
•  Decrease i n re d bl o o d cells, w hic h are t he o x y ge n carr yi n g cells, w hic h c o ul d ma ke y o u feel tire d  
( A ne mia) 
•  Decrease i n w hite bl o o d cell ( ne utr o p hil) c o u nt a n d p ote ntial f or i ncrease d i nfecti o n ris k (se psis)  
•  Decrease i n platelet cell c o u nt (re q uire d f or bl o o d cl otti n g)  
•  Decrease i n l y m p h oc yte c o u nt (i n v ol ve d i n i m m u ne s yste m)  
•  Bl urre d visi o n  
•  S welli n g or feeli n g of f ull ness a n d ti g ht ness i n t he a b d o me n ( bell y) 
•  Bell y pai n  
•  Diffic ult y passi n g st o ol ( C o nsti pati o n)  
•  Irritati o n or s ores i n t he m o ut h S welli n g of t he face  
•  Fe ver   
•  I ncrease d bl o o d le vel of a li ver e nz y me ( A L T/ S G P T) 
•  I ncrease d bl o o d le vel of a li ver e nzy me ( A S T/ S G O T)  
•  I ncrease d bl o o d le vels of p h os p hate 
•  L oss of a p petite  (a n ore xia) 
•  J oi nt pai n  
•  Bac k pai n  
•  Se nsati o n of li g ht hea de d ness, u nstea di ness, gi d di ness, s pi n ni n g or r oc ki n g ( Dizzi ness)  
•  Hea dac he or hea d pai n  
•  Feeli n gs of sa d ness, w ort hless ness, t h o u g hts o f s uici de or deat h ( De pressi o n) 
•  Diffic ult y slee pi n g or falli n g aslee p   
•  C o u g h  
•  S h ort ness of breat h   
•  Hair l oss   
•  Dr y s ki n   
•  Nail c ha n ges  
•  Itc hi n g S ki n ras h wit h t he prese nce of mac ules (flat disc ol ore d area) a n d pa p ules (raise d b u m p)  
•  Hi g h bl o o d press ure ( h y pertensi o n)  
•  L o w bl o o d p otassi u m  
•  I ncrease d le vels of creati ni ne p h os p h o ki nase/creati ni ne ki nase 
•  S ki n i nfecti o ns (i n c o m bi nati o n wit h d oceta xel)  
•  Oral st o matitis (i n c o m bi nati o n wit h d oceta xel), ( m o ut h blisters/s ores)  
•  Dr y m o ut h  
 
R are b ut seri o us ris ks of Sel u meti n i b (eve nts occ urri n g less t h a n 2-3 % of t he ti me)  
•  Decrease i n heart's a bilit y t o p u m p bl o o d d uri n g t he "acti ve" p hase of t he heart beat ( S yst ole)  a n d 
heart fail ure  
  A p pe n di x I  
A d de n d u m 9  
  Pa ge 9  of 1 7  
 
 •  Pr o ble ms/ da ma ge wit h t he reti na p orti o n of t he e ye, w hic h ca n lea d t o bl urre d visi o n.  
•  I ntesti nal perf orati o n (a h ole i n t he b o wel)  
•  Ki d ne y i nj ur y  
•  Li ver i nj ur y/fail ure  
•  I nterstitial l u n g disease (i n c o m bi nati o n wit h d oceta xel) 
•  P ne u m o nitis (i n c o m bi nati o n wit h d oceta xel)  
•  P ne u m o nia (i n c o m bi nati o n wit h d oceta xel)  
•  Fe brile ne utr o pe nia (i n c o m bi nati o n wit h  d oceta xel), ( Fe ver wit h da n ger o usl y l o w w hite bl o o d 
cell c o u nt) 
•  L o w al b u mi n  
•  Re pr o d ucti ve ris ks: A d verse effects o n offs pri n g gr o wt h a n d de vel o p me nt ( i ncl u di n g 
malf or mati o ns, cleft palate, e ye c ha n ges)  
 
W h en sel u meti ni b is us ed i n co m bi n ati o n wit h radi o acti ve i o di ne, t he n u m b er of  p atients wit h si de 
effects or t he stren g t h of s o me si de effects ass ociated wit h eit her treat ment m ay  b e i ncreased. W e d o n ot 
k n o w w h at t hese risk s may  b e. 
 
Earl y i nf or mati o n fr o m cli nical st u dies i n pe o ple of Asia n ori gi n, w hic h ha ve l o o ke d at   t he le vels of 
sel u meti ni b i n t he bl o o d, s u g gest t hat pe o ple of Asia n ori gi n ma y e x perie nce hi g her bl o o d le vels of 
sel u meti ni b t ha n ot her pe o ple (w h o are n ot of Asia n ori gi n). Hi g her le vels of sel u meti ni b i n t he bl o o d 
ma y ca use a greater a m o u nt of si de effects.  Y o ur St u d y D oct or will disc uss w het her t his i nf or mati o n has 
a n y effect o n y o ur partici pati o n i n t his st u d y.  
 
Re pr o d ucti ve ris ks:  Y o u s h o ul d n ot bec o me pre g na nt or fat her a ba b y w hile o n t his st u d y beca use t he 
dr u gs i n t his st u d y ca n af fect a n u n b or n ba b y. W o me n s h o ul d n ot breastfe e d a ba b y w hile o n t his st u d y. 
W o me n of c hil d -beari n g p ote ntial a n d me n m ust a gree t o use a de q uate  c o ntrace pti o n  pri or t o st u d y e ntr y, 
f or t he d urati o n of st u d y partici pati o n, a n d [ADDRESS_410868] b o or sel u meti ni b. A de q uate c o ntrace pti o n c o ul d be eit her 1) h or m o nal/ n o n -h or m o nal pi[INVESTIGATOR_4382] P L U S a 
barrier met h o d (e. g. male c o n d o m) or 2) t otal a bsti ne nce.   
 
Sel u meti ni b/ place b o ca ps ules c o ntai n vita mi n E. W hile ta ki n g st u d y  me dicati o n, y o u will be as ke d n ot t o 
ta ke a n y s u p ple me ntal vita mi n E beca use hi g h le vels of vita mi n E ca n i nterr u pt t he b o d y’s cl otti n g 
pr ocesses. If y o u are c urre ntl y ta ki n g a ntic oa g ula nt ( bl o o d cl otti n g s uc h as warfari n) me dicati o ns, 
a d diti o nal bl o o d te sts ma y be or dere d t o m o nit or y o ur cl otti n g a bilit y w hile y o u are ta ki n g st u d y 
me dicati o n if y o ur p h ysicia n feels it is necessar y. Y o ur p h ysicia n ma y als o a dj ust y o ur a ntic oa g ula nt 
me dicati o n d osa ge if necessar y.  
 
As wit h a n y me dicati o n, aller gic reacti o ns  are a p ossi bilit y 
 
T he ris ks of dra wi n g bl o o d i ncl u de pai n, br uisi n g or rarel y i nfecti o n at t he nee dle site.  
 
F or m ore i nf or m ati o n a b o ut risks a n d si de effects, ask y o ur st u dy d oct or.  
 
 
Are t here be nefits t o t a ki n g p art i n t he rese arc h st u d y ?  
 
Ta ki n g part  i n t his st u d y ma y or may n ot ma ke y o ur healt h better. W hile d oct ors h o pe usi n g sel u meti ni b 
i n a d diti o n t o ra di oacti ve i o di ne t hera p y will be m ore usef ul a gai nst ca ncer c o m pare d t o t he us ual 
treat me nt, t here is n o pr o of of t his yet. We d o k n o w t hat t he i nf or mati o n fr o m t his st u d y will hel p d oct ors 
lear n m ore a b o ut a d di n g sel u meti ni b t o ra di oacti ve i o di ne t hera p y as a treat me nt f or ca ncer. T his 
  A p pe n di x I  
A d de n d u m [ADDRESS_410869] u d y ? 
Y o u d o n ot ha ve t o be i n t his st u d y t o recei ve treat me nt f or y o ur ca ncer.  
 
Y o ur ot her c h oices ma y i ncl u de:  
 
•  Getti n g treat me nt or care f or y o ur ca ncer wit h o ut bei n g i n a st u d y  
•  Ta ki n g part i n a n ot her st u d y  
•  Getti n g n o treat me nt  
•  Getti n g c o mf ort care , als o calle d palliati ve care. T his t y pe of care hel ps re d uce pai n, tire d ness, 
a p petite pr o ble ms a n d ot her pr o bl e ms ca use d b y t he ca ncer. It d oes n ot treat t he ca ncer directl y, b ut 
i nstea d tries t o i m pr o ve h o w y o u feel. C o mf ort care tries t o kee p y o u as act i ve a n d c o mf orta ble as 
p ossi ble.  
 
Tal k t o y o ur d oct or a b o ut y o ur c h oices bef ore y o u deci de if y o u will ta ke part i n t his st u d y.  
 
 
Will m y me dic al i nf or m ati o n be ke pt pri v ate ?  
 
We will d o o ur best t o ma ke s ure t hat t he pers o nal i nf or mati o n i n y o ur me dica l rec or d will be ke pt 
pri vate. H o we ver, we c a n n ot g uara ntee t otal pri vac y. Y o ur pers o nal i nf or mati o n ma y be  gi ve n o ut if 
re q uire d b y la w. If i nf or mati o n fr o m t his st u d y is p u blis he d or prese nte d at scie ntific meeti n gs, y o ur na me 
a n d ot her pers o nal i nf or mati o n  will n ot be use d.  
 
Als o, y o ur rec or ds ma y be re vie we d b y t he f oll o wi n g gr o u ps (as a p plica ble t o t he researc h):  
 
•  Office f or H u ma n Researc h Pr otecti o ns or ot her fe deral, state, or i nter nati o nal re g ulat or y 
a ge ncies; 
•  U. S. F o o d a n d Dr u g A d mi nistrati o n;  
•  L ocal I nstit uti o nal Re vie w B oar ds; 
•  P har mace utical c o m pa n y s u p p orti n g t he st u d y ( Astra Ze neca);  
•  Y o ur i ns ura nce c o m pa n y (if c har ges are bille d t o i ns ura nce);  
•  I nter nati o nal T h yr oi d O nc ol o g y Gr o u p (I T O G); 
•  Aca de mic a n d C o m m u nit y Ca ncer Researc h U nite d ( A C C R U) C o or di na ti n g Ce nter. 
 
A descri pti o n of t his cli nical trial will be a vaila ble o n htt p:// w w w. Cli nical Trials. g o v , as re q uire d b y U. S. 
La w. T his We b site will n ot i ncl u de i nf or mati o n t hat ca n i de ntif y y o u. At m ost, t he We b site will i ncl u de 
a s u m mar y of st u d y res ults.  Y o u ca n searc h t his We b site at a n y ti me.  
 
Tests d o ne at h os pit als or cli nics ot her t h a n t he st u d y cli nic  
 
If y o u ha ve bl o o d tests or ot her me dical tests s uc h as sca ns or x-ra ys at a cli nic or h os pi[INVESTIGATOR_332061] n t he 
st u d y cli nic [i nsert n a me of i nstit uti o n], y o ur st u d y d oct or ma y nee d t o re vie w res ults of t hese tests as 
t he y relate t o t his st u d y.  
 
Ple ase re a d t he f oll o wi n g st ate me nts a n d m ar k y o ur c h oice:  
 
I per mit     [i nvesti g at or’s n a me(s)] t o o btai n me dic al i nf or mati o n fr o m m y pri mar y 
care gi ver     [pri m ary c are giver’s  n a me (s)] as it relates t o t his st u d y. T his 
ma y i ncl u de i nf or mati o n re gar di n g a n y bl o o d tests, x -ra ys or sca ns. 
 
  A p pe n di x I  
A d de n d u m [ADDRESS_410870] u d y ?  
 
Y o u will n ot be pai d f or ta ki n g part i n t his st u d y.  
 
W h at are t he c osts of t a ki n g p art i n t his rese arc h st u d y ?  
 
Y o u a n d/ or y o ur healt h pla n/ i ns ura nce c o m pa n y will nee d t o pa y f or s o me or all of t he c osts of treati n g 
y o ur c a ncer i n t his st u d y. S o me healt h pla ns will n ot pa y t hese c osts  f or pe o ple ta ki n g part i n st u dies. 
C hec k wit h y o ur healt h pla n or i ns ura nce c o m pa n y t o fi n d o ut w hat t he y will pa y f or. Ta ki n g part i n t his 
st u d y ma y or ma y n ot c ost y o ur i ns ura nce c o m pa n y m ore t ha n t he c ost of ge tti n g re g ular ca ncer 
treat me nt. 
 
Tests s uc h as p h ysical e xa mi nati o ns, sca ns, T h yr o ge n ™ , ra di oacti ve i o di ne, a n d r o uti ne bl o o d tests t hat 
w o ul d n or mall y be perf or me d as part of y o ur re g ular me dical care will be t he res p o nsi bilit y of y o u a n d 
y o ur healt h pla n.  
 
Y o u will n ot nee d t o pa y f or a n y tests  d o ne o nl y f or researc h. T his w o ul d i n v ol ve t he researc h st u dies 
d o ne o n t he bl o o d a n d tiss ue sa m ples.  
 
T he st u d y a ge nt, sel u meti ni b  or place b o , will be pr o vi de d free of c har ge w hile y o u are ta ki n g part i n t his 
st u d y. 
 
F or m ore i nf or m ati o n o n cli nic al tri a ls a n d i ns ur a nce c over a ge, y o u c a n visit t he N ati o n al C a ncer 
I nstit ute’s We b site at htt p://c a ncer. g ov/cli nic altri als/ u n derst a n di n g/i ns ur a nce -c over a ge  . Y o u c a n 
pri nt a c o py  of t he  “ Cli nic al Tri als a n d I ns ur a nce C over a ge ” i nf or m ati o n fr o m  t his We b site. 
 
A n ot her w ay t o get t he i nf or m ati o n is t o c all 1 -8 0 0 -4 -C A N C E R ( 1 -8 0 0 -4 2 2 -6 2 3 7) a n d as k t he m t o se n d 
y o u a free c o py. 
 
 
W h at h a p pe ns if I a m i nj ure d bec a use I t o o k p art i n t his  rese arc h st u d y ? 
 
It is i m p orta nt t hat y o u tell y o ur st u d y d oct or, _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ [i nvesti g at or’s n a me(s)], if y o u feel 
t hat y o u ha ve bee n i nj ure d beca use of ta ki n g part i n t his st u d y. Y o u ca n tell t he d oct or i n pers o n or call 
hi m/ her at _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ [tele p h o ne n u m ber]. 
 
Y o u will get me dical treat me nt if y o u are i nj ure d as a res ult  of ta ki n g part i n t his st u d y. Y o u a n d/ or y o ur 
healt h pla n will be c har ge d f or t his treat me nt.   T he st u d y will n ot pa y f or me dical treat me nt.   
 
 
W h at are m y ri g hts if I t a ke p art i n t his rese arc h st u d y ? 
 
Ta ki n g part  i n t his st u d y is y o ur c h oice. Y o u ma y c h o ose eit her t o ta ke part or n ot t o ta ke part i n t he 
st u d y. If y o u deci de t o ta ke part i n t his st u d y, y o u ma y lea ve t he st u d y at a n y ti me. N o matter w hat 
decisi o n y o u m a ke, t here will be n o pe nalt y t o y o u a n d y o u will n ot l ose  a n y of y o ur re g ular be nefits. 
Lea vi n g t he st u d y will n ot affect y o ur me dic al care. Y o u ca n still get y o ur me dic al care fr o m o ur 
i nstit uti o n. 
 
We will tell y o u a b o ut ne w i nf or mati o n or c ha n ges i n t h e st u d y t hat ma y affect y o ur healt h or y o ur 
willi n g ness t o c o nti n ue i n t he st u d y.  
  A p pe n di x I  
A d de n d u m [ADDRESS_410871] u d y ? 
 
Y o u ca n tal k t o y o ur st u d y d oct or a b o ut a n y q uesti o ns or c o nce r ns y o u ha ve a b o ut t his st u d y. C o ntact 
y o ur st u d y d oct or _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ [ n a me(s)] at _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ [tele p h o ne n u m ber]. 
 
 
F or q uesti o ns a b o ut y o ur ri g hts w hile t a ki n g p art i n  t his st u d y, c all t he _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
[ n a me of ce nter] I nstit uti o n al Re vie w B o ar d ( a gr o u p of pe o ple w h o re vie w t he rese arc h t o pr otect 
y o ur ri g hts) at _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  (tele p h o ne n u m ber). [ N ote t o L oc al I nvesti g at or: C o nt act 
i nf or m ati o n f or p atie nt re prese nt atives or ot her i n divi d u als i n a l oc al i nstit uti o n w h o are n ot o n t he 
I R B or rese arc h te a m b ut t a ke c alls re g ar di n g cli nic al tri al q uesti o ns c a n be liste d here.]    
 
Ple ase n ote:  T his secti o n of t he i nf or me d c o nse nt f or m is a b o ut a d diti o n al rese arc h st u dies t h at are 
bei n g d o ne wit h pe o ple w h o are t a ki n g p art i n t he m ai n st u d y. Y o u m a y t a ke p art i n t hese 
a d diti o n al st u dies if y o u w a nt t o. Y o u c a n still be a p art of t he m ai n st u d y e ve n if y o u s a y ‘ n o’ t o 
t a ki n g p art i n a n y of t hese a d diti o n al st u dies. 
 
 
Y o u c a n s a y “ yes ” or “ n o ” t o e ac h of t he f oll o wi n g st u dies. Ple ase m ar k y o ur c h oice f or e ac h st u d y.   
 
 
A b o ut Usi n g Bi ol o gic al S a m ples f or Rese arc h  
 
T his st u d y als o has la b orat or y tests t hat will be perf or me d t o st u d y s mal l sa m ples of bl o o d a n d tiss ue. A 
bl o o d sa m ple will be d o ne b y d ra wi n g s o me bl o o d fr o m a vei n. T he bl o o d will be ta ke n j ust bef ore 
treat ment starts. T he bi o ps y tiss ue sa m ple will  be fr o m y o ur ori gi nal bi o ps y. N o a d diti o nal bi o psies will 
be d o ne t o get t his tiss ue.  
 
T he bl o o d a n d t iss ue will be se nt t o A C C R U/I T O G la b orat ories w here t he tests will be d o ne. T hese tests 
will be d o ne i n or der t o u n dersta n d h o w y o ur  ca ncer res p o n ds t o treat me nt. It is h o pe d t hat t his will hel p 
i n vesti gat ors better un dersta n d y o ur t y pe of ca ncer. T he res u lts of t hese tests will n ot be se nt t o y o u or 
y o ur st u d y d oct or a n d will n ot be use d i n pla n ni n g y o ur care.  T hese tests are f or researc h p ur p oses o nl y 
a n d y o u will n ot ha ve t o pa y f or t he m.   
 
 
Ple ase re a d t he f oll o wi n g st ate me nts a n d m ar k y o ur c h oice:  
 
1.  I a gree t o pr o vi de bl o o d sa m ples t o A C C R U/I T O G la b orat ories f or researc h testi n g pla n ne d as part of 
t his st u d y: 
 
   Yes     N o   Please i nitial here: _ _ _ _ _ _ _ _  Date: _ _ _ _ _ _ _ _  
 
 
2. I a gree t o pr o vi de m y ori gi nal bi o ps y tiss u e sa m ple(s) t o A C C R U/I T O G la b orat ories ass ociate d wit h 
A C C R U, f or researc h testi n g pla n ne d as part of t his st u d y:  
  A p pe n di x I  
A d de n d u m 9  
  Pa ge 1 4  of 1 7  
 
  
   Yes     N o   Please i nitial here: _ _ _ _ _ _ _ _  Date: _ _ _ _ _ _ _ _  
 
We w o ul d li ke t o kee p s o me of t he bl o o d a n d tis s ue t hat is left o ver f or f ut ure researc h. If y o u a gree, t hese 
sa m ples will be ke pt a n d ma y be use d i n researc h t o lear n m ore a bo ut ca ncer a n d ot her diseases. Please 
rea d t he b o o klet  calle d " Pr o vi di n g Y o ur Tiss ue F or Researc h: W hat Y o u Nee d T o K n o w " t o lear n m ore 
a b o ut tiss ue researc h . A c o p y of t his b o o klet ca n be f o u n d at: htt p:// w w w.ca ncer. g o v/ p u blicati o ns/ patie nt -
e d ucati o n/ pr o vi di n g -tiss ue. 
 
Y o ur bl o o d a n d tiss ue ma y be hel pf ul f or researc h w het her  y o u d o or d o n ot ha ve ca ncer. T he researc h 
t hat ma y be d o ne wit h y o ur bl o o d a n d tiss ue is n ot desi g ned s pecificall y t o hel p y o u. It mi g ht hel p pe o ple 
w h o ha ve ca ncer a n d ot her diseases i n t he f ut ure.  
 
Re p orts a b o ut resear c h d o ne wit h y o ur bl o o d a n d tiss ue will n ot b e gi ve n t o y o u or y o ur d oct or. T hese 
re p orts will n ot be p ut i n y o ur healt h rec or d. T he researc h will n ot ha ve a n effect o n y o ur care.  
 
 
T hi n gs t o T hi n k A b o ut  
T he c h oice t o let us kee p left o ver bl o o d a n d tiss ue f or  f ut ure researc h is u p t o y o u. N o matter w hat y o u 
deci de t o d o, it will n ot affect y o ur care.  
 
If y o u deci de n o w t hat y o ur bl o o d a n d tiss ue ca n be ke pt f or researc h, y o u ca n c ha n ge y o ur mi n d at a n y 
ti me. J ust c o ntact us a n d let us k n o w t hat y o u d o not wa nt us t o use y o ur tiss ue. T he n a n y bl o o d a n d tiss ue 
t hat re mai ns will no l o n ger be use d f or researc h.  
 
I n t he f ut ure, pe o ple w h o d o researc h ma y nee d to k n o w m ore a b o ut y o ur healt h. W hile A C C R U ma y 
gi ve t he m re p orts a b o ut y o ur healt h, it will n ot gi ve  t he m y o ur na me, a d dress, p h o ne n u m ber, or a n y ot her 
i nf or mati o n t hat will let t he researc hers k n o w w h o y o u are.  
 
S o meti mes bl o o d a n d tiss ue is use d f or ge netic researc h (a b o ut diseases t h at are passe d o n i n fa milies). 
E ve n if y o ur bl o o d a n d tiss ue  are us e d f or t his ki n d of researc h, t he res ults will n ot be p ut i n y o ur healt h 
rec or ds.  
 
Y o ur bl o o d a n d tiss ue will be use d o nl y f or researc h a n d will n ot be s ol d. T he researc h d o ne wit h y o ur 
bl o o d a n d tiss ue ma y hel p t o de vel o p ne w pr o d ucts i n t he f ut ure.  
 
 
B e nefits  
T he be nefits of researc h usi n g bl o o d a n d tiss ue  i ncl u de lear ni n g m ore a b o ut w hat ca uses ca ncer a n d ot her 
diseases, h o w t o pre ve nt t he m, a n d h o w t o treat t he m.   
 
 
Ris ks  
T he greatest ris k t o y o u is t he release of i nf or ma ti o n fr o m y o ur healt h rec or ds. We will d o o ur best t o 
ma ke s ure t hat y o ur pers o nal i nf or mati o n will be ke pt pri vate. T he c ha nce t hat t his i nf or mati o n will be 
gi ve n t o s o me o ne else is ver y s mall.  
 
 
  A p pe n di x I  
A d de n d u m [ADDRESS_410872] " Yes" or 
" N o". If y o u ha ve a n y q uesti o ns, please tal k t o y o ur d oct or or n urse, or call o ur researc h re vie w b oar d at 
[i nsert t he I R B's p h o ne n u m ber].  
 
N o matter w hat y o u deci de t o d o, it will n ot affect y o ur care.  
 
1. M y bl o o d ma y be ke pt f or use i n researc h t o lear n a b o ut, pre ve nt, or treat ca ncer.  
 
   Yes     N o   Please i nitial here: _ _ _ _ _ _ _ _  Date: _ _ _ _ _ _ _ _  
 
2. M y bl o o d ma y be ke pt f or use i n researc h t o lear n a b o ut, pre ve nt or treat ot her  healt h pr o ble ms (f or 
e xa m ple: dia betes, Alz hei mer's disease, or heart disease).  
 
   Yes     N o   Please i nitial here: _ _ _ _ _ _ _ _  Date: _ _ _ _ _ _ _ _  
 
3. M y tiss ue ma y be ke pt f or use i n researc h t o lear n a b o ut, pre ve nt, or treat  ca ncer.  
 
   Yes     N o   Please i nitial here: _ _ _ _ _ _ _ _  Date: _ _ _ _ _ _ _ _  
 
4. M y tiss ue ma y be ke pt f or use i n researc h t o lear n a b o ut, pre ve nt or treat ot her healt h pr o ble ms (f or 
e xa m ple: dia betes, Alz hei mer's disease, or he art disease).  
 
   Yes     N o   Please i nitial here: _ _ _ _ _ _ _ _  Date: _ _ _ _ _ _ _ _  
 
If y o u wa nt y o ur sa m ple(s) destr o ye d at a n y ti me, write t o t he Secretar y of t he _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
I nstit uti o nal Re vie w B oar d _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _.   
 
A C C R U/I T O G has t he ri g ht t o e n d st ora ge of t he sa m ple(s) wit h o ut telli n g y o u.  
 
T he sa m ple(s) will be t he pr o pert y of A C C R U/I T O G.  O utsi de researc hers ma y o ne da y as k f or a part of 
y o ur sa m ple(s) f or st u dies n o w or f ut ure st u dies.  
 
 
H o w d o o utsi de rese arc hers get t he s a m ple ?  
Researc hers fr o m u ni versities, h os pi[INVESTIGATOR_600], a n d ot her healt h or ga nizati o ns d o researc h usi n g bl o o d a n d 
tiss ue. T he y ma y call A C C R U a n d as k f or sa m ples f or t heir st u dies. A C C R U l o o ks at t he wa y t hat t hese 
st udies will be d o ne, a n d deci des if a n y of t he sa m ples ca n be use d. A C C R U se n ds t he  sa m ples a n d s o me 
i nf or mati on a b o ut y o u t o t he researc her. A C C R U will n ot se n d y o ur na me, a d dress, p h o ne n u m ber, s ocial 
sec urit y n u m ber, or a n y ot her i de ntif yi n g i nf or mati o n to t he researc her. If y o u all o w y o ur sa m ple(s) t o be 
gi ve n t o o utsi de researc hers, it will be gi v e n t o t he m wit h a c o de n u m ber. If researc hers o utsi de A C C R U 
use t he sa m ple(s) f or f ut ure researc h, t he y will deci de if y o u will be c o ntacte d a n d, if s o, t he y w o ul d ha ve 
t o c o ntact t he researc hers at A C C R U. T he n A C C R U will c o ntact t he cli nic w here y o u re gistere d f or t his 
st u d y, w h o will c o ntact y o u. 
 
 
  A p pe n di x I  
A d de n d u m [ADDRESS_410873] ate me nts a n d m ar k y o ur c h oice:  
 
I per mit A C C R U/I T O G t o gi ve m y sa m ple(s) t o o utsi de researc hers:  
 
  Yes     N o   Please i nitial here:    Date:    
 
 
 
 
W here c a n I get m ore i nf or m ati o n ?  
 
Y o u ma y call t he Nati o nal Ca ncer I nstit ute's Ca ncer I nf or mati o n Ser vice at:  
 
1 -8 0 0 -4 -C A N C E R ( 1 -8 0 0 -4 2 2 -6 2 3 7)  
 
Y o u ma y als o visit t he N CI We b site at  htt p://ca ncer. g o v/    
 
•  F or N CI’s cli nical trials i nf or mati o n, g o t o: htt p://ca ncer. g o v/cli nicaltrials/  
 
•  F or N CI’s ge neral i nf or mati o n a b o ut ca nc er, g o t o htt p://ca ncer. g o v/ca nceri nf o/  
 
Y o u will get a c o p y of t his f or m.  If y o u wa nt m ore i nf or mati o n a b o ut t his st u d y, as k y o ur st u d y d oct or.  
 
 
  A p pe n di x I  
A d de n d u m 9  
  Pa ge 1 7  of 1 7  
 
 Si g n at ure  
 
I h a ve bee n gi ve n a c o p y of all _ _ _ _ _ [i nsert t otal of n u m ber of p a ges]  p a ges of t his f or m. I h a ve re a d 
it or it h as bee n re a d t o me. I u n derst a n d t he i nf or m ati o n a n d h a ve h a d m y q uesti o ns a ns were d.  I 
a gree t o t a ke p art i n t his st u d y.  
 
 
Pri nte d P artici p a nt N a me: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
P artici p a nt Si g n at ure: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
D ate: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
Pri nte d n a me of pers o n o bt ai ni n g i nf or me d c o nse nt:  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
Si g n at ure of pers o n o bt ai ni n g i nf or m e d c o nse nt: 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
D ate _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
T his m o del i nf or me d c o nse nt f or m h as bee n re vie we d b y t he A C C R U a n d is t he offici al c o nse nt 
d oc u me nt f or t his st u d y. L oc al I R B c h a n ges t o t his d oc u me nt are all o we d.  Secti o ns “ W h at are t he 
ris ks of t he rese arc h st u d y ” or “ W h at ot her c h oices d o I h a ve if I d o n’t t a ke p art i n t his rese arc h 
st u d y ? ” s h o ul d al w a ys be use d i n t heir e ntiret y if p ossi ble. E dit ori al c h a n ges t o t hese secti o ns m a y 
be m a de as l o n g as  t he y d o n ot c h a n ge i nf or m ati o n or i nte nt. If t he i nstit uti o n al I R B i nsists o n 
m a ki n g deleti o ns or m ore s u bst a nti ve m o dific ati o ns t o t hese secti o ns, t he y m a y be j ustifie d i n 
writi n g b y t he i n vesti g at or a n d a p pr o ve d b y t he I R B. U n der t hese circ u mst a nces, t h e re vise d 
l a n g u a ge a n d j ustific ati o n m ust be f or w ar de d t o t he Ac a de mic a n d C o m m u nit y C a ncer Rese arc h 
U nite d ( A C C R U) O per ati o ns Office f or a p pr o v al bef ore a p atie nt m a y be re gistere d t o t his st u d y.  
 
C o nse nt f or ms will h a ve t o be m o difie d f or e ac h i nstit uti o n as it rel ates t o w here i nf or m ati o n m a y 
be o bt ai ne d o n t he c o n d uct of t he st u d y or rese arc h s u bject. T his i nf or m ati o n s h o ul d be s pecific f or 
e ac h i nstit uti o n. 
 
 
A p pe n di x II 
A d de n d u m 9  
Pa ge 1  of 2  
 P A TI E N T’ S M E DI C A TI O N  DI A R Y  
 
T o da y’s date _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Patie nt Na me _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _   Patie nt St u d y I D _ _ R U 2 4 1 3 0 6 I_ _ _ _ _ _  
(i niti als acce pt a ble) 
I N S T R U C TI O N S T O T H E P A TI E N T: 
1.  C o m plete o ne f or m f or eac h 2 8 -da y c ycle . 
2.  Y o u will ta ke y o ur d ose [ _ _ _ _ _ _ m g ( _ _ _ _ _ _ 2 5 m g pi[INVESTIGATOR_3353])] T WI C E  eac h da y  (f or a t ot al d ose of _ _ _ _ _ _  
m g  per d a y ) be gi n ni n g o n Wee k 1, Da y 1 a n d c o nti n ue d t hr o u g h 2 da ys after t hera pe utic 1 3 1I t hera p y has 
bee n a d mi nistere d  .  It is rec o m me n de d t o ta ke sel u meti ni b ( or place b o) o n a n e m pt y st o mac h ( 1 h o ur bef ore 
or 2 h o urs after a meal), a p pr o xi matel y  1 2 h o urs a part wit h a glass of water.   ( N O T E: A v oi d e xcessi ve s u n 
e x p os ure a n d use a de q uate s u nscree n pr otecti o n if s u n e x p os ure is a ntici pate d. D o n ot ta ke vita mi n E or 
m ulti vita mi n s u p ple me nts t hat pr o vi de a t otal dail y d ose i n e xcess of 1 0 0 % of t he rec o m me n de d dail y 
all o wa nce f or vita mi n E.)  
3.  Rec or d t he date  a n d t he ti me y o u t o o k t he m.   
4.  If y o u ha ve a n y c o m me nts or n otice a n y si de effects, please rec or d t he m i n t he C o m me nts c ol u m n. 
3.  B ri n g y o ur pi[INVESTIGATOR_4382] b ottle a n d t his f or m t o y o ur p h ysicia n w he n y o u g o f or y o ur ne xt a p p oi nt me nt.  
 
D ate   
D a y  Ti me  
T a ke n   
C o m me nts   
D ate   
D a y  Ti me  
T a ke n   
C o m me nts  
 1     1 1    
        
 2     1 2    
        
 3     1 3    
        
 4     1 4    
        
 5     1 5    
        
 6     1 6    
        
 7     1 7    
        
 8     1 8    
        
 9     1 9    
        
 1 0     2 0    
        
        
 
A p pe n di x  III 
A d de n d u m 9  
Pa ge 1  of 5  
 T he L o w I o di ne Diet  
 
W h at is I o di ne ?  
I o di ne is a mi neral. It pla ys a n i m p orta nt r ole i n se veral pr ocesses t hat ta ke place i n t he b o d y. O ne is t he 
pr o d ucti o n of a h or m o ne calle d t h yr o xi ne, w hic h occ urs i n t he t h yr oi d gla n d.  
 
W here is I o di ne F o u n d ?  
T he a m o u nt  of i o di ne f o u n d i n f o o d varies. M uc h of t he i o di ne we get c o mes fr o m i o dize d salt a n d 
brea ds. A d ults nee d 1 5 0 micr o gra ms of i o di ne a da y. T his b o o klet descri bes a l o w i o di ne diet. T his is a 
diet wit h less t ha n 5 0 micr o gra ms of i o di ne per da y.  
 
W h y is a L o w I o di ne Diet Necess ar y ?  
T he i o di ne i n y o ur diet ca n bl oc k t he u pta ke of ra di oacti ve i o di ne b y t he t h yr oi d gla n d. Y o ur d oct or c o ul d 
p ut y o u o n a l o w i o di ne diet o ne or t w o wee ks bef ore y o u get t he ra di oacti ve i o di ne. Sta y o n t his diet u ntil 
y o ur test or tr eat me nt is c o m plete. Y o ur d oct or will tell y o u w he n t o be gi n a n d w he n t o st o p t his diet. If 
y o u ha ve a n y q uesti o ns, s pea k wit h y o ur d oct or. Y o u ma y als o see a dietitia n if necessar y. If y o u ha ve 
a n y q uesti o ns a b o ut y o ur diet, call ( 2 1 2) 6 3 9 -7 3 1 2 t o s pea k t o a dietitia n.  
 
W h at S h o ul d Y o u A v oi d ?  
 
Rea d all f o o d la bels t o c hec k f or i o di ne c o nte nt. D o N O T eat or use:  
 
•  I o dize d salt. 
•  Sea salt i n a n y f or m.  
•  O ni o n salt.  
•  Celer y salt.  
•  Garlic salt.  
•  Seas o ne d salt.  
•  Kel p (sea wee d).  
•  A n y f o o d t hat has:  
o   I o dates 
o   I o di des 
o   Al g i n 
o   Al gi nates  
o   Carra gee n  
o   A gar  
•  C o m mercial brea ds a n d ba ker y pr o d ucts beca use t he y ofte n c o ntai n i o date.  
•  Mil k (e xce pt f or 1 o u nce a da y), e g gs, a n d seaf o o d.  
•  Vita mi ns a n d f o o d s u p ple me nts if t he y ha ve i o di ne. If y o u ha ve a n y d o u bt, d o n ot ta ke t he m.  
•  F o o d, pi [INVESTIGATOR_3353], or ca ps ules wit h f o o d d yes or t hat are ora n ge, re d, or br o w n i n c ol or. E xa m ples i ncl u de 
re d or pi n k cereals or ca n dies. 
•  A ntise ptics, s uc h as ti nct ure of i o di ne ( Beta di ne ®) a p plie d o n a c ut.  
•  C o u g h me dici nes (es peciall y t h ose wit h re d c ol ori n g).  
•  S u p ple m e nts s uc h as: 
o   E ns ure ®  
o   B o ost ®  
o   C o m mercial s ha kes  
o   N utra me nt ®  
•  Resta ura nt a n d pr ocesse d f o o ds, beca use t he y are ofte n hi g h i n i o di ne c o nte nt.  
•  S o y pr o d ucts s uc h as e da ma me, t of u, s o y b ur gers (e. g., B oca ®), etc.  
A p pe n di x  III 
A d de n d u m 9  
Pa ge 2  of 5  
 •  All ca n ne d f o o ds, beca use t he li ni n g of t he ca n  c o ntai ns i o di ne. 
 
D o n ot st o p ta ki n g a n y of y o ur me dici nes u nless y o ur d oct or tells y o u. If y o u are recei vi n g t u be fee di n g 
f or m ula, as k y o ur dietitia n or d oct or w hat t o d o. T his l o w i o di ne diet d oes n ot meet t he s u g geste d dail y 
all o wa nce f or all n utrie nts . Y o u will be o n it f or a s h ort ti me o nl y. 
 
Dri n k Ple nt y of Fl ui ds  
N ote: U nless y o ur d oct or tells y o u differe ntl y, y o u m ust dri n k at least 8 t o 1 0, 8 -o u nce c u ps of fl ui d a da y. 
T his i ncl u des t he dri n ks i n t he diet g ui deli nes a n d as m uc h water as y o u wa nt.  
 
L o w I o di ne Diet G ui deli nes:  
 
Bre a ds a n d Cere als  
T otal n u m ber of ser vi n gs per da y: 6 -8  
( 1 ser vi n g e q uals 1 slice of brea d or 1/ 2 c u p of c o o ke d pasta) 
 
I ncl u de 
Plai n c o o ke d barle y, oats, millet, b uc k w heat, b ul g ur w heat, q ui n oa; u nsalte d, u n pr ocesse d preser v ati ve-
free b o xe d cereals s uc h as p uffe d rice a n d s hre d de d w heat; rice, plai n macar o ni, s pa g hetti, n o o dles; crea m 
of rice or crea m of w heat h ot cereals; u nsalte d rice ca kes, u nsalte d plai n matza h, E n glis h m uffi ns, plai n 
u nsalte d p o pc or n, h o me ma de brea ds pre pare d wit h o ut c o m mercial d o u g h.  
 
A v oi d  
All c o m mercial brea ds a n d r olls, pr ocesse d b o xe d cereals, salte d crac kers, p otat o c hi ps, pretzels, ba gels, 
bial ys, Mel ba t oast, all ot her crac kers, e g g n o o dles, pac ka ge d rice a n d pasta mi xes.  
 
Me at a n d Me at S u bstit ute s 
T otal n u m ber of ser vi n gs per da y: T w o – t hree 
( 1 ser vi n g e q uals 3 o u nces of meat, fis h, p o ultr y, or 2 Ta bles p o o ns of u nsalte d pea n ut or al m o n d b utter) 
 
I ncl u de 
Fres h beef, veal, p or k, la m b, c hic ke n a n d t ur ke y; u nsalte d pea n ut or al m o n d b utter; fres h -water fis h s uc h 
as car p, ri ver  bass, la ke tr o ut, a n d ri ver perc h; fres h e g g w hite.  
 
A v oi d  
E g g y ol ks a n d w h ole e g gs, f o o ds ma de wit h e g gs; all fast f o o ds; all ca n ne d fis h s uc h as sal m o n a n d t u na; 
seaf o o d, s hellfis h (cla ms, cra bs, o ysters, l o bsters), or a n y f o o d m a de wit h fis h st oc k; all pr ocesse d meats; 
li ver a n d all or ga n meats; all ca n ne d, drie d, salte d, or c ure d meats s uc h as bac o n, sa usa ge, ha m, 
fra n kf urters, c hi p pe d beef, l u nc he o n meats (sala mi, b ol o g na, pastra mi); s pic y meats s uc h as c hili, beef 
jer k y, li verw urst; all ca n ne d or pr ocesse d p o ultr y s uc h as t ur ke y or c hic ke n r oll; t of u a n d s o y pr o d ucts, 
s uc h as s o y b ur gers (e. g., B oca); salte d pea n ut b utter. 
 
Mil k a n d Mil k Pr o d ucts  
T otal n u m ber of ser vi n gs per da y: Zer o  
 
I ncl u de 
N o ne all o we d  
E xce pti o n: O nl y 1 o u n ce of mil k a da y i n y o ur c offee  or tea.  
 
A p pe n di x  III 
A d de n d u m 9  
Pa ge 3  of 5  
 A v oi d  
All mil k (e xce pt f or o ne o u nce dail y) a n d mil k pr o d ucts s uc h as c o n de nse d or e va p orate d mil k, c heese, 
y o g urt, p u d di n gs, ice crea m, c ustar d; a n y crea m s uc h as hea v y or li g ht crea m, w hi p pe d crea m, s o ur 
crea m; a n y f o o ds ma de wit h crea m or mil k or c heese s uc h as crea m s o u p, pi[INVESTIGATOR_6107], macar o ni a n d c heese.  
 
Fr uits  
T otal n u m ber of ser vi n gs per da y: Fi ve  
( 1 ser vi n g e q uals 1 s mall pi[INVESTIGATOR_332062] 3/ 4 c u p of j uice) 
 
I ncl u de 
All fres h fr uit, e xce pti o n: li mit ba na nas t o 1 ser vi n g per da y; fres h a p ple sa uce; all nat ural fr oze n fr uits; 
fres h fr uit j uices (i ncl u di n g b ottles or cart o ns of fr uit j uice wit h o ut artificial c ol ori n g or preser vati ves); 
w hite gra pe j uice.  
 
A v oi d  
Cra n berries, all drie d fr uits, all ca n ne d fr uits a n d ca n ne d fr uit j uices; jarre d a p plesa uce; cra n berr y a n d 
gra pe j uice, ca n ne d or b ottle d c herries; r h u bar b.  
 
Ve get a bles  
T otal n u m ber of ser vi n gs per da y: F o ur  
( 1 ser vi n g e q uals 1/ 2 c u p of c o o ke d or 1 c u p ra w ve geta ble) 
 
I ncl u de 
All fres h ve geta bles e xce pt s pi [INVESTIGATOR_73567] h , fres h p otat oes wit h o ut s ki n, all plai n fr oze n ve geta bles wit h o ut a d de d 
salt, fres h or drie d le g u mes s uc h as le ntils a n d peas. 
 
A v oi d  
All ca n ne d ve geta bles a n d all ca n ne d ve geta ble j uices, fres h or drie d bea ns s uc h as re d ki d ne y bea ns, li ma  
bea ns, na v y be a ns, pi [INVESTIGATOR_11731] o bea ns a n d c o w peas; ca n ne d le g u mes (s uc h as bea ns, peas, a n d le ntils); ca n ne d 
s o u ps; sa uer kra ut, celer y; c o m merciall y pre pare d p otat oes (e. g. i nsta nt mas he d p otat oes); fr oze n 
ve geta bles wit h a d de d salt; s pi [INVESTIGATOR_73567] h.  
 
F at  
T otal n u m ber of ser vi n gs per da y:  
S u g gest f o ur t o si x ser vi n gs a da y  
( 1 ser vi n g e q uals 1 teas p o o n of b utter or oil) 
 
I ncl u de 
U nsalte d mar gari ne or s weet b utter ( n ot m ore t ha n 1 teas p o o n of eac h per da y), oils, ve geta ble s h orte ni n g, 
plai n oil a n d w hite vi ne gar dressi n g.  
 
A v oi d  
Salte d n uts a n d see ds, ma y o n naise, c o m mercial sala d dressi n gs, a n d lar d.  
 
Be ver a ges  
T otal n u m ber of ser vi n gs per da y: N o restricti o ns  
O ne ser vi n g e q uals 1 2 o u nces of a car b o nate d be vera ge or 1 c u p  
( 8 o u nces) of a n y of t he ot her be vera ges liste d 
 
A p pe n di x  III 
A d de n d u m 9  
Pa ge 4  of 5  
 I ncl u de 
Water; b o ttle d car b o nate d be vera ges wit h o ut a d de d c ol ori n g (s uc h as S prite ®, 7-U p ®, s o di u m -free 
seltzer); bre we d c offee, tea stee pe d fr o m tea lea ves; w hite tea ba gs; fres h le m o na de or fres h ora n gea de.  
 
A v oi d  
Mi neral water c o ntai ni n g s o di u m; all b ottle d, ca n ne d, or p o w dere d: ice d tea, le m o na de, i nsta nt c offee, 
i nsta nt tea, i nsta nt ice d-tea, fr uit p u nc h, a n d ot her p o w dere d or c o m mercial dri n ks, s uc h as Hi-C ® a n d 
K o ol -Ai d ®; tea stee pe d fr o m tea ba gs; s o y mil k a n d rice mil k ( w hic h c o ntai n sea salt); gi n ger ale, 
C o ke ®, Pe psi ® or a n y ot her car b o nate d be vera ges wit h a d de d c ol ori n g.  
 
Desserts a n d s weets  
T otal n u m ber of ser vi n gs per da y: T w o  
( See bel o w f or ser vi n g e q ui vale nts) 
 
I ncl u de 
Eac h of t he f oll o wi n g e q uals  1 ser vi n g:  
•  1 c u p K n o x ® clear gelati n  
•  2 ta bles p o o ns ( T) s u gar  
•  2 T H o ne y  
•  2 T Ma ple s yr u p  
•  2 re g ular size Mars h mall o ws  
•  1/ 2 c u p Nat ural s or bets wit h n o c ol ori n g or a d de d salt  
 
A v oi d  
All ba ker y pr o d ucts s uc h as pi[INVESTIGATOR_014], ca kes, pastries,  da nis hes, m uffi ns, d o n uts a n d c o o kies; gra ha m crac kers;  
Jell-O ®, c ol ore d gelati ns; c h oc olat e a n d c h oc olate  desserts; ca n d y.  
 
Miscell a ne o us  
T otal n u m ber of ser vi n gs per da y: U nli mite d  
 
I ncl u de 
Pe p per, s pi[INVESTIGATOR_187621] s uc h as ci n na m o n; her bs s uc h as ore ga n o; w hite vi ne gar, a n d n o n -i o dize d salt (c o ntai ns 
trace a m o u nts of i o di ne, use s pari n gl y). 
 
A v oi d  
All s alte d f o o ds s uc h as salte d n uts, C hi nese f o o d, s o y sa uce, cats u p, W orcesters hire sa uce, c hili sa uce, all  
c o m mercial sa uces, t o mat o sa uce, all gra vies, oli ves, pic kles, relis h, b o uill o n c u bes, s o u p bases, i o dize d 
salt, sea salt, o ni o n salt, garlic salt, celer y salt, seas o ne d salt, kel p (sea wee d); m olasses; a n y f o o d 
c o ntai ni n g f o o d c ol ori n g, i o dates, i o di des, i o date d o u g h c o n diti o ners or sta bilizers, al gi n, al gi nate, 
carra gee ns, a gar, or n ori (sea wee d); all s us hi; re d wi ne vi ne gar, balsa mic vi ne gar ( wit h cara mel c ol ori n g);  
all a d diti ves, preser vati ves, or artificial c ol ori n gs.  
 
S a m ple Me n u f or a L o w I o di ne Diet  
 
B R E A K F A S T  
1 Fr uit 1⁄ 2 c u p ora n ge j uice  
3 Brea ds 1⁄ 2 c u p oat meal ( n o mil k)  
[ADDRESS_410874]  beef  
2 Brea ds 1 ba ke d p otat o ( n o s ki n)  
2 Ve geta bles 1 c u p fres h br occ oli  
2 Fats 2 ts p oil ( use d i n c o o ki n g)  
1 Fr uit 1 ora n ge  
1 Be vera ge 1 c u p w hite tea  
 
B E D TI M E S N A C K  
1 Fr uit 1 s mall pear  
1 Be vera ge 1 c u p tea ma de fr o m fres h tea lea ves  
 
 
 
© 1 9 9 7 Me m orial S l oa n-Ketteri n g Ca ncer Ce nter  
1 2 7 5 Y or k A ve n ue, Ne w Y or k, Ne w Y or k 1 0 0 6 5  
Re vise d 2 0 0 2, 2 0 0 4, 2 0 0 6, 2 0 0 8 
A p pe n di x  I V 
A d de n d u m 9  
Pa ge 1  of 9  
  
G ui d a nce F or M a n a ge me nt a n d I n vesti g ati o n of Sel u meti ni b Rel ate d A d verse E ve nts  
 
T he f oll o wi n g are rec o m me n de d, n ot ma n dat or y , assess me nts a n d/ or i nter ve nti o ns f or p ote ntial 
sel u meti ni b-relate d a d verse e ve nts. 
 
1.  Rec o m me n d ati o ns f or di arr he a m a n a ge me nt  
Diarr hea ma y occ ur d uri n g treat me nt wit h sel u meti ni b ( A Z D 6 2 4 4) a n d acti o n s h o ul d be ta ke n as 
s o o n as s y m pt o ms de vel o p.  T he rec o m me n dati o ns f or diarr hea ma na ge me nt i n are base d o n 
g ui deli nes fr o m t he A merica n S ociet y of Cli nical O nc ol o g y (J  Cli n O nc ol 2 0 0 4; 2 2: 2 9 1 8 -2 6). 
T hese g ui deli nes rec o m me n d t hat treat me nt -i n d uce d diarr hea s h o ul d be caref ull y m o nit ore d a n d 
treate d a g gressi vel y t o e ns ure t hat se vere c o m plicati o ns are a v oi de d a n d t hat treat me nt is n ot 
dela ye d.  
 
Patie nts s h o ul d be ma de a ware t hat t he y are li kel y t o e x perie nce diarr hea  a n d be e nc o ura ge d t o 
rec or d t he n u m ber of st o ols a n d re p ort p ossi ble ass ociate d s y m pt o ms 
 
Patie nts s h o ul d be gi ve n l o pera mi de (i n acc or da nce wit h l ocal re g ulati o n a n d l ocal practice) t o 
ta ke h o me wit h t he m a n d be a d vise d t o start i m me diatel y after t he first e pis o de of u nf or me d st o ol. 
 
Patie nts s h o ul d be gi ve n dietar y a d vice i n case of diarr hea  (e. g. B R A T [ ba na nas, rice, a p ple 
sa uce, t oast, plai n pasta] diet; rea dil y di gesti ble f o o d; a v oi da nce of lact ose -c o ntai ni n g pr o d ucts, 
frie d, fatt y or s pic y f o o d) a n d i ncrease fl ui d i nta ke ( 8– 1 0 glasses of clear fl ui ds dail y, i ncl u di n g 
water a n d fl ui ds c o ntai ni n g salt a n d s u gar,  s uc h as s p orts dri n ks a n d clear br ot h). 
 
Patie nts s h o ul d see k a d vice earl y, fr o m t heir p h ysicia n or st u d y n urse, if  
 
•  Persiste nt Gra de 1 or 2 diarr hea (see 2. 2) or  
•  Gra de 3 or 4 diarr hea  
•  Diarr hea  bec o mes c o m plicate d b y ass ociate d v o miti n g or i na bilit y t o t a ke oral fl ui ds; mar ke d 
a b d o mi nal diste nsi o n or cra m pi n g; bl o o d y st o ols, fe ver or s y m pt o ms of h y p ote nsi o n.  
 
T a ble 1  C T C A E ( versi o n 4) gr a di n g f or di arr he a  
C T C A E 
Gr a de  P atie nts wit h o ut c ol ost o mies  P atie nts wit h c ol ost o mies  
Gra de [ADDRESS_410875] o ols per 
da y ( < 4)  Mil d i ncrease i n l o ose water y c ol ost o m y o ut p ut 
c o m pare d wit h pre -treat me nt 
Gra de [ADDRESS_410876] o ols per 
da y ( 4 -6) or n oct ur nal e pis o des  M o derate i ncrease i n l o ose water y c ol ost o m y 
o ut p ut c o m pare d wit h pre -treat me nt, n ot 
i nterferi n g wit h n or mal acti vit y 
Gra de [ADDRESS_410877] o m y o ut p ut 
c o m pare d wit h pre -treat me nt a n d i nterferi n g wit h 
n or m al acti vit y 
Gra de 4  Life -t hreate ni n g c o nse q ue nces (e g,  he m o d y na mic c olla pse) 
 
I nitial ma na ge me nt of u nc o m plicate d Gra de [ADDRESS_410878] e pis o de of diarr hea  ( 4 m g i nitiall y) 
a n d c o nti n ue l o per a mi de ( [ADDRESS_410879] o ol)  u ntil t he y ha ve bee n 
free fr o m diarr hea  f or at least [ADDRESS_410880] t he ce nte r a n d t o i ncrease t o hi g h d ose l o pera mi de ( 2 m g e ver y 2 
h o urs, or 4 m g e ver y 4 h o urs at ni g ht) a n d c o nti n ue t o ta ke l o pera mi de u ntil t he y ha ve bee n free 
fr o m diarr hea  f or at least 1 2 hrs.  A d diti o nal treat me nt ma y be c o nsi dere d acc or di n g t o l ocal 
practice.  
 
Ma na ge me nt of persiste nt ( > 2 4 h) Gra de [ADDRESS_410881] u d y n urse f or f ull e val uati o n a n d t he f oll o wi n g 
s h o ul d be c o nsi dere d: 
 
•  Re h y drati o n a n d electr ol ytes re place me nt as a p pr o priate  
•  I nfecti o us ca uses a n d eti ol o gies s uc h as Cl ostri di u m difficile or viral gastr oe nteritis; 
•  A nti bi otics if a p pr o priate (f or e xa m ple a n oral fl ur o q ui n ol o ne f or 7 da ys) partic ularl y if t he 
patie nt is ne utr o pe nic ( < 1 x 1 09/ L) or has a fe ver; 
•  Disc o nti n uat i o n of l o pera mi de a n d start of octre oti de ( Sa n d ostati n); 
 
It ma y als o be a p pr o priate t o c o nsi der: 
 
•  A d diti o n of ot her sec o n d -li ne a nti-diarr heal a ge nts acc or di n g t o l ocal practice  
•  Sel u meti ni b ( or matc hi n g place b o) i nterr u pti o n u ntil res ol uti o n of t he diarr h ea 
•  H os pi[INVESTIGATOR_1314] o n  
 
I n st u dies i n v ol vi n g c o m bi nati o n of sel u meti ni b ( or matc hi n g place b o) wit h ot her a nti-ca ncer 
treat me nt, i nterr u pti o n or dela y of t he c o m bi nati o n a ge nt ma y be c o nsi dere d acc or di n g t o 
ma n ufact urer’s g ui da nce or l ocal practice.  
 
Ma na ge me n t of a n y gra de u nc o ntr olle d or c o m plicate d diarr hea, or Gra de 3-4 diarr hea  
H os pi[INVESTIGATOR_55500] o n a n d f ull e val uati o n,  
I ntra ve n o us fl ui ds, electr ol ytes a n d a nti bi otics if nee de d (e. g. fl uo r o q ui n ol o ne) 
I nterr u pt sel u meti ni b ( or matc hi n g place b o) u ntil diarr hea  a nd ass ociate d s y m pt o ms res ol ve  
Start octre oti de ( Sa n d ostati n).  
 
I n st u dies i n v ol vi n g c o m bi nati o n of sel u meti ni b ( or matc hi n g place b o) wit h ot her a nti-ca ncer 
treat me nt, i nterr u pti o n or dela y of t he c o m bi nati o n a ge nt ma y be c o nsi dere d acc or di n g t o 
ma n ufact ure r’s g ui da nce or l ocal practice.  
A p pe n di x  I V 
A d de n d u m 9  
Pa ge 4  of 9  
 2.  G ui d a nce f or t he M a n a ge me nt of P atie nts wit h R as h  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T a ble 1: E x a m ple t o pic al ster oi ds a n d a nti bi otics ( use acc or di n g t o l oc al g ui deli nes)  
T o pi[INVESTIGATOR_127349] d s 
m o derate stre n gt h  Tria mci n ol o ne acet o ni de 0. 0 2 5 %  Des o ni de 0. 0 5 %  
Fl uticas o ne pr o pri o nate 0. 0 5 %  Acl o metas o ne 0. 0 5 %  
T o pi[INVESTIGATOR_2855] a nti bi otics  Cli n da m yci n 1 - 2 %   Er yt hr o m yci n 1 % - 2 %  
Metr o ni daz ole 1 %   Sil ver s ul p ha diazi ne 1 %   
Oral a nti bi otics  D o x yc ycli ne 1 0 0 m g b d    Mi n oc ycli ne 1 0 0 m g b d O x ytetrac ycli ne 
5 0 0 m g b d  
‡ sel u meti ni b or matc hi n g place b o  Rec o m me n d ati o ns t o st art o n d a y 1 of tre at me nt wit h sel u meti ni b‡ a n d f or t he d ur ati o n 
of tre at me nt  
 
•  Use s ki n m oist urizer (t hic k, al c o h ol -free) at be dti me 
•  A v oi d e xcessi ve e x p os ure t o s u nli g ht  
•  Use s u n glasses/s u nscree n ( P A B A -free, S P F ≥ 1 5; U V A a n d U V B pr otecti o n) as 
nee de d  
•  Use of t o pi[INVESTIGATOR_332063] n oi ds or be nz o yl per o xi de is n ot rec o m me n de d  
 
C T C gr a de   3 r as hes  
C T C gr a de 2 r as hes c o nsi dere d b y t he p atie nt t o be i nt oler a ble  
 
M o derate stre n gt h t o pi[INVESTIGATOR_127349] d  
 
a n d oral a nti bi otic  
(c o nsi der br oa d s pectr u m/ gra m ne gati ve c o ver if i nfecti o n s us pecte d) 
 
C o nsi der referral  t o a der mat ol o gist: ma na ge ras h per rec o m me n dati o n 
 
I nterr u pt sel u meti ni b‡  u ntil r as h i m pr o ves t o gr a de 2 or less  
 
Sel u meti ni b‡ m a y be rest arte d at ori gi n al d ose or re d uce d at t he discreti o n of  t he 
i n vesti g at or C T C Gr a de 1 r as hes  
 
Mil d or m o derate stre n gt h t o pi[INVESTIGATOR_127349] d  
 
a n d/ or t o pi[INVESTIGATOR_2855] a nti bi otic  
 C T C Gr a de 2 r as hes  
 
M o derate stre n gt h t o pi[INVESTIGATOR_127349] d  
 
a n d oral a nti bi otic 
 
 
A p pe n di x  I V 
A d de n d u m 9  
Pa ge 5  of 9  
  
3 . G ui d a nce f or m a n a ge me nt of p atie nts wit h a n as y m pt o m atic  re d ucti o n i n L V E F  ( pr o vi de d 
b y Astr a Ze nec a)  
 
A p pe n di x  I V 
A d de n d u m 9  
Pa ge 8  of 9  
 6. Rec o m me n d ati o ns of Or al C are ( pr o vi de d b y Astr a Ze nec a)  
 
Or al C ar e Rec o m me n d ati o ns f or P atie nts tre ate d wit h Sel u meti ni b:  
Patie nts s h o ul d be e nc o ura ge d t o ta ke res p o nsi bilit y f or t heir o w n oral care w here ver p ossi ble. T his 
ma y re q uire fre q ue nt e nc o ura ge me nt a n d e d ucati o n. T he ge neral rec o m me n dati o ns of R u be nstei n et 
al ( 2 0 0 4) are t o mai ntai n a clea n a n d pai n-free m o ut h w hic h re d uces patie nt disc o mf ort a n d hel ps 
pre ve nt i nfecti o n a n d pr o m ote dietar y i nta ke. E vi de nce fr o m t he literat ure re gar di n g i m ple me ntati o n 
a n d efficac y of oral pr ot oc ols a n d patie nt e d ucati o n, s u g gest t hat patie nts w h o are ta u g ht oral care 
pr ot oc ols perf or m oral care m ore dili ge ntl y, ta ke m ore res p o nsi bilit y f or t heir care a n d ma y s h o w a n 
i m pr o ve me nt i n oral s y m pt o ms.  
 
Pre ve nti o n, earl y dia g n osis a n d ma na ge me nt of st o matitis ma y re d uce t he nee d f or d os e i nterr u pti o n 
a n d / or re d ucti o ns of t he st u d y me dicati o ns d ue t o se vere st o matitis a n d s o all o w t he patie nt t o 
c o nti n ue o n t he st u d y dr u gs. It is str o n gl y rec o m me n de d t hat patie nts recei ve a d vice re gar di n g dail y 
oral healt h care re gi mes, b ot h bef ore a n d d uri n g treat me nt.  
 
M o ut h w as hes:  
Patie nts wit h a healt h y m o ut h ma y use n o nalc o h olic m o ut h was h se veral ti mes ( 4 t o 6 ti mes dail y, or 
acc or di n g t o t he i nstr ucti o ns) dail y (e. g. after eac h meal) d uri n g t he st u d y.  
 
Sali ne m o ut h was hes ( S o di u m c hl ori de 0. 9 %) s h o ul d be preferre d i n cases of st o matitis, a n d s h o ul d be 
use d at a differe nt ti me t o t o ot h br us hi n g (e. g. after tea).  
 
Use of a m o ut h was h i m me diatel y after sel u meti ni b i nta ke is rec o m me n de d.  
 
T he t o n g ue ca n be ge ntl y br us he d (if n ot s ore) wit h a s oft t o ot h br us h.  
 
Patie nts wit h, or at ris k of, st o matitis s h o ul d n ot use c o m mercial / o ver -t he-c o u nter m o ut h was hes 
beca use of t he alc o h ol c o nte nt a n d astri n ge nc y. C hl or he xi di ne m o ut h was hes are n ot rec o m me n de d f or 
t he treat me nt of esta blis he d st o matitis.  
 
T he m o ut h  s h o ul d be re g ularl y i ns pecte d b y t he patie nt a n d healt hcare pr ofessi o nals. 
 
S m o ki n g s h o ul d be str o n gl y disc o ura ge d; patie nts s h o ul d be offere d hel p wit h s m o ki n g cessati o n if 
necessar y i n t he f or m of nic oti ne re place me nt t hera p y or referral t o s m o ki n g cess ati o n ser vices.  
 
A hi g h alc o h ol i nta ke s h o ul d be disc o ura ge d a n d patie nts a d vise d t o a v oi d pai nf ul sti m uli s uc h as 
s pic y f o o ds, h ot f o o d a n d dri n k. 
 
De nt al c are:  
 
De nt ate p atie nts:  
•  Patie nts w h o are free fr o m de ntal pr o ble ms ma y be at less ris k of st o matit is 
•  Teet h s h o ul d be br us he d t wice dail y wit h a fl u ori de t o ot h paste a n d s oft t o ot h br us h, i n t he 
m or ni n g bef ore brea kfast a n d last t hi n g i n t he e ve ni n g bef ore be d, a b o ut [ADDRESS_410882] o matitis s h o ul d c ha n ge t heir t o ot h br us h e ver y 4 - 6 wee ks.  
•  Use of s oft t o ot h br us h is rec o m me n de d  
•  De ntal fl oss s h o ul d be use d o nce dail y (ca uti o n i n patie nts wit h c oa g ul o pat hies i ncl u di n g a 
l o w platelet c o u nt) 